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ABSTRACT 
STRUCTURAL ANALYSIS OF PROTEIN THERAPEUTICS USING 
COVALENT LABELING – MASS SPECTROMETRY 
 
MAY 2020 
 
PATANACHAI  LIMPIKIRATI, 
 
B.Sc. (Pharm), CHULALONGKORN UNIVERSITY 
 
Ph.D., UNIVERSITY OF MASSACHUSETTS AMHERST 
 
Directed by: Professor Richard W. Vachet 
 
 
Using mass spectrometry (MS) to obtain information about a higher order structure 
of protein requires that a protein’s structural properties are encoded into the mass of that 
protein. Covalent labeling (CL) with reagents that can irreversibly modify solvent 
accessible amino acid side chains is an effective way to encode structural information into 
the mass of a protein, as this information can be read-out in a straightforward manner using 
standard MS-based proteomics techniques. The differential reactivity of proteins under two 
or more conditions can be used to distinguish protein topologies, conformations, and/or 
binding sites. CL-MS methods have been effectively used for the structural analysis of 
proteins and protein therapeutics.  
This dissertation focuses on the use of a diethylpyrocarbonate (DEPC-based CL-
MS method to characterize the higher-order structure of protein therapeutics. DEPC is a 
simple to use, commercially-available covalent labeling reagent that can readily react with 
a range of nucleophilic residues in proteins. We find that in intact proteins weakly 
nucleophilic side chains (Ser, Thr, and Tyr) can be modified by DEPC in addition to other 
residues such as His, Lys, and Cys, providing very good structural resolution. We 
x 
 
hypothesize that the microenvironment around these side chains, as formed by a protein’s 
higher order structure, tunes their reactivity such that they can be labeled. To test this 
hypothesis, we compare DEPC labeling reactivity of Ser, Thr, and Tyr residues in intact 
proteins with peptide fragments from the same proteins. Results indicate that these residues 
almost never react with DEPC in free peptides, supporting the hypothesis that a protein’s 
local microenvironment tunes the reactivity of these residues. From a close examination of 
the structural features near the reactive residues, we find that nearby hydrophobic residues 
are essential, suggesting that the enhanced reactivity of certain Ser, Thr, and Tyr residues 
occurs due to higher local concentrations of DEPC. 
Monoclonal antibodies (mAbs) are among the fastest growing therapeutics in the 
pharmaceutical industry. Detecting higher-order structure changes of antibodies upon 
storage or mishandling, however, is a challenging problem. In this dissertation, we describe 
the use of DEPC-based CL-MS to detect conformational changes caused by heat stress, 
using rituximab as a model system. The structural resolution obtained from DEPC CL-MS 
is high enough to probe subtle conformation changes that are not detectable by common 
biophysical techniques. Results demonstrate that DEPC CL-MS can detect and identify 
sites of conformational changes at the temperatures below the antibody melting 
temperature (e.g., 55 ᴼC).  The observed labeling changes at lower temperatures are 
validated by activity assays that indicate changes in the Fab region. At higher temperatures 
(e.g., 65 ᴼC), conformational changes and aggregation sites are identified from changes in 
CL levels, and these results are confirmed by complementary biophysical and activity 
measurements. Given the sensitivity and simplicity of DEPC CL-MS, this method should 
be amenable to the structural investigations of other antibody therapeutics. 
xi 
 
 Reliable information about antibody higher-order structure can be obtained, 
though, only when the protein’s structural integrity is preserved during labeling. In this 
dissertation, we have evaluated the applicability of DEPC reaction kinetics for ensuring the 
structural integrity of mAbs during labeling. By monitoring the modification extent of 
selected proteolytic fragments as a function of DEPC concentration, we find that a common 
DEPC concentration can be used for different monoclonal antibodies in formulated 
samples without perturbing their higher-order structure. Under these labeling conditions, 
we find that the antibodies can accommodate up to four DEPC modifications without being 
structurally perturbed, indicating that multi-domain proteins can withstand more than one 
label, which contrasts to previously studied single-domain proteins. This more extensive 
labeling provides a more sensitive measure of structure, making DEPC-based CL-MS 
suitable for the higher-order structural analyses of mAbs. 
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CHAPTER 1 
 
COVALENT LABELING – MASS SPECTROMETRY FOR STRUCTURAL 
ANALYSIS OF PROTEINS AND PROTEIN THERAPEUTICS 
Majority of this chapter is part of a review article published as: Limpikirati, P.♯;  Liu, T.♯; 
Vachet, R. W., Covalent labeling-mass spectrometry with non-specific reagents for 
studying protein structure and interactions. Methods 2018, 144, 79-93. (♯with equal 
contributions) 
 
1.1 Introduction to Covalent Labeling – Mass Spectrometry 
 A protein’s higher order structure (HOS) determines its function, and so methods 
that provide insight into protein structure are important for understanding protein 
reactivity. Traditionally, NMR spectroscopy or X-ray crystallography have been the 
methods of choice because of the atomic-level resolution afforded by these techniques. 
Recently, cryo-electron microscopy (cryo-EM) has also emerged as a very powerful tool 
for studying protein structure. In some cases, however, protein HOS cannot be properly 
studied by these techniques because of limited sample amounts, a given protein’s tendency 
to aggregate, or sample incompatibility. Moreover, in certain applications (e.g. protein 
therapeutic design) more rapid structural analysis tools are needed. Because of the inherent 
sensitivity, specificity, and speed of mass spectrometry (MS), methods based on this 
technique have emerged for the analysis of a protein’s solution HOS. These MS-based 
methods add to the toolbox of protein biochemists by offering approaches that give much 
higher structural resolution than techniques such as circular dichroism (CD) spectroscopy 
or fluorescence spectroscopy while at the same time being more routinely applicable and 
devoid of the limitations associated with NMR, X-ray crystallography, or cryo-EM. 
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 Using MS to obtain information about a protein’s structure in solution requires that 
the protein’s structural properties are encoded into the mass of the protein. Three primary 
methods of encoding this structural information have been utilized, including hydrogen-
deuterium exchange (HDX),1-7 cross-linking,8-10 and covalent labeling.11-13 When coupled 
with MS, HDX relies on the replacement of hydrogens by deuteriums on backbone amides, 
leading to mass increases in regions of the protein that are the least protected from this 
exchange. In doing so, HDX/MS provides insight into structured/unstructured and 
rigid/dynamic regions of a protein that can then be related to HOS. Cross-linking uses 
multi-functional reagents that can form new intra- or inter-molecular bonds between amino 
acid side chains in a protein or protein-protein complex. The choice of the cross-linking 
agent leads to defined distance constraints for the linked side chains that enables one to 
deduce HOS information. Covalent labeling (CL) methods are analogous to cross-linking 
methods in that they modify protein side chains, but they report on a protein’s surface 
structure, which can then be used to infer information about its HOS. 
All three MS-based approaches typically use proteolytic digestion, liquid 
chromatographic separation, and mass spectrometric analysis to identify modification sites 
as a way to provide localized or amino acid-level structural information; however, HDX 
and cross-linking methods have analysis challenges that are not present in CL techniques. 
In HDX, the inherent reversibility and lability of the modification can lead to back-
exchange and scrambling that must be minimized via the use of specialized sample 
handling techniques. In cross-linking experiments, branched polypeptide chains are 
necessarily produced, requiring custom software and often specially-designed reagents to 
facilitate identification of the cross-linked sites. CL methods do not suffer from these 
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limitations. Side chain modifications are irreversible, enabling the use of well-established 
proteomics workflows and sample handling techniques to facilitate the identification of 
protein modification sites. In comparison to cross-linking methods, identifying modified 
peptides and pinpointing their labeled residues is more straightforward. 
CL methods also offer some valuable attributes for the structural analysis of 
proteins. CL reactions occur on protein side chains, providing complementary information 
to HDX/MS, which probes the protein backbone. Because most protein complexes (e.g. 
protein-protein, protein-ligand) are primarily mediated by side chain interactions, it can be 
argued that amongst MS-based methods CL techniques are perhaps best suited for 
identifying interaction sites in protein complexes. A unique attribute of some CL reagents 
is the ability to study protein folding reactions that occur on the µsec timescale, which is a 
timeframe inaccessible by most techniques. The very fast reaction kinetics of reagents such 
as hydroxyl radicals and carbenes makes this possible. Given the advantages associated 
with analyzing covalently labeled proteins and peptides, as well as the distinctive features 
this technique offers, there has been an increasing interest in developing CL methods for 
studying protein HOS.  
The goal of this introductory chapter is to provide an overview of the most 
commonly used CL approaches. While there have been a large number of studies using 
amino acid specific labeling reagents together with MS to study protein structure12, this 
chapter will focus on labeling reagents that are non-specific. Non-specific reagents are ones 
capable of modifying a wide variety of amino acid side chains simultaneously, thereby 
enabling broader structural coverage in a single experiment. The basic CL experiment is 
illustrated in Figure 1.1. A protein or protein complex of interest is exposed to a particular 
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labeling reagent (see below for details), allowing solvent exposed amino acids to be 
modified. After halting the reaction, the modification sites on the protein are then identified 
using MS. Typically, this is done via proteolytic digestion and LC/MS/MS analysis to 
pinpoint the specific amino acid sites that have been modified, so structural information 
can be deduced. Structural information about a protein or protein complex is usually 
gathered by comparing a protein’s differential reactivity under two conditions (e.g. 
monomer vs. dimer to determine a binding interface as illustrated in Figure 1.1). A key 
assumption in all CL experiments is that amino acid residue will react to an extent that 
depends on their solvent accessibility, although solvent accessibility is not the only factor 
that influences the reactivity of a given amino acid residue. 
 
Figure 1.1: Scheme showing CL with MS detection.  
The label modifies solvent accessible amino acids. The modified protein or protein 
complex is subjected to proteolytic digestion and the modified peptides are analyzed using 
LC-MS/MS. Sites of protein conformational changes and/or protein-protein interactions 
can be revealed by changes in the extent of labeling at specific residues. 
1.2 Factors Affecting Covalent Labeling Reactivity 
1.2.1 Reagent factors 
Several reagents have been used to covalently modify amino acid side chains 
through oxidation or bioconjugate chemical reactions.12, 14, 15 A portion of these reagents 
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are used in covalent labeling – mass spectrometry (CL-MS) techniques for structural 
analysis of proteins and other macromolecules. In this section, we will describe how CL 
reactions are initiated and quenched, and the types of products that are generated. 
1.2.1.1 Hydroxyl Radicals 
Hydroxyl radicals (●OH) have been the most commonly used CL reagents when 
combined with MS detection. They are typically generated through radiolysis or photolysis 
of water or hydrogen peroxide (H2O2).
11 The resulting ●OH radicals then modify amino 
acid side chains on a protein’s surface via a cascade of reactions that typically begins with 
hydrogen abstraction and ends with formation of a new covalent bond on the side chain. 
High-flux X-ray or γ-ray radiation sources (e.g from a synchrotron) can be used to directly 
generate ●OH radicals via the radiolysis of water.16 Several excellent reviews from the 
Chance group have described synchrotron footprinting and its applications.17, 18 One 
challenge associated with this CL approach is that a synchrotron source is necessary to 
directly produce ●OH radicals, which limits its wide availability and applicability. In this 
synchrotron approach, ●OH radicals are generated on a millisecond timescale, meaning 
protein unfolding could conceivably occur and compete with the labeling,19, 20 although 
adding radical scavengers to the solution can shorten the lifetime of the hydroxyl radicals 
and therefore shorten the reaction time frame. It is important to stress that the applicability 
of oxidative labeling reactions is determined not only by the radical lifetime but also the 
timescale of radical formation. 
UV-light induced photolysis of H2O2 in aqueous solution is another common way 
to generate ●OH radicals;21 however, long UV irradiation times and concentrations of H2O2 
up to 15% by volume are needed unless a UV laser is used.22, 23 Laser photolysis by a 
6 
 
Nd:YAG laser (266 nm)22 or KrF excimer (248 nm) laser23 was developed by Sze and co-
workers and Gross and co-workers, and this approach allows H2O2 concentrations of less 
than 1% to be used, thereby limiting direct oxidation of sulfur groups by H2O2. Short laser 
pulses can shorten the time scale of radical formation to the nsec and µsec timescale.22, 23 
When used with the appropriate solution additives, this laser irradiation approach can 
oxidize proteins faster than they unfold, ensuring that there is no structural perturbation 
during labeling.24 Gross and co-workers later coined the term “fast photochemical 
oxidation of protein” or FPOP for this approach.  
Other reactions can also be used to generate ●OH radicals for macromolecular 
labeling, including electron pulse radiolysis,25 metal-catalyzed oxidation (MCO) 
reactions,26-28 Fenton chemistry,29-31 disproportionation of peroxynitrous acid,32, 33 high 
voltage electrical discharge,34-36 electrochemical oxidation,37 and more recently, plasma 
generation.38 Each of these ●OH radical generation methods has unique aspects to their 
chemistry, but because they are not as widely used in CL of proteins, they will not be 
discussed further here. Interested readers are referred to a comprehensive review of 
hydroxyl radical CL by Xu and Chance.11 
The general oxidation reactions that occur during radiolysis or UV photolysis are 
briefly summarized in Figure 1.2a. These reactions typically follow pseudo first-order 
kinetics16, 24, 39 because of the excess concentration of ●OH radicals. At least 14 of the 20 
common amino acid side chains can be modified by ●OH radicals, and over 50 different 
modification types on proteins can be generated.11, 13 The most common products of 
aliphatic amino acids are addition of a hydroxyl group or a carbonyl group on the side 
chain, resulting in mass shifts of +16 Da and +14 Da, respectively. For aromatic residues, 
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the addition of one or multiple hydroxyl groups to the aromatic ring results in mass shifts 
of +16. Asp and Glu residues generally undergo a -30 Da mass change due to oxidative 
decarboxylation, while basic side chains give rise to a series of unique oxidized products 
that include mass additions and side chain cleavages.11, 13 More information about the 
residue-specific oxidation products can be found elsewhere.11 
While ●OH radicals can undergo self-quenching reactions in aqueous solution, 
supplemental reagents are typically added to solution to control the lifetime of the radicals 
or prevent unwanted side reactions. Secondary reactions from the presence of H2O2 and 
other oxidative species produced upon radiolysis are found to over-oxidize Met and Cys 
residues, thereby affecting analytical reproducibility and data interpretation regarding 
solvent accessibility.40 Often, amino acids or other molecules possessing good reactivities 
towards ●OH are selected as reaction quenchers. Addition of catalase or methionine have 
been found to minimize this secondary oxidation and improve quantitative protein labeling 
40. In FPOP, Gln or Phe is usually added prior to irradiation to scavenge ●OH radicals and 
shorten their lifetimes in solution to the μsec time scale, so that oxidation can occur before 
any significant protein structural changes.23, 24 Even with these solution additives to control 
the highly reactive ●OH radical chemistry, evidence has been provided that the timescale 
of protein oxidation can extend to tens of msec because of the formation of longer-lived 
secondary or higher order radicals.41 
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Figure 1.2: Modification reactions of amino acid residues used in non-specific 
covalent labeling with (a) hydroxyl radicals, (b) carbenes, (c) trifluoromethylation, 
and (d) diethylpyrocarbonate. 
1.2.1.2 Carbenes 
Highly reactive singlet carbenes can be generated from the photolysis of diazirine 
derivatives (Figure 1.2b) by using near-UV wavelengths (350 nm) and like hydroxyl 
radicals, they can also be used for CL.42-44 Carbenes can rapidly insert into any X−H bond 
(where X can be C, O, N, or S), and thus can potentially label any amino acid residues on 
a protein surface.44, 45 Diazirine gas (CH2N2) was first used as a carbene precursor,
46-49 but 
its poor solubility limits the extent to which proteins can be labeled with this reagent. A 
more useful carbene precursor is L-2-amino-4,4-azipentanoic acid (or photoleucine), 
which has good stability and solubility in water and has been successfully used to label 
proteins in several studies.44, 50, 51 Recently, Manzi et al. reported a new aromatic diazirine 
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precursor, 3-trifluoromethyl-3-phenyldiazirine, that has higher reaction efficiency than 
photoleucine.52 
The common reactions that occur during carbene production and labeling are 
briefly summarized in Figure 1.2b. The products of carbene labeling will have a 
substituent group of the diazirine precursor inserted into the amino acid side chains, whose 
mass shift is readily detected using MS. Carbene labeling is rapid, irreversible, and 
independent of protein concentration, implying the zero-order kinetics.44 However, 
protein-dependent reactivity has been observed in some protein systems.52  Addition of 
quenching agents is not necessary as carbenes are readily quenched by water. The lifetime 
of carbenes in aqueous solution is on the nsec time scale due to its rapid reaction with 
water, which allows carbene labeling to be faster than protein unfolding.44, 50 A range of 
intermediates generated from aliphatic diazirines upon photolysis, such as triplet-state 
carbenes and diazo-mediated carbocations (diazo isomers), can result in side reactions.53 
These side reactions have been reported to be reduced somewhat by tuning functional 
groups on the diazirine precursor.52, 54 Oxidation side products have also been observed 
after irradiation but typically at low levels.53 
1.2.1.3 Trifluoromethylation (CF3)  
Very recently, ●CF3 radicals have been introduced as labeling reagents that can be 
generated by pulsed laser photolysis of triflinate (Langlois’ reagent).55 Laser irradiation is 
performed in the presence of H2O2 (
●OH source) and the water-soluble salt NaSO2CF3. The 
resulting ●OH rapidly reacts with excess [SO2CF3]
- to generate ●CF3 (Figure 1.2c). The 
highly reactive ●CF3 can insert into X-H bonds (where X is C, O, N, or S) of amino acid 
side chains, resulting in a mass shift of +67.987 Da. ●CF3 reacts with 18 of the 20 common 
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amino acids, including those that are relatively unreactive with hydroxyl radicals (Gly, Ala, 
Ser, Thr, Asp, and Glu). Because hydroxyl radicals are necessary to generate ●CF3, side 
reactions with ●OH or dissolved oxygen species during photolysis yield oxygen-
incorporated products, although CF3-substitued products dominate.
55 Radical 
trifluoromethylation likely follows pseudo first-order kinetics because of the excess 
concentration of [SO2CF3]
- in the reaction mixture, but this has not been verified yet. There 
is no need for addition of quenchers as the reactive ●CF3 is readily quenched in water, 
having a lifetime of  30 msec.56 Using the FPOP platform along with the appropriate 
solution quenchers (e.g. catalase and methionine), ●CF3-based CL should be faster than 
protein unfolding, ensuring structural integrity upon labeling.24 
1.2.1.4 Diethylpyrocarbonate (DEPC)  
Diethylpyrocarbonate (DEPC) is a commercially-available reagent that can react 
with a range of nucleophilic residues. Unlike the radical reagents where specialized 
equipment is needed to generate the radicals, DEPC directly labels proteins when added to 
solution. A stock solution of the reagent is typically prepared in anhydrous acetonitrile due 
to its limited solubility and propensity to be hydrolyzed in water. DEPC concentrations 
ranging from 0.01 mM to 40 mM are readily soluble in aqueous solutions and are also 
useful concentrations for labeling proteins.57 While DEPC will eventually be hydrolyzed 
in water, reactions between this reagent and proteins are typically quenched after a short 
time (10 sec – 60 sec) by adding relatively high concentrations (~20 mM) of a nucleophilic 
compound such as imidazole.12, 58 
DEPC is a reactive electrophile that can modify nucleophilic side chains (Cys, His, 
Lys, Thr, Tyr, Ser) and N-termini via nucleophilic substitution reactions (Figure 1.2d).12, 
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57-59 Under the most relevant protein labeling conditions, the reaction follows second-order 
kinetics, meaning the reaction rate depends on both protein and DEPC concentrations.58 
Because DEPC reacts more slowly than radical reagents, its concentration and reaction 
time must be carefully controlled to prevent over-modification and preserve the structural 
integrity of the protein during the labeling reaction. Carbethoxylated products with a mass 
shift of +72.021 Da are obtained for Cys, His, Lys, Thr, Tyr, Ser, and the N-terminus. One 
key advantage of this labeling reagent is that it generates a single type of product, which 
simplifies identification of labeled sites and improves sensitivity as the signal is not 
distributed among numerous products. The addition of a second carbethoxyl group to His 
residues has been reported, but this modification is typically avoided by labeling at the low 
DEPC concentrations necessary to ensure the structural integrity of proteins.12 Some 
modified residues, especially Ser and Thr, are subject to hydrolysis and thus label loss if 
they remain in solution too long, so proteolytic digestion and LC/MS/MS analysis must be 
performed soon after the labeling reaction is completed.59 Moreover, DEPC label 
scrambling can happen in solution if free Cys residues are available. This label scrambling 
can be easily avoided, though, by alkylating any free thiols after disulfide reduction,60 as 
is typically done in most proteomics experiments.  
1.2.2 Protein Factors 
Structural analysis of proteins using CL-MS relies on the fact that in different 
protein conformers a certain set of residues possesses differential reactivity with the 
labeling reagent, and the resulting difference in modification extents of those amino acids 
can be used to distinguish protein topologies, conformations, and/or binding sites. The 
protein factors that affect the reactivity of amino acid side chains are described below. 
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1.2.2.1 Solvent Accessibility  
All CL reactions used to study protein structures are performed in the aqueous 
phase, to preserve the HOS of proteins. The implicit assumption in CL-MS is that amino 
acids that are exposed to solvent and accessible to the CL reagent can be modified. 
Meanwhile, buried residues will be modified slowly or not at all (Figure 1.3). However, 
solvent accessibility is not the sole factor that governs reactivity. Different amino acid side 
chains can react differently with a given labeling reagent, as will be discussed in Section 
1.2.2.2. Several groups have established that a qualitative relationship exists between 
solvent accessible surface area (SASA) and extent of labeling for certain types of 
residues.11 For example, Chance and co-workers have found that hydroxyl radicals 
primarily react with surface accessible residues11, 16, 61, 62 and that residues at protein-
protein interfaces are generally protected from modification.61 Moreover, in several 
proteins, oxidation rates are found to correlate fairly well with calculated SASAs of 
residues from known NMR and X-ray crystal structures.21, 23, 62 A clear relationship 
between SASA of individual amino acid residues and carbene reactivity has not been 
observed, possibly due to the carbene precursor’s affinity for certain residues, the high 
inherent reactivity of the carbene itself, and the different intrinsic reactivities of amino acid 
residues towards carbene labeling.44, 50  Despite these issues, Delfino and co-workers have 
shown using diazirine gas as a carbene precursor that global levels of solvent accessibility 
for different -lactalbumin and β-lactamase conformers are related to carbene labeling.47, 
49 This group also found a similar relationship for antibody-bound lysozyme.48 More 
recently, an improved correlation between SASA and extent of carbene labels at the residue 
level has been demonstrated in experiments where the protein sample is flash-frozen during 
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irradiation53 (see Section 1.2.2.2 for further discussion of this observation). For 
trifluoromethylation, Gross et al. have reported that this reagent’s reactivity patterns are 
consistent with SASA in a model membrane protein.55 Our group has also demonstrated 
that DEPC labeling can be used to study protein topology, and DEPC modification extents 
for certain types of residues are found to be consistent with solvent accessibility.58 
Similarly, decreases in DEPC modification levels upon binding to transition metals are 
consistent with the general trend, and actually allow metal binding sites to be determined.28, 
58, 63 
Differences in SASA of reactive side chains, resulting from their involvement in a 
conformational change and/or protein-ligand binding, will also cause amino acids to be 
more or less accessible to a given CL reagent and therefore, react to greater or lesser 
extents. Most recently, researchers have attempted to further refine and quantify the 
relationship between SASA and labeling extent. Yang et al. and Sharp et al. have proposed 
the use a protection factor (PF) to quantitatively relate hydroxyl radical reaction rates to 
amino acid SASA using well-characterized protein models.64, 65  These PF are obtained by 
normalizing the measured labeling rate constant with the side chain’s intrinsic reactivity. 
More details about the applications of PF in mapping conformation changes and in 
modeling protein structures can be found elsewhere.13, 66 
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Figure 1.3: Protein factors that affect the reactivity of CL reagents. 
Factors include (a) solvent accessible surface area (SASA), (b) the intrinsic reactivity of 
amino acid residues, and (c) primary and tertiary structure. 
1.2.2.2 Intrinsic Reactivity of Amino Acid Side Chains 
Attempts to use a PF to quantify the relationship between SASA and reactivity 
imply that the intrinsic reactivity of a given amino acid side chain influences its reactivity 
(Figure 1.3). Thus, this factor must be considered when interpreting CL data. While ●OH 
is highly reactive and can modify a wide range of amino acid side chains, rate constants 
for reactions with the 20 common amino acid residues vary over three orders of magnitude 
with the following reactivity order: Cys > Met > Trp > Tyr > Phe > His > Leu, Ile > Arg, 
Lys, Val > Ser, Thr, Pro > Gln, Glu > Asp, Asn > Ala > Gly.67 Although every amino acid 
can react with hydroxyl radicals, practically speaking Gly, Ala, Ser, Thr, Asp, and Glu are 
often not found labeled during protein CL experiments with hydroxyl radicals. Therefore, 
only 14 of the 20 side chains are useful in typical labeling experiments with hydroxyl 
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radicals, and these residues typically account for ∼65% of the sequence of the average 
protein.11, 67 Sharp et al. have demonstrated that normalization of a residue’s intrinsic 
reactivity via a PF is needed to obtain a qualitative correlation between SASA and labeling 
extent.65 
While CL with carbenes was initially predicted to be affected less by differences in 
amino acid side chain chemistry than hydroxyl radicals, studies suggest that there is a 
decidedly non-uniform distribution in carbene labeling of proteins.44 Schriemer and co-
workers have found that using photoleucine as a diazirine precursor leads to Glu residues 
being preferentially modified, which might be explained by the reagent’s affinity for 
negatively charged residues or the reactive carbenes favoring polar protic bond (O-H) 
insertion rather than C-H bond insertion.50 Oldham et al. have also found that hydrophobic 
and basic residues are favored in the carbene labeling using an aryldiazirine precursor.52 In 
the more recent study from Schriemer et al, surface bias is still found in the CL with 
carbenes generated from other different aliphatic diazirine precursors.53 By performing 
carbene footprinting on flash-frozen samples to limit the diffusion of carbenes to sites of 
higher reactivity during irradiation, the preferred sites of labeling tend to reflect the 
sidechain interactions with diazirine precursor, which is influenced by the diazirine 
substituents rather than the intrinsic reactivity of residues.50, 52, 53  The resulting surface 
biases can be avoided somewhat by tailoring the diazirine precursor or changing solution 
conditions to reduce the reagent’s affinity toward specific residues.50, 52 
Because ●CF3 radicals have only recently emerged as CL reagents, the full details 
of their reactivity have not been studied enough yet. However, aromatic residues (e.g. Trp 
and Phe) are found to be modified at relatively high levels, indicating their good intrinsic 
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reactivity toward ●CF3 labeling.
55 For DEPC labeling, the intrinsic reactivity of side chains 
is governed by the nucleophilicity of residues.57-59 Thus, the reactivity of Tyr, Ser, and Thr 
residues is lower than the reactivity of Cys, His, and Lys residues due to their weakly 
nucleophilic hydroxyl groups.58 
1.2.2.3 Primary and Higher Order Structure Effects 
In the structure of an intact protein, the sequence context (primary structure) may 
contribute to the reactivity of amino acid due to electron donating and/or electron 
withdrawing effects. This fact appears to be true even for hydroxyl radical labeling. Sharp 
and co-workers have demonstrated that accurate measures of SASA for residues with poor 
intrinsic reactivity (e.g. Arg, Lys, Val, Thr, Ser, Pro, Glu, Gln, Asn, Asp, Ala) during 
hydroxyl radical CL experiments require the normalization of sequence effects by 
comparing label profiles of native and denatured structures.65 For highly reactive residues 
(e.g. Trp, Tyr, Phe, His, Ile), the effects of primary structure on reactivity are relatively 
minimal.65 In addition, the microenvironment (Figure 1.3) caused by the tertiary structure 
around an amino acid residue can influence the acid/base characteristics of side chains 
because of charge-charge interactions, charge-dipole interactions, dipole-dipole 
interactions, and/or hydrophobic effects.68-71 For example, in dimethyl labeling proteins, 
Wang and co-workers found that hydrogen bonding and electrostatic interactions around 
lysine residues can influence the methylation reactivity of lysine residues.72 The effects of 
local structural contacts of amino acid side chains, especially those with lower intrinsic 
reactivity, have been found to contribute to their reactivity with hydroxyl radicals.64, 65 In 
CL with carbenes, the surface bias caused by the reagent’s affinity for specific protein 
surface sites might be explained by primary and/or tertiary effects. Sequence context and 
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non-covalent molecular interactions (higher-order structures) may drive and steer the 
selectivity of diazirine precursors toward certain residues.50, 52, 53 However, no definitive 
experiments have been performed to demonstrate this hypothesis yet. For reagents like 
DEPC that are inherently less reactive than hydroxyl radicals and carbenes, the effect of 
primary or tertiary structure might be expected to be more pronounced since changes in the 
pKa values of a given residue lead to changes in its protonation state and thus 
nucleophilicity. The relatively poor correlation observed between SASA and the DEPC 
reactivity of Ser and Thr residues58, 59, 73 might imply that the microenvironment around 
these amino acids, as formed by a protein’s tertiary structure, tunes their reactivity. 
1.3 Using Covalent Labeling with Mass Spectrometry Detection 
1.3.1 Principle of Experiment Design 
During CL experiments only solvent exposed residues are modified and thus 
provide direct structural information, while the buried residues are unmodified and thus 
indirectly provide structural information. As illustrated in Figure 1.1, any structural 
information obtained from a CL experiment comes from comparing the labeling ratio of 
the protein reacted under at least two conditions, with one of the conditions usually being 
the protein in its native state. The resulting differential reactivity is used to deduce 
structural information. Another important principle of CL experiments is that the labeling 
reagent must be used in such a way as to not perturb a protein’s HOS. Clearly, if the probe 
itself changes the protein’s structure, then the resulting data will not correctly report on the 
protein’s structure. 
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There are at least three general ways that are used to assess that a protein’s structure 
is not perturbed during CL. The first is to use a complementary measurement such as CD, 
fluorescence, or an activity assay to monitor if the protein’s structure has changed during 
labeling.52, 58, 73, 74 Our group has demonstrated in previous work, that while these methods 
are easy to implement, they tend to indicate global structural changes and lack the 
resolution to identify local protein structural changes.58 A comparable approach is to 
measure the charge-state distributions of a protein via electrospray ionization (ESI)-MS75 
as a protein will undergo a shift in its charge-state distribution upon a structural change. 
However, like with CD and fluorescence spectroscopy, changes in ESI-MS charge-state 
distributions are typically not sensitive enough to monitor local changes in HOS, so it is 
debatable whether these approaches are sufficient for assessing if a protein’s structure is 
perturbed or not from the labeling reaction. 
A second commonly used approach for assessing a protein’s structural integrity 
during CL is to measure labeling reaction kinetics (Figure 1.4). Chance and co-workers 
pioneered this approach with synchrotron-based hydroxyl radical labeling in which the 
unmodified fraction of a peptide or protein is monitored as a function of the reagent dose 
(e.g. radiolysis time). In this way, dose-response plots can be generated, and adherence to 
the proper reaction order kinetics indicates whether a protein’s structure has been perturbed 
or not.76, 77 These plots can be generated for all modified peptides that are produced from 
a proteolytic digestion and provide a measure of the structural integrity throughout the 
entire protein. Our group has successfully used an analogous approach with DEPC 
labeling58, 59, 63, 78, 79, which follows second order kinetics, and we have found this approach 
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to offer much higher sensitivity than CD or fluorescence spectroscopy for ensuring 
structural integrity through all regions of a protein.  
 
Figure 1.4: Hypothetical dose-response plot, showing first-order labeling reaction 
kinetics. 
When the extent of labeling is low enough to prevent structural perturbation, reaction 
kinetics are monotonic (i.e. four lowest reagent doses in the plot). When over-labeling 
perturbs the structure of the protein, the reaction kinetics change, indicating variations in 
the microenvironment around one or more residue. 
 
A third method of guaranteeing a protein’s HOS is not been perturbed by CL is to 
ensure labeling chemistry happens faster than structural changes can occur. As indicated 
in previous sections (see Section 1.2.1), FPOP-based hydroxyl radical labeling and carbene 
labeling have extremely fast labeling rates that are comparable to or faster than protein 
folding rates.23-25, 44, 50 The fastest protein structural changes occur in a few µsec,20, 80 and 
thus if hydroxyl radical or carbene labeling occurs faster, then protein modification should 
take place before any significant protein structural changes occur. In the FPOP 
experimental setup, hydroxyl radicals are generated during the nsec pulse of the laser,23 
and radical scavengers that are present in solution limit the overall lifetime of the hydroxyl 
radicals. Calculated lifetime profiles23 and time-resolved UV spectroscopy25 suggest that 
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reactive hydroxyl radical species are consumed in 0.1-1 µsec when radical scavengers are 
present. Such short lifetimes allow the radical-protein reactions to happen faster than 
protein structural changes. Further proof that proteins are modified before they can undergo 
structural changes comes from the Poisson distribution of modification extents, which 
suggest that only a single protein species is reacting.24 Despite evidence that hydroxyl 
radical labeling by FPOP occurs on the µsec timescale, recent work by Konermann and 
coworkers suggests that the time window for FPOP-based labeling may be much longer 
than one millisecond as secondary and higher order radicals have longer lifetimes and are 
possibly not effectively quenched.41 At this point, however, it is unclear the extent to which 
secondary radicals are responsible for the measured protein oxidation. 
It should be noted that there are numerous examples in the literature in which 
nothing is done to ensure a protein’s structural integrity during CL. This approach can be 
successful if “single-hit” conditions are achieved.81 In other words, as long as there is one 
label per protein on average, the labeling chemistry should have successfully probed the 
original protein structure. Any additional label, by definition, would be probing a possibly 
perturbed structure because the protein would now have a covalent modification that it did 
not have originally. While this has commonly been acknowledged, recent work by Madsen 
et al82 on monoclonal antibodies (mAbs) suggests that multiple labels can be 
accommodated while still obtaining the desired information. It is unclear at this point how 
generalizable this observation is. 
1.3.2 Experiment Design and Workflow 
The goal of a CL experiment is to encode structural information into the mass of 
the protein. The commonly used workflow for CL experiments is sample preparation, 
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labeling reaction, and, if necessary, quenching to consume excess reagent. After the CL 
experiment, the labeled protein sample can be directly analyzed by MS or LC-MS, or more 
typically, the labeled protein can be proteolytically digested prior to LC-MS (Figure 1.5).  
While standard proteomics techniques are typically used to analyze covalently labeled 
proteins to obtain the desired structural information, the following unique aspects of the 
CL approach must be taken into consideration. 
 
Figure 1.5: Example workflow for covalent labeling combined MS.  
Before MS analysis, a protein sample is prepared and labeled, during which the structural 
information is encoded into the mass of the protein. The labeled intact protein sample can 
be analyzed by ESI-MS to monitor the overall extent of modification, or more typically the 
labeled protein is subjected to “bottom-up” analysis via proteolytic digestion and 
LC/MS/MS to determine labeling ratios at each modified residue. 
Unlike in typical proteomics experiments, CL-MS experiments require complete or 
near complete protein sequence coverage to obtain the desired structural information. 
Moreover, a semi-quantitative measure of labeling extents at residues throughout the 
protein is needed to deduce structural information in a differential experiment (see Figure 
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1.1). Like in proteomics studies, the two primary strategies for determining labeling sites 
are “top-down” sequencing83-85 and “bottom-up” sequencing.83, 86, 87 In top-down 
sequencing, the entire, intact protein is analyzed with MS/MS, and therefore complete 
sequence coverage is inherently available. In top-down sequencing, it is possible to select 
and apply MS/MS to the protein with only one label. This is beneficial if there is a concern 
that multiple labeling events could have perturbed the structure (“single-hit” principle). 
Despite these advantages, very limited work has been published using top-down MS to 
analyze proteins covalently labeled by non-specific reagents. The limited utility of top-
down sequencing for CL-MS is mostly due to the relatively poor ability of top-down 
sequencing to localize modification sites, especially for large protein systems. Often large 
fragment ions containing multiple possible modification sites are produced, making it 
difficult to assign labeling sites to specific residues with high confidence. This difficulty 
effectively results in low structural resolution. In addition, semi-quantitative information 
that is usually required in CL-MS experiments is challenging to obtain with top-down 
sequencing. One study by Gross et al. compared top-down and bottom-up sequencing for 
analyzing covalently labeled proteins and concluded that top-down sequencing had limited 
sensitivity, a low dynamic range, and sometimes difficulty pinpointing modified residues 
in regions with numerous modified sites.88 It should be noted that the utility of top-down 
sequencing for CL-MS experiments might improve with the use of UV photodissociation, 
as this dissociation technique has shown utility for identifying modified sites during amino-
acid specific labeling experiments.89 
Bottom-up sequencing is a more commonly used strategy to analyze covalently 
labeled proteins. Because MS/MS is more effective on smaller peptides, this strategy 
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provides high spatial resolution, usually pinpointing labeled sites down to 1 or 2 amino 
acids. Moreover, modification extents can usually be determined as low as 0.1% or lower. 
Bottom-up sequencing of covalently labeled proteins still suffers from the usual challenges 
associated with bottom-up sequencing, such as biases associated with proteolytic cleavages 
and peptides going undetected during LC/MS experiments. For large proteins, where 
sequence coverage during bottom-up sequencing can be low, using multiple enzymes for 
proteolytic digestions can be used to improve coverage.90 
An important consideration associated with bottom-up sequencing is the choice of 
dissociation techniques during the MS/MS stage of the experiment. Collision-induced 
dissociation (CID) remains the most commonly used dissociation technique and provides 
accurate information in most cases. There are examples, however, in which CID has 
difficulty with certain types of modifications and modified amino acid residues. For 
example, CID provides very poor sequence coverage for peptides containing oxidized 
cysteine or methionine residues.91 The dissociation technique has also been known to lead 
to label misassignments for peptides in which histidines are oxidized, especially when more 
than one modification site exists in a peptide, as oxidation causes new dissociation 
pathways to emerge.92 Sharp and co-workers reported a similar conclusion based on studies 
of several oxidatively modified peptides.93 Significant neutral losses are also observed in 
CID of peptides modified by carbenes, making it difficult to pinpoint modification sites.50 
Another issue observed with a subset of DEPC-labeled peptides is the possibility of the 
label to “scramble” from one site on a peptide to another during CID, presumably due to 
an intramolecular nucleophilic attack during the CID process.94 In each of the cases in 
which CID provided incomplete or misleading information about modification sites, 
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electron transfer dissociation (ETD) was successfully used to correct the problem. In fact, 
it has been argued that ETD generally provides improved identification and quantitation of 
labeled sites produced during oxidative labeling experiments.50, 94, 95 
1.3.3 Data Analysis and Presentation 
The desired results from CL-MS experiments are measurable labeling levels at 
residues throughout the protein so that structural information can be obtained. The more 
labeled sites that are measured, the higher the structural resolution will be from the CL-MS 
experiment. In addition, some semi-quantitative measure of the labeling extent at each 
residue is desired so that any corresponding structural change can be deduced. It is rare that 
a particular residue is labeled in 100% of the protein molecules. More commonly, only a 
fraction of the protein molecules in a sample are labeled at a given site, and this labeling 
extent is usually provided as a labeling percentage from LC-MS measurements. Decreases 
in labeling percentages at given residues typically indicate a drop in solvent accessibility 
that could, for example, indicate a protein-protein interaction site (Figure 1.6). In contrast, 
increases in labeling percentages at a given site would suggest unfolding in that region of 
the protein.  
While residue labeling identification is achieved using tandem MS, the labeling 
extent is usually determined by the ion abundance or chromatographic peak area of the 
labeled peptide that contains the modified residue. In addition to the use of standard 
software packages for analyzing such data (e.g. Mascot96, 97), other programs such as 
ByOnic,51 ProtMapMS,98 a custom-designed version of Proteome Discoverer,99 and other 
specialized software pipelines73 have been created to facilitate CL-MS data analysis. A key 
difference between these specialized software and traditional proteomics software is that 
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they are much more efficient at finding labeling sites, especially at low levels, while also 
providing a measure of the labeling percentage at every identified site. 
While it is important to obtain a measure of labeling extent, it should be noted that 
explicit quantitation is not attainable through most CL-MS experiments. There are many 
reasons for this fact. First off, modified and unmodified peptides are distinct chemical 
species that have different inherent ionization efficiencies. Moreover, a difference in 
chromatographic retention times of modified and unmodified peptides during reversed-
phase LC gradient elutions leads to a different percentage of organic solvents from which 
each peptide is electrosprayed, resulting in further differences in ionization efficiencies. 
These ionization efficiency differences cause there to be a distinct relationship between 
solution concentration and ion abundance for modified and unmodified peptides. To 
remediate the ionization efficiency bias that occurs during LC-MS analyses, Sharp and co-
workers have employed size-exclusion chromatography (SEC) instead of reversed-phase 
LC to separate labeled peptides. SEC ensures all peptides are electrosprayed under 
common solvent conditions, thereby eliminating one cause of ionization efficiency 
differences. A drawback of this approach is that isomeric labeled peptides co-elute, making 
it more difficult to quantify labeling extents for peptides with more than one modified 
residue. To some degree, this drawback can be overcome using ETD, as tandem mass 
spectra from ETD can often correctly report modification levels of each residue in an 
isomeric mixture.93 
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Figure 1.6: An example of how changes in labeling level can be applied to predict the 
protein dimer interface demonstrated with β2m dimer structure extracted from β2m 
H13F hexamer (PDB 3CIQ).  
Blue colored residues indicate significant decreases in labeling level from monomer to 
dimer, which helps locate the dimer interface. Yellow colored residues show no significant 
change in labeling level, which indicates these residues are at a region away from dimer 
interface. The red colored residues are examples of residues with increases in labeling 
levels, indicating these residues becomes more solvent exposed upon dimer formation. 
1.4 Applications of Covalent Labeling – Mass Spectrometry Methods  
The use of CL-MS methods to obtain structural information about protein topology 
has gained popularity because of its moderate to high structural resolution, straightforward 
implementation, and/or ability to probe structural changes on a µsec time scale. In this 
section, we describe some select examples of CL-MS applications. 
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1.4.1 Protein Folding/Unfolding 
In most proteins, specific biological functions can be exerted only after folding into 
their appropriately folded forms. Deciphering protein folding/unfolding is necessary to 
understand protein-energy landscapes, the biological processes of protein misfolding 
disorders,100-102 and is essential for the development of therapeutics against these 
disorders.101 While numerous techniques, including other MS-based techniques, have been 
developed to monitor conformation dynamics during protein folding/unfolding,3, 103 protein 
surface mapping with CL-MS can provide information with high spatial and temporal 
resolution, in a way that many other techniques cannot.  Laser-based CL methods, such as 
FPOP, have proven to be useful tools for protein folding studies because proteins are 
labeled on the µsec time scale, which is faster than protein unfolding, due to the pulsed 
nature of reagent production and the rapid reaction quenching.23, 24 Using FPOP together 
with denaturants such as temperature and pH, sub-msec protein folding experiments can 
be performed. For example, Gross and co-workers used temperature jump experiments to 
study the region-specific folding of the protein barstar. Barstar in aqueous buffer undergoes 
reversible unfolding at low temperature ( 0 ᴼC)104, and ‘pump/probe’ experiments can be 
conducted to study the protein’s refolding (Figure 1.7a). Refolding of unfolded barstar 
was created by rapid IR laser-induced heating of a solution containing the protein (‘pump’ 
from  0 ᴼC to  room temperature), and then FPOP with a ‘probe’ UV laser was used to 
oxidize the protein at different times after it began refolding. By limiting the lifetime of the 
hydroxyl radicals in solution to around 1 µsec, ‘snapshots’ of the protein as it folded could 
be obtained.105-107 Their results confirmed the presence of partially-folded intermediate 
conformations of barstar during its refolding (possibly a molten globule state), which was 
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consistent with previous UV absorbance, fluorescence, and CD spectroscopic studies.108-
111 The CL-MS experiments also revealed residue-level information about conformational 
changes during barstar folding, which was not available from previous spectroscopic 
measurements. In a similar manner, the same group studied the refolding kinetics of the 
paramyxovirus fusion protein, which is essential in mediation of virus-host cell fusion and 
genetic transfer.112 Besides temperature-triggered folding experiments, Konermann and co-
workers established a platform to study short-lived protein folding/unfolding intermediates 
using continuous-flow mixing and pulsed laser-induced oxidative labeling.113-116 To 
examine protein unfolding, a protein of interest is premixed with H2O2 in a reaction 
capillary and unfolding is initiated by rapid mixing with acid or denaturant.113, 115 To study 
protein folding, a denatured protein is prepared by acid or denaturant, and the folding is 
then initiated via a pH jump or rapid denaturant dilution.114, 116 To study conformations at 
different time points after initiating unfolding or folding, a pulsed laser beam is focused at 
different positions along the mixing capillary, and a certain amount of the resulting 
oxidized sample is collected for further bottom-up LC-MS/MS analysis (Figure 1.7b). 
Folding/unfolding intermediates of bacteriorhodopsin, apo- and holo-myoglobin have been 
studied by this method, and the in-depth residue-level information from the rapid pulsed 
CL, in combination with the global structural features obtained from optical spectroscopy, 
can provide good spatial and temporal resolution of protein folding/unfolding pathways.113-
116 
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Figure 1.7: An illustration of the experimental setups used for studying protein 
folding/unfolding using laser-based CL methods.  
Schematic diagrams are shown for (a) temperature jump (T jump) and (b) continuous-flow 
mixing experiments coupled with pulsed laser-induced oxidative labeling. Details about 
each experiment are provided in the text. 
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1.4.2 Amyloid-Forming Proteins 
Amyloids are insoluble protein aggregates that are associated with several human 
diseases, including Alzheimer’s and Parkinson’s.117 Numerous efforts have been devoted 
to deciphering the aggregation process in vitro, but this information is challenging to obtain 
because amyloid proteins usually aggregate rapidly.118 Moreover, pre-amyloid oligomers, 
which may in some cases be disease causing119-121 are short-lived and can be difficult to 
structurally interrogate.81, 122, 123 As compared to NMR and X-ray crystallography, CL can 
provide better time resolution for studying transient pre-amyloid structures, and various 
CL approaches have been used to gain insight into the aggregation interfaces for several 
amyloid proteins. This structural information can be obtained by comparing the CL ratio 
of residues before and during oligomer formation to help identify aggregation interfaces. 
As an example, Chance and coworkers applied synchrotron-based hydroxyl radical CL to 
Aβ40, which is the protein that aggregates in Alzheimer’s disease.124 Protection factors 
were used to indicate the degree of change in solvent accessibility. Structural information 
of full-length Aβ40 monomer in fibrils and the core structure of two- and three-filament 
conformers were acquired and were compared to the previously reported structures by solid 
state NMR. Gross and co-workers applied FPOP in a time-dependent manner to study the 
pre-amyloid formation process of Aβ1-42.125 By plotting the fraction of modified intact 
Aβ1-42 as a function of time, a kinetic scheme of the aggregating process was revealed. 
Similarly, by plotting the labeling percentages of modified peptides over time, the regions 
with significantly decreased labeling ratios indicated the aggregating core structure. 
Moreover, because MS/MS can indicate the exact labeled residues, even more detailed 
structural information could be obtained. DEPC labeling has also been successfully used 
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to study the pre-amyloid oligomers of β-2-microglobulin (β2m), which is the protein that 
forms amyloids in dialysis-related amyloidosis.126 By conducting DEPC labeling at 
different time points after initiating amyloid formation with Cu(II), the structural changes 
to the monomer caused by Cu(II) binding,63 as well as structural models for the pre-amyloid 
dimer78 and tetramer79 could be determined. 
1.4.3 Protein-Ligand Systems 
CL is also well suited for studying protein-ligand complex binding sites when 
traditional methods, such as NMR and X-ray crystallography, are too time-consuming or 
fail due to limited sample amounts, protein instability, sample heterogeneity, protein 
molecular weight limitations, or difficulties with crystallization. In its most straightforward 
implementation, CL-MS can report on ligand binding sites via decreases in labeling extents 
at specific residues in the protein. Ligand binding protects residues on the protein surface 
from being labeled. Many examples of CL used for protein-ligand binding studies are 
available.81, 95, 127-132 One example by Manzi et al. demonstrated that carbene-based 
labeling is capable of reporting the binding site of the lysozyme-NAG complex.52 Multiple 
residues showed a significant decrease in labeling extent in the presence of the ligand, 
clearly correlating those residues to the well-studied binding pocket of the complex. 
Similarly, our group has applied DEPC labeling together with two other site-specific 
labeling reagents to study β2m binding to small molecules that inhibit its amyloid forming. 
The simplicity and speed of the labeling chemistry allows for ligand binding site 
information on a fast aggregating protein whose ligand binding site could not otherwise be 
determined.81 Combining CL-MS with computational docking further refines the structural 
information that is acquired. CL-MS can test the pose predicted by docking81, 131, 132 or 
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restrain the region of protein to which the ligand is bound, but CL-MS is usually unable to 
show the orientation of the ligand, which is information that computational docking can 
provide. In one example reported by Chance and co-workers,131 a hybrid structural 
approach that include synchrotron-based hydroxyl radical CL, homology modeling, 
computational modeling, and protein ligand docking was used to predict the structure of 
the membrane protein Serotonin Type 4 Receptor (5-HT4R) and bound ligands. In addition 
to providing protein-ligand binding site information, CL has been shown to provide 
information about conformational changes upon ligand binding.95, 129, 130 Gross and co-
workers applied FPOP to study heme binding and conformational changes in myoglobin.129 
Several residues that are close to the heme binding site show significant differences in their 
ability to be modified in apo or holo form of myoglobin. In another case, the structural 
changes caused by the binding of the peptides melittin and mastoparan to calmodulin were 
compared to the known structure of the calmodulin-M13 complex.130 The CL results 
indicated statistically similar patterns in labeling extents, leading to the conclusion that 
ligand binding changed the structure of calmodulin but the ligand bound calmodulin 
retained a similar structure when bound to M13, melittin, or mastoparan. It should be noted 
that distinguishing between ligand binding and ligand-induced conformational changes 
must be done carefully. For protein-ligand complexes with unknown binding sites, a 
decrease in labeling of a given residue (or a set of residues) might be due to protection from 
ligand binding or it could be due to allosteric changes that decrease the solvent accessibility 
of residues not directly involved in ligand binding. Further application of CL to protein-
ligand binding should reveal whether such allosteric changes are likely to significantly 
change labeling patterns. 
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1.4.4 Covalent Labeling with Computational Modeling 
The structural resolution provided by CL-MS is lower than that provided by NMR 
or X-ray crystallography because only information about the solvent accessible side chains 
is obtained, and this information is only a fraction of the amino acids in a protein. Even 
with relatively limited information, CL-MS has been successfully used to confirm or rule 
out proposed structural models.133, 134 CL-MS has the potential to provide even higher 
resolution structural information when it is combined with computational modeling. 
Several groups have explored the combination of CL-MS and computational modeling 
techniques. For example, Gerega and Downard developed an algorithm, known as 
PROXIMO, that is specially designed to model protein-peptide complex structures based 
on oxidative labeling data from radical probe MS.135 Similarly, Chance and co-workers 
have developed the ClusPro program for predicting protein complexes using the restraints 
from hydroxyl radical labeling to facilitate homology modeling and associated protein 
structural prediction for protein complexes with no NMR or X-ray crystal structure.136 In 
addition, Sharp and co-workers have developed a strategy that correlates oxidative labeling 
levels with SASA at each modified residue, which can be utilized to assess the quality of 
protein structural models65 or model protein complex structures.137 While each of these 
above approaches have helped refine the protein structural information obtained by CL-
MS, they have not been adopted broadly. Recent work has shown the promise of combining 
multiple complementary experimental methods to improve structural modeling. For 
example, methods like limited proteolysis,138 small-angle X-ray scattering,139 chemical 
crosslinking combined with native MS140 have been combined with CL-MS and 
computational methods to arrive at protein structural models. It appears that CL-MS 
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research is in the very early stages of identifying the best methods to efficiently combine 
constraints from CL-MS, complementary methods, and computational modeling to obtain 
higher resolution protein structural information. 
1.4.5 Membrane Protein Footprinting 
Another promising area in which CL-MS has the potential to have an impact is in 
the study of membrane proteins. Membrane proteins are inherently more difficult to study 
as compared to water-soluble proteins. CL-MS would appear to be a promising tool for 
structural analysis of membrane proteins because CL can often be done under conditions 
that preserve conformation and topologic information. Several groups have demonstrated 
the promise of CL in studying membrane proteins.55, 141-147 Hydroxyl radical labeling has 
been shown to map the topology of intrinsic membrane proteins in their natural lipid 
environment,141 in nanodiscs,145 within amphipols,146 and even within living cells.147 New 
hydrophobic-based CL labeling reagents, e.g. based on triflinate,55 might be able to further 
improve the information accessible by CL-MS by allowing the labeling of protein regions 
that are inserted into membranes themselves. 
1.4.6 In-Cell/In-Organism Covalent Labeling 
Beyond live-cell membrane protein CL,147 Jones and co-workers recently 
performed in-cell FPOP of live Vero cells. They demonstrated that proteins in different 
cellular compartments can be labeled and residue-level oxidative modification extents can 
be measured, and these labeling extents correlate well with the SASA of the residues 148. It 
is reasonable to assume that this application of CL-MS could be expanded for studying 
protein interactions and conformational changes in living cells. 
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1.5 Structural Analysis of Protein Therapeutics Using CL-MS  
Protein therapeutics are the fastest growing pharmaceuticals on the market and have 
important roles in almost every field of medicine.149, 150 In 2016, more than 50% of new 
drug approvals were biologics,151 of which the vast majority are protein 
biopharmaceuticals, and this number is estimated to rise to around 70% in 2025.152 Protein 
therapeutics are classified as enzymes, hormones, growth factors, fusion proteins, 
cytokines, anticoagulants, antibodies, antibody-drug conjugates, protein vaccines, and 
protein diagnostics.153, 154 Monoclonal antibodies (mAbs) belong to the fastest growing 
segment.155, 156 In contrast to small molecule drugs, the three-dimensional structure of 
therapeutic proteins contributes to the higher binding specificity towards drug targets, 
leading to greater therapeutic efficacy and less side effects.153 Growing concerns on the 
quality, efficacy, and safety of protein biopharmaceuticals have led the developments of 
many analytical methods to investigate quality attributes of therapeutic proteins at different 
levels, from primary structure (e.g. amino acid sequence and post-translational 
modifications) to higher-order structure (e.g. protein conformation) [Figure 1.8].152, 156, 157 
During manufacturing, biopharmaceutical products must be well characterized and lot-by-
lot comparable. In the case of biosimilars (i.e. follow-on versions), in addition to their lot-
by-lot comparability, their quality attributes must be proven to be comparable to a reference 
product (i.e. an innovator product).152, 156   
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Figure 1.8: Higher-order structure is one of quality attributes of therapeutic proteins 
that require proper analytical tools to characterize in order to ensure quality, 
efficacy, and safety of biopharmaceutical products. 
 
Changes in HOS, e.g. protein misfolding and aggregation, can reduce drug efficacy, 
enhance unwanted drug actions, and/or induce immunogenicity.158, 159 Reliable analytical 
tools are currently needed for characterizing the HOS of biopharmaceuticals to ensure the 
quality, efficacy and safety throughout a product life cycle – from manufacturing to dose 
administration.158, 160-163 Several low-resolution spectroscopic methods are still commonly 
used to characterize HOS,158, 164 but information about small localized conformation 
changes, some of which may potentially affect drug efficacy and safety, cannot be 
provided. Hence, there is a growing need for novel analytical tools with good sensitivity 
and moderate structural resolution to characterize HOS at the amino acid level.  
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CL-MS techniques have the ability to probe the structure of protein therapeutics 
with moderate structural resolution and could be used in a semi-high throughput manner to 
monitor numerous therapeutic preparations.73, 165, 166 FPOP along with MS detection has 
been shown by Watson and Sharp to be sensitive enough to detect subtle structural changes 
of expired and mishandled granulocyte colony-stimulating factor (GCSF) samples.165 
Deperalta et al. demonstrated the ability of hydroxyl radical labeling to characterize the 
dimer interface of an antibody dimer commonly found in formulated therapeutic IgG1 
mAbs. Hydroxyl radical labeling data obtained using synchrotron radiolysis of water has 
shown that the Fab domain displays decreased oxidation rates and is likely involved in 
dimer interface.166 Our group has also demonstrated that DEPC labeling along with MS 
can identify minor conformation changes in thermally-stressed human growth hormone 
(hGH) and IgG1 mAb samples. Heat-stressed hGH undergoes very subtle structural change 
that other biophysical techniques (CD, fluorescence spectroscopy, dynamic light 
scattering) are not sensitive enough to detect, but DEPC labeling along with MS detection 
can detect with good structural resolution. We have also found that DEPC labeling can 
reveal the aggregation interface in a heat-stressed IgG1 mAb sample.73 Epitope/paratope 
mapping of the specific residues involved in antibody-antigen and other protein-receptor 
interactions is particularly valuable for assessing epitope novelty, predicting 
immunogenicity, evaluating binding characteristics, and for optimizing binding.167 
Recently, Gross and co-workers used FPOP techniques to identify the interface of anti-
thrombin mAb/thrombin,96 anti-vascular endothelial growth factor (VEGF) Fab-1 
fragment/VEGF,97 anti-interleukin-23 (IL-23) mAb/IL-23,90 and IL-6/IL-6 receptor 
interactions.168 
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1.6 Summary  
In this chapter, we have provided an overview of CL-MS methods that use reagents 
that react with a wide range of amino acid residues, including hydroxyl and trifluoromethyl 
radicals, carbenes, and DEPC. These broadly reactive reagents are making CL-MS 
methods of increasing interest for the structural analysis of macromolecules. CL-MS fills 
in the gap among current structural characterization techniques, with higher resolution than 
CD and fluorescence spectroscopies, and faster measurement times than NMR and X-ray 
crystallography. At the same time, it retains the limited sample consumption common to 
most MS-based methods and can be applied to protein systems that are difficult to study 
by other techniques. CL-MS has very limited label loss and label scrambling, allowing 
greater sensitivity to structural changes in some cases and better reproducibility in most 
cases than HDX-MS. The fact that only solvent accessible amino acid resides are modified 
makes the technique particularly well suited for studying protein interactions with ligands 
and other proteins, including aggregating proteins. Radical and carbene-based labeling can 
monitor protein structural changes on the µsec timescale, allowing the study of protein 
folding and unfolding.  
While significant progress has been made with CL methods to address protein 
structure, some technique limitations remain. Unlike most spectroscopic methods, CL-MS 
relies on changing a protein in order to be probe its structure. Covalent modification of 
amino acid residues is needed to encode a protein’s structural properties into its measured 
mass, and this necessarily changes the protein. Thus, every labeling procedure has to be 
carefully controlled and understood to ensure that accurate structural information is 
obtained. Our understanding of the underlying chemistry in most cases is still incomplete, 
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and this lack of understanding can give rise to ambiguous structural information in some 
cases. Another limitation of CL is that not every amino acid in a protein can be probed, and 
this inherently limits the structural resolution obtainable by this approach. No one CL 
reagent has been found to react with every type of amino acid side chain. A related issue 
is that every amino acid residue reacts to a different extent with a given CL reagent. This 
fact complicates attempts to find correlations between reactivity and higher order structure. 
Despite these limitations, and in some cases because of these limitations, several 
opportunities still exist for the future development of CL-MS. 
This dissertation focuses on the use of DEPC-based CL-MS techniques to address 
the need in pharmaceutical industry, specifically the protein therapeutics field. 
Characterizing HOS of mAbs is challenging given their size and the multidomain nature. 
As one of the non-specific reagents, DEPC can modify a wide range of amino acid side 
chains simultaneously, providing good structural resolution to probe site-specific HOS 
changes of therapeutic mAbs. 
In Chapter 2, we demonstrated the effect of residue microenvironment on DEPC 
labeling reactivity. We find that in intact proteins weakly nucleophilic side chains (Ser, 
Thr, and Tyr) can be modified by DEPC in addition to other residues such as His and Lys, 
which allows for higher structural resolution to obtain insight into conformational changes 
of therapeutic proteins. From a close examination of the structural features near the reactive 
residues, we find that nearby hydrophobic residues are essential to the enhanced reactivity 
of certain Ser, Thr, and Tyr residues. 
Chapter 3 describes the use of DEPC-based CL-MS to detect conformational 
changes of a therapeutic mAb caused by heat stress. DEPC directly probes solvent 
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accessibility and the microenvironment of side chains, and any changes in DEPC reactivity 
are indicative of changes in protein conformation. Using rituximab as a model mAb 
therapeutic, we demonstrate the ability to site-specifically detect subtle HOS changes at 
the temperatures far below the melting point of the mAb therapeutic, changes that are not 
detected by common characterization techniques. At higher stress temperature, 
conformational changes and aggregation sites are also identified. 
In Chapter 4, we evaluated applicability of DEPC reaction kinetics to ensure site-
specific structural integrity of mAbs during labeling as reliable information about HOS can 
be obtained only when the protein’s structural integrity is preserved. We find that multi-
domain mAbs can withstand many more than one label, which contrasts to previously 
studied single-domain proteins. This more extensive labeling provides a more sensitive 
measure of structure, making DEPC-based CL-MS suitable for the HOS analyses of mAbs. 
Finally, Chapter 5 contains conclusions and future directions of this research. 
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CHAPTER 2 
 
COVALENT LABELING WITH DIETHYLPYROCARBONATE: SENSITIVE TO 
RESIDUE MICROENVIRONMENT, PROVIDING IMPROVED ANALYSIS OF 
PROTEIN HIGHER ORDER STRUCTURE BY MASS SPECTROMETRY 
This chapter is part of a research article published as: Limpikirati, P.; Pan, X.; Vachet, R. 
W., Covalent Labeling with Diethylpyrocarbonate: Sensitive to the Residue 
Microenvironment, Providing Improved Analysis of Protein Higher Order Structure by 
Mass Spectrometry. Analytical Chemistry 2019, 91 (13), 8516-8523. 
2.1 Introduction 
Covalent labeling (CL) with mass spectrometry (MS) has been increasingly utilized 
for the higher order structural analysis of proteins and for studying protein-protein 
interactions. From reactions with labeling reagents, a protein’s structural properties or 
interactions can be encoded into the mass of protein, which can then be read-out in a 
straightforward site-specific manner via MS-based bottom-up analysis. The differential 
reactivity of proteins under different conditions can be used to distinguish and deduce 
protein conformations, topologies, and/or binding sites. Common applications of CL-MS 
techniques include protein folding/unfolding,1-4 amyloid-forming proteins,5-9 protein-
ligand systems,10-13 and structural analysis of protein therapeutics,14-19 among others. 
Several review articles are dedicated to these relatively new MS-based structural 
techniques.20-26 The wider use of CL-MS techniques as an orthogonal method to probe 
structures of proteins results from their unique advantages over other analytical methods 
because of (a) a more rapid, sensitive, and sample-efficient analysis compared to NMR, X-
ray crystallography, and cryo-EM, (b) the ability to obtain much higher structural 
resolution than optical spectroscopy, i.e. residue-level structural information can be 
obtained from CL-MS, and (c) the limited label loss and scrambling due to irreversible 
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nature of labeling, compared to hydrogen-deuterium exchange (HDX) – MS. CL reagents 
modify solvent-exposed amino acid side chains either at specific residues (e.g. Lys 
labeling, Trp labeling, and carboxylic acid labeling) or a wide range of residues. In the 
latter case, non-specific reagents, e.g. hydroxyl radicals, carbenes, and 
diethylpyrocarbonate, can be used to gain greater structural resolution as they can probe a 
range of side chains simultaneously.  
Diethylpyrocarbonate (DEPC) is a simple-to-use, commercially-available reagent 
that reacts with a range of nucleophilic residues and the N-terminus of proteins.20, 21 Unlike 
radical and carbene reagents, DEPC can readily label proteins once added to solution and 
no specialized instrumentation is needed to generate a reactive species.20, 21 CL-MS 
methods based on DEPC have been extensively developed by our group.27-30 We have 
shown its capability to obtain insight into protein-ligand and protein-protein interactions 
and conformational changes of therapeutic proteins with a structural resolution as low as 8 
– 10 Å because up to 30% of surface exposed residues on proteins can be labeled.5-7, 12, 16 
In addition to Cys, His and Lys which are good nucleophiles that readily react with DEPC 
and account for around 10% coverage of the average protein sequence,31 side chains of 
weakly nucleophilic residues, such as Ser, Thr, and Tyr, are also found to be modified by 
DEPC. We find that in many different proteins,16, 19, 27-29 these weak nucleophiles can be 
modified by DEPC to a significant extent in intact proteins. The reactivity of these residues 
is valuable because Ser, Thr, and Tyr are the third, seventh, and sixteenth most commonly-
found amino acids in proteins, respectively, and the three of them account for about 17% 
of the average protein sequence.31 Indeed, the ability of DEPC to label Ser, Thr, and Tyr 
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residues in proteins increases the resolution of structural analyses using DEPC-based CL-
MS.  
While Ser, Thr, and Tyr residues in proteins can be reactive with DEPC, we have 
found a relatively poor correlation between the solvent accessibility of these residues and 
the extent of their DEPC reactivity, which contrasts with the more reactive Lys and His 
residues. This contrast suggests that microenvironment might affect the reactivity of Ser, 
Thr, and Tyr residues.16, 19, 27, 29 Previous experimental and computational studies suggest 
that the reactivity of amino acid side chains in proteins can be tuned by the 
microenvironment in different ways. Microenvironment can influence the acid/base 
characteristics and the reactivity of side chains because of polar interactions (i.e. charge-
charge, charge-dipole, or dipole-dipole)32, 33 or hydrophobic effects via Born or desolvation 
effects.32, 34-37 Steric hindrance as created by intra/intermolecular interactions of nearby 
side chains can limit reactivity.38 Also, certain microenvironments have been suggested to 
increase local concentrations of reactants and/or a reagent’s affinity for specific protein 
surface sites, thus enhancing the reactivity of some side chains.33, 39-41 In this work, we have 
investigated whether microenvironment effects explain the relatively poor correlation 
between DEPC reactivity and the solvent accessibility of Ser, Thr, and Tyr residues in 
proteins by comparing the DEPC reactivity of model peptides to proteins containing the 
same sequences but in a 3-dimensional context. We find that free peptides with Ser, Thr, 
and Tyr residues rarely react with DEPC under normal labeling conditions, whereas these 
residues in intact proteins can be very reactive. A careful study of the microenvironment 
around reactive Ser, Thr, and Tyr residues in proteins indicate that nearby hydrophobic 
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patches increase the reactivity of these residues, presumably through an increased local 
concentration effect. 
2.2 Experimental Section 
2.2.1 Materials 
Human full-length beta-2-microglobulin (2m) (#126-11) and recombinant human 
growth hormone (hGH) (#4769) were obtained from Lee Biosolutions (Maryland Heights, 
MO) and BioVision (Milpitas, CA), respectively. Bovine ubiquitin (#U6253), bradykinin 
(#B3259), diethylpyrocarbonate (DEPC) (#D5758), imidazole (#I5513), iodoacetamide 
(#I6125), tris(2-carboxyethyl)phosphine (TCEP) (#C4706), 3-morpholinopropane-1-
sulfonic acid (MOPS) (#M1254), and MOPS sodium salt (#M9381) were all purchased 
from Sigma-Aldrich (St. Louis, MO). Preproenkephalin was ordered from American 
Peptide Company (Sunnyvale, CA). Model peptides (Fmoc-DGXGG-amide, where X = H, 
K, Y, S, or T) were custom synthesized by GenScript USA Inc (Piscataway, NJ). PierceTM 
sulfo-NHS-Acetate (#26777) was obtained from Thermo Scientific (Waltham, MA). 
Sodium phosphate monobasic monohydrate (#S0710) was purchased from EM Science 
(Darmstadt, Hesse, Germany). Sodium phosphate dibasic anhydrous (#S374), N,N-
Dimethylformamide (#D119), formic acid (#A117), acetonitrile (#A998), and water (#W7) 
were obtained from Fisher Scientific (Fair Lawn, NJ). Immobilized trypsin (#EN-251) and 
chymotrypsin (#EN-261) were purchased from Princeton Separations (Adelphia, NJ). 
Amicon centrifugal filters (#UFC5010 and #UFC5003) were bought from EMD 
Millipore (Burlington, MA). All reagents used in this study have no known potential 
hazards.  
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2.2.2 Sample Preparation and DEPC Labeling Reactions 
β-2-microglobulin (2m) and ubiquitin were prepared in 10 mM MOPS buffer (pH 
7.4), while human growth hormone (hGH) was prepared in 10 mM phosphate buffer (pH 
8.0). Stock solutions of DEPC at a concentration of 69 mM were freshly prepared in 
acetonitrile. DEPC labeling of 2m (50 μM) was initiated by adding DEPC in a molar 
excess of 4, and the solution was reacted for 1 min at 37 °C. DEPC labeling of ubiquitin 
(10 μM) was performed at 37 °C for 5 min at a DEPC to protein molar ratio of 4 to 1. 
DEPC labeling of hGH (30 μM) was performed at 5:1 (DEPC:protein) molar ratio for 1 
min at 37 °C. In all cases, the reaction was quenched by the addition of imidazole at a 1:50 
DEPC to imidazole molar ratio, and the final amount of acetonitrile present was 1%, which 
does not perturb the structure of protein during the labeling. Labeling experiments with 
these intact proteins were performed in triplicate or quadruplicate. 
For the DEPC reactions of free peptides, peptides from the same proteins were first 
produced via proteolytic digestion (see Section 2.2.3). The N-termini of the peptides were 
acetylated before labeling them with DEPC. N-terminal blocking was achieved by reacting 
sulfo-NHS-acetate in a molar excess of 1,000 for 1 h at room temperature. The N-
terminally blocked peptides were labeled and quenched under the same conditions as those 
used for the intact proteins. It was important to ensure that the digested peptide 
concentrations were as close as possible to the intact protein concentration so that the 
DEPC reactivity for the free peptide and intact protein could be appropriately compared. 
To ensure that the concentrations were as close as possible, the proteolytic digest was 
prepared using a stock solution with a higher protein concentration, so that upon the various 
dilutions steps associated with digestion and acetylation, the final concentration of digested 
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peptides was identical to the intact protein concentration. Three or four replicate reactions 
and analyses were conducted on each protein digest.  
2.2.3 Proteolytic Digestion 
After the DEPC reactions, labeled 2m and hGH samples were desalted and 
preconcentrated in 10 mM MOPS buffer (pH 7.4) and 10 mM phosphate buffer (pH 8.0), 
respectively, using a centrifugal filter with a 10 kDa molecular weight cutoff (MWCO). 
The resulting samples were incubated with 10% (v/v) acetonitrile at 50°C for 45 min to 
denature the intact protein. TCEP was added in a 40-fold molar excess to reduce the 
disulfide bonds, and iodoacetamide was simultaneously added in an 80-fold molar excess 
to alkylate the reduced Cys residues. The samples were kept in the dark at room 
temperature for 20 min. Subsequently, the proteolytic enzyme was added to the resulting 
samples at a 1:10 (w/w) enzyme to substrate, and the protein was digested at 37 °C. 
Digestion was performed with immobilized chymotrypsin and trypsin for 2m (3 h) and 
immobilized trypsin for hGH (5 h). For ubiquitin, the labeled samples were desalted and 
preconcentrated in 25 mM ammonium bicarbonate (pH 7.8) using a centrifugal filter with 
a 3 kDa MWCO. 80% (v/v) acetonitrile was added to the desalted samples to denature the 
protein for 45 min at 50 °C. Overnight digestion was then performed with immobilized 
trypsin at a 1:10 (w/w) enzyme to substrate. Following digestion, the immobilized enzyme 
was separated from the protein digest by centrifugation. The supernatant was collected for 
LC-MS/MS analysis. 
To prepare peptides for DEPC labeling reactions, free peptides from the same 
proteins were produced via the same digestion conditions, except for ubiquitin 
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preconcentration where 10 mM MOPS buffer (pH 7.4) was used instead of ammonium 
bicarbonate in order not to suppress the subsequent N-terminal blocking and DEPC 
labeling reactions. 
2.2.4 Liquid Chromatography (LC) 
For on-line LC-MS/MS analyses, a labeled sample containing approximately 0.5 
μg ubiquitin peptides or 2 μg 2m or hGH peptides was loaded on a Thermo Scientific 
Easy-NanoLC 1000 system (Waltham, MA). Samples were loaded, trapped, and desalted 
on a Thermo Scientific Acclaim™ PepMap™ C18 trap column (2 cm x 75 μm, 3 μm 
particle size). Separation of peptides was performed using an Acclaim™ PepMap™ RSLC 
C18 nanocolumn (15 cm x 75 μm, 3 μm particle size; Thermo Scientific) with a flow rate 
of 300 nL/min. LC/MS-grade water (solvent A) and acetonitrile (solvent B), each 
containing 0.1% formic acid, were used as mobile phases. A linear gradient for separation 
of the peptides consisted of 0% B to 50% B over 60 min (2m), 0% B to 50% B over 30 
min (ubiquitin), and 0% B to 45% B over 35 min (hGH). 
2.2.5 Mass Spectrometry (MS) 
Mass spectra were acquired on a Thermo Scientific Orbitrap Fusion mass 
spectrometer (Waltham, MA). The nano-electrospray ionization (ESI) was operated using 
a positive mode at a needle voltage of 2100 V, and the ion transfer tube temperature was 
set to 325 ᴼC. Mass spectra were acquired on an Orbitrap analyzer, with a resolution of 
60,000. Tandem mass spectrometry (MS/MS) was conducted on a linear quadrupole ion 
trap using collision induced dissociation (CID) with a normalized collision energy of 35 
%. Tandem mass spectra were collected for most intense peptides with ion abundances 
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above 5000 from each mass spectral scan. Dynamic exclusion of 30 sec was activated after 
3 spectra were acquired for any given precursor ion within 5 sec. Mass detection during 
MS and MS/MS was performed in centroid mode to simplify data analysis. 
2.2.6 Peptide Identification and Peak Quantification 
Thermo Scientific Xcalibur™ software was used to visualize total ion 
chromatograms (TICs) from raw mass spectral data files obtained from the LC-MS/MS 
analyses using Thermo Scientific Orbitrap Fusion. Extracted ion chromatograms (XICs) of 
specific masses of unmodified and modified peptides were generated. Peptide sequencing 
and labeling site identification were achieved using CID tandem mass spectra. 
Assignments of b and y ions were performed with a mass tolerance of 0.5 Da. A custom 
software pipeline described previously16, 19 and specifically designed for protein CL-MS 
studies with DEPC was used to identify labeling sites and quantify peak areas. The search 
parameters were set as follows: a precursor mass tolerance of 10 ppm, 
carbamidomethylation of Cys as a variable modification, DEPC modification of His, Lys, 
Ser, Thr, Tyr, and N-terminus as a user variable modification. DEPC modification results 
in mass addition of 72.0211 Da (Figure 2.1). For N-terminally blocked peptides, 
acetylation of N-termini was set as a fixed modification, while its side reaction at Lys was 
set as a variable modification. Acetylation of N-terminus or Lys leads to mass addition of 
42.0106 Da (Figure 2.2).  
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Figure 2.1: DEPC labeling reactions of Cys, His, Lys, Tyr, Ser, and Thr 
 
 
 
Figure 2.2: Acetylation reaction of peptide N-terminus 
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Figure 2.3: Illustration of how the DEPC modification levels are calculated.  
After DEPC labeling and proteolytic digestion, (a) LC-MS analysis of the digested protein 
is performed. Peak areas of (b) unlabeled and (c) labeled peptides in a chromatogram are 
used to calculate the labeling percentage. During LC-MS, peptides are subjected to CID 
MS/MS. Tandem mass spectra of (d) unlabeled and (e) & (f) labeled peptides obtained at 
specific retention time are used for peptide sequencing and/or identification of DEPC 
labeled site. 
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2.2.7 Determination of Modification Percentages 
DEPC modification levels (%) of each labeled residue were calculated as follows. 
(Equation 2.1) 
              % 𝐷𝐸𝑃𝐶 𝑙𝑎𝑏𝑒𝑙𝑖𝑛𝑔 =  
∑ ∑ 𝐴𝑖,𝑧
𝑚𝑜𝑑𝑖𝑚
𝑧=1
𝑛
𝑖=1
∑ ∑ 𝐴𝑖,𝑧
𝑚𝑜𝑑𝑖𝑚
𝑧=1
𝑛
𝑖=1 + ∑ ∑ 𝐴𝑖,𝑧
𝑢𝑛𝑚𝑜𝑑𝑖𝑚
𝑧=1
𝑛
𝑖=1
 × 100              (2.1) 
where 𝐴𝑖,𝑧
𝑢𝑛𝑚𝑜𝑑𝑖 is the peak area of DEPC-unmodified peptide whose sequence (i) contains 
the residue of interest and possesses a certain charge state (z), and  𝐴𝑖,𝑧
𝑚𝑜𝑑𝑖 is the peak area 
of peptide in which the residue of interest is DEPC-modified. An illustration of this 
calculation can be found in Figure 2.3.  
Note that DEPC modification percentages calculated by Equation 2.1 are only used 
for the relative quantitation, i.e. comparing the DEPC labeling at the same residue under 
different conditions (labeling on intact protein vs. protein digest). The modification levels 
do not reflect the absolute quantitation of modified species as the addition of a carbethoxyl 
group to the modified peptide and different LC solvent conditions during gradient elution 
of peptides result in different ionization efficiencies of the unmodified and modified 
peptides. 
2.2.8 Solvent Accessible Surface Area (SASA) calculation 
SASA of amino acid side chain was calculated from the Protein Data Bank (PDB) 
atomic coordinates using GETAREA 1.0 beta.42 A probe radius of 1.4 Å which represents 
the van der Waals sphere of water was used in a calculation. Atomic coordinates of the 3D 
structures of 2m (PDB ID: 1JNJ),43 ubiquitin (PDB ID: 1UBQ),44 and hGH (PDB ID: 
1HGU)45 were submitted to calculate individual side-chain SASA. Note that human and 
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bovine ubiquitin have the same amino acid sequence. Even though bovine ubiquitin was 
used in experiments, the SASA and structural features considered in this study were 
obtained from the PDB structure of human ubiquitin (PDB ID: 1UBQ). The calculated 
SASA was compared to the surface area of the side chain in a Gly-X-Gly tripeptide, where 
X is a side chain of interest, to generate a percent ratio (%SASA).  
2.2.9 DEPC Labeling and LC-MS/MS Analyses of Model Peptides  
2.2.9.1 DEPC Labeling Reactions 
A lyophilized powder of model peptide (Fmoc-DGXGG-amide, where X = H, K, 
Y, S, or T) was first reconstituted in water (His and Lys) or dimethylformamide (Ser, Thr, 
and Tyr), and the resulting solution of peptide was then diluted in 10 mM MOPS buffer 
(pH 7.4) to make a final solution. Each model peptide (50 μM) was reacted with DEPC at 
37 °C for 5 min at a DEPC to protein molar ratio of 5 to 1 (His, Lys, and Tyr) or 50 to 1 
(Ser and Thr). The reaction was then quenched by the addition of imidazole at a 1:50 DEPC 
to imidazole molar ratio. 
Bradykinin and preproenkephalin peptides were reconstituted in water. A peptide 
mixture was prepared in 10 mM MOPS buffer (pH 7.4) containing 10 μM of each peptide. 
The N-termini of the peptides were acetylated before labeling them with DEPC. The N-
terminal blocking was initiated by adding sulfo-NHS-acetate in a molar excess of 600, and 
the solution was reacted for 1 h at room temperature. Subsequently, the peptide mixture 
was reacted with DEPC at 37 °C for 5 min at a molar excess of 50. The reaction was then 
quenched by the addition of imidazole. 
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2.2.9.2 Liquid Chromatography (LC) 
Following quenching online LC-MS/MS analyses were conducted on a Thermo 
Scientific Ultimate 3000 HPLC (Waltham, MA). LC separation was performed on a 
Thermo Scientific Acclaim™ PepMap™ RSLC C18 column (15 cm x 300 μm, 2 μm 
particle size). LC/MS-grade water (solvent A) and acetonitrile (solvent B), each containing 
0.1% formic acid, were used as mobile phases. A flow rate of 4 μL/min was used, and 1 
μL of sample was first loaded and desalted at 5%B during the first 5 min. An isocratic 
elution mode at 40%B over 15 min was then applied to separate unmodified and modified 
peptides.  
 For a mixture of bradykinin and preproenkephalin peptides, 5 μL of sample was 
first loaded and desalted during the first 5 min. After that a linear gradient was increased 
from 5%B to 50%B over 50 min to separate unmodified and modified peptides. 
2.2.9.3 Mass Spectrometry (MS) 
Mass spectra from the online LC-MS/MS were acquired on a Bruker AmaZon 
quadrupole ion trap (Billerica, MA). The electrospray needle voltage was operated using a 
positive mode at 4 kV, and the capillary temperature was set to 300 ᴼC. Tandem spectra 
were collected for the top intense species with ion abundances above 1,000 from each mass 
spectrum. Collisional-induced dissociation (CID) was conducted with a ramp energy 60% 
to 180% of 1.5 V amplitude. 
2.2.9.4 Peptide Identification and Peak Quantification 
Bruker Compass™ Data Analysis software was used to reconstruct extracted ion 
chromatograms (XICs) of unmodified and modified peptides. Peptide identification and 
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peak quantification were performed in a manual manner using tandem spectra and mass 
spectral peak areas, respectively. DEPC modification levels (%CL) of each labeled residue 
were calculated using Equation 2.1 (see Section 2.2.7). 
2.2.10 LC-MS/MS Analyses of Chymotryptic Protein Digests  
Chymotryptic digests obtained from the DEPC reactions on 2m intact proteins 
underwent LC-MS/MS analyses using a Thermo Scientific Dionex Ultimate 3000 HPLC 
(Waltham, MA) and a Bruker AmaZon quadrupole ion trap mass spectrometer (Billerica, 
MA).  
2.2.10.1 Liquid Chromatography (LC) 
Chymotryptic digests obtained from the DEPC reactions on 2m intact proteins 
were analyzed using a Thermo Scientific Dionex Ultimate 3000 HPLC (Waltham, MA). 5 
μL of sample was loaded and separation of peptides was performed on a Thermo Scientific 
Acclaim™ PepMap™ RSLC C18 column (15 cm x 300 μm, 2 μm particle size). A flow 
rate of 4 μL/min was used, and desalting was performed at 5%B during the first 5 min after 
sample injection. A 50-min linear gradient was applied with %B increased from 5%B to 
50%B to separate peptides. The gradient was finally elevated to and held at 95%B to flush 
a column. 
2.2.10.2 Mass Spectrometry (MS) 
Mass spectra were acquired on a Bruker AmaZon quadrupole ion trap (Billerica, 
MA). The electrospray needle voltage was kept at 4 kV (positive mode), and the capillary 
temperature was set to 300ᴼC. The top intense peptides with ion abundances above 1,000 
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from each mass spectrum were selected for MS/MS acquisition. CID was conducted at 1.5 
V amplitude with a ramp energy 60% to 180%. Because of the large number of measured 
peaks, active exclusion of 0.5 min was activated after 2 spectra were acquired for any given 
precursor ion. 
2.2.10.3 Peptide Identification and Peak Quantification 
See Section 2.2.9.4 
 
2.3 Results and Discussion 
2.3.1 DEPC Labeling Reactivity of Weakly Nucleophilic Residues 
Solvent accessible nucleophilic side chains (Cys, His, Lys, Thr, Tyr, Ser) and N-
termini of proteins can be modified by DEPC via a nucleophilic substitution at a carbonyl 
group (Figure 2.1) to yield a mass addition of +72.021 Da. The specific modification sites 
in proteins can be identified and semi-quantified using MS-based bottom-up sequence 
analysis (Figure 2.3). As indicated in the introduction, Ser, Thr, and Tyr residues in 
proteins are readily modified by DEPC. Indeed, from four proteins studied previously, 
including equine myoglobin,29 human  2m,16, 29 hGH,16 murine IgG1,16 and rituximab,19 
which have a total of 1,770 amino acids, 154 out of 198 Ser residues, 100 out of 136 Thr 
residues, and 48 out of 71 Tyr residues were labeled in intact proteins at relative levels 
ranging from 0.01 to 90%. In stark contrast, these residues in small peptides are relatively 
unreactive after 5 min with DEPC at a DEPC:peptide molar ratio of 5:1, which is the 
commonly used time and labeling ratio for intact proteins. As an example, Ser and Thr 
residues in the model peptide sequence of Fmoc-DGXGG-amide, where X = Ser or Thr, 
are completely unreactive (Figure 2.4a and b), whereas the same peptide with Tyr (i.e. 
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Fmoc-DGYGG-amide) produces a relative modification extent of 5% (Figure 2.4c). By 
comparison, the same peptide sequence with His (Fmoc-DGHGG-amide) and Lys (Fmoc-
DGKGG-amide) are much more reactive, having modification percentages of 88% and 
43%, respectively, under the same labeling conditions (Figure 2.4d and e).  
 
Figure 2.4: DEPC labeling of model peptides.  
Extracted ion chromatograms (XICs, left) of the +1 ions of the unmodified and DEPC-
modified peptides Fmoc-DGXGG-amide, where X is a DEPC modifiable residue (a) Ser, 
(b) Thr, (c) Tyr, (d) His, or (e) Lys, after allowing the peptide to react with DEPC at a 
DEPC:peptide molar ratio of 5:1. Modification percentages are calculated from peak areas 
in XICs. Tandem mass spectra acquired after CID of the labeled precursor ions are used to 
confirm the site of modification. MS/MS assignments of the modified peptides are shown 
in Figure 2.5. Note that two chromatographic peaks for the labeled peptide in (d) are 
observed because the His side chain has two nitrogens that are separately labeled to 
produce isomers that can be separated by LC. 
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Figure 2.5: DEPC labeling of model peptides.  
MS/MS assignments for nucleophilic residues that are modified in model peptides Fmoc-
DGXGG-amide, where X is a DEPC modifiable residue (a) Tyr, (b) His, or (c) Lys, after 
allowing the peptide to react with DEPC at a molar ratio of 5:1 (DEPC:peptide). 
 
 
 
 
Figure 2.6: DEPC labeling of model peptides.  
Extracted ion chromatograms (XICs, left) of the +1 ions of the unmodified and DEPC-
modified peptides Fmoc-DGXGG-amide, where X is a DEPC modifiable (a) Ser or (b) 
Thr, after allowing the peptide to react with DEPC at a DEPC:peptide molar ratio of 50:1. 
Modification percentages are calculated from peak areas in XIC. Tandem mass spectra 
(right) are used to confirm the site of modification. MS/MS assignment of the modified 
peptide is shown above the XICs. 
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Modification of Ser and Thr residues in this peptide is still negligible (0% and 0.3%, 
respectively) even with a 50-fold molar excess of DEPC (Figure 2.6). The same lack of 
reactivity at Ser, Thr, and Tyr residues is observed in other peptides too, including 
bradykinin and preproenkephalin, even when the N-terminus is blocked to reduce 
competitive reaction with DEPC (Figure 2.7). 
 
Figure 2.7: DEPC labeling of bradykinin and preproenkephalin peptides.  
Extracted ion chromatograms (XICs, left) of the +2 ions of the unmodified and DEPC-
modified versions of the N-terminally blocked peptides (a) bradykinin, (b) & (c) 
preproenkephalin, after reacting the peptide mixture with DEPC at a DEPC to peptide 
molar ratio of 50 to 1. Tyr and Ser residues in these peptides are unreactive with DEPC 
even when the other reactive site (N-terminus) are blocked via acetylation with sulfo-NHS-
acetate in these peptides (Figure 2.2). Tandem mass spectra (right) were used to confirm 
the site of modification. MS/MS assignments of the modified peptides are shown above 
the XICs. 
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2.3.2 Influence of Higher-Order Structure on the Covalent Labeling Based Structural 
Analysis of Proteins  
One possible reason for the significant reactivity of Ser, Thr, and Tyr residues in 
proteins but not in free peptides could be due to local sequence effects that are not fully 
accounted for in the model peptides. To test this possibility, we compared the labeling 
reactivity of intact proteins with their peptide fragments as produced by proteolysis (Figure 
2.8). In the first scenario (Figure 2.8a), three proteins, β2m, ubiquitin, and hGH, were 
reacted with DEPC under native conditions (37 °C, pH ~ 7.5) using a DEPC molar excess 
of 4 or 5, which has previously been found to prevent labeling-induced structural 
perturbations to proteins during the labeling reaction.12, 16, 27 In the second scenario (Figure 
2.8b), peptide fragments from the same three proteins were first produced via the same 
digestion conditions and then reacted with DEPC under the same labeling conditions. In 
this second set of experiments, the N-termini of the peptide fragments were blocked via 
acetylation with sulfo-NHS-acetate (Figure 2.2) before labeling them with DEPC because 
many new N-termini are produced upon protein digestion and these newly-formed N-
termini could potentially outcompete Ser, Thr, and Tyr residues.  
Upon comparing the modification extents of Ser, Thr, and Tyr residues under the 
two DEPC reaction scenarios shown in Figure 2.8, we find that these residues are rarely 
modified in free peptides but are modified in the intact proteins (Table 2.1). When intact 
proteins are reacted with DEPC, 18 out of 67 Ser, Thr, and Tyr residues (9 in 2m, 2 in 
ubiquitin, and 7 in hGH) are labeled at levels ranging from 0.02% to 64%. When the same 
proteins are first digested into peptide fragments, N-terminally blocked, and then reacted 
with DEPC under the same labeling conditions, only two residues in the peptide fragments 
are found to be modified, and these are modified at very low levels (< 3%) (see MS/MS 
71 
 
data in Figure 2.9).  Moreover, only one of these residues (Tyr136 in hGH) is modified in 
the intact protein. All modifiable Ser, Thr, and Tyr residues along with all the modified His 
and Lys sites (His, Lys, Ser, Thr, Tyr) and their labeling levels in 2m, ubiquitin, and hGH 
are listed in Tables A.1, A.2, and A.3 in Appendix A, respectively. Together, the results 
indicate that the weak nucleophilic side chains, without the influence of protein higher-
order structure, are poorly reactive with DEPC. These observations imply that the 
microenvironment around specific Ser, Thr, and Tyr residues in proteins tune their 
reactivity such that they can only be labeled in the 3D context of the protein.        
 
 
Figure 2.8: Experimental workflow to evaluate the influence of higher-order 
structure (i.e. microenvironment effects) on covalent labeling by comparing the 
DEPC labeling reactivity of (a) intact proteins with that of (b) their N-terminally 
acetylated peptide fragments. 
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Table 2.1: DEPC modification percentages of Ser, Thr, and Tyr residues in intact 
proteins and peptide fragments for 2m, ubiquitin, and hGH.  
Each experiment was performed in triplicate or quadruplicate (n = 3 or 4). Error bars shown 
in a table are standard deviations. Listed are side-chain solvent accessible surface areas 
(SASA) and brief details of the microenvironment around each residue. The presence (✔) 
or absence (✖) of nearby charged polar contact(s) and hydrophobic residue(s) within 4 Å 
and 6 Å, respectively, are presented in a table. (+) and (-) represent positively charged and 
negatively charged polar contacts, respectively. 
 
Residue DEPC modification (%) SASA 
(%)* 
Microenvironment 
Charged polar 
contact(s) 
[within 4 Å] 
Hydrophobic 
residue(s) 
[within 6 Å] Intact protein Peptide fragments 
β-2-microglobulin (β2m) 
T4 59 ± 5 
(N-term & T4) 
N.D.
ǂ
 
81.5  ✖ ✔ 
Y10 15 ± 2 N.D. 41.6 ✖ ✔ 
S11 3.0 ± 0.5 N.D. 10.3  ✖ ✔ 
S20 N.D. 2.6 ± 0.6 61.6 H-bonding with Glu (-) ✖ 
S33 1.6 ± 0.4 N.D. 70.1  ✖ ✔ 
S55 0.6 ± 0.3 N.D. 55.3  ✖ ✔ 
S57 1.8 ± 0.9 N.D. 34.9 H-bonding with Asp (-) ✔ 
S61 10 ± 1 N.D. 28.1 H-bonding with Arg (+) ✔ 
Y63 0.3 ± 0.2 N.D. 27.7  ✖ ✔ 
Y66 0.3 ± 0.2 N.D. 7.5 ✖ ✔ 
Ubiquitin 
T7 13 ± 2 N.D. 14.2 ✖ ✔ 
S65 2.4 ± 0.2 N.D. 9.2 ✖ ✔ 
Human growth hormone (hGH)  
T28 1.3 ± 0.6 N.D. 10.7 H-bonding with Asp (-) ✔ 
Y29 0.2 ± 0.1 N.D. 4.1 H-bonding with Lys (+) ✔ 
Y36 0.4 ± 0.3 N.D. 37.2 ✖ ✔ 
S56 0.02 ± 0.01 N.D. 20.8 ✖ ✔ 
S58 64 ± 4 N.D. 3.3 ✖ ✔ 
T136 0.15 ± 0.09 0.1 ± 0.1 35.9 H-bonding with Arg (+) ✔ 
Y144 0.66 ± 0.05 N.D. 31.1 ✖ ✔ 
 
* SASA calculation is explained in detail in Section 2.2.8. 
ǂ N.D. = not detected (less than DEPC labeling threshold of 0.01%19) 
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Figure 2.9: MS/MS assignments for weakly nucleophilic residues that are modified at 
peptide level.  
When reacting the N-terminally blocked peptides at DEPC to peptide molar ratios of 4 to 
1 or 5 to 1, the reactivity of the Ser, Thr, and Tyr residues in free peptides are found to be 
lower than in the intact proteins. Only two residues in three model proteins are found to be 
modified. This Figure S-hows tandem mass spectra acquired after CID of (a) HN(Ac)-
SRHPAENGK(Ac)S*NFL-COOH peptide from chymotryptic digest of -2-microglobulin 
(2m), where Ser20 is the DEPC modification site, and (b) HN(Ac)-T*GQIFK-COOH 
peptide from tryptic digest of human growth hormone (hGH), where Thr136 is the 
modification site. Product ions with DEPC-modified residue have mass addition of 72.02 
Da while acetylated N-terminus or Lys contributes to mass addition of 42.01 Da. 
 
2.3.3 Identifying Structural Features that Tune the Reactivity of Weak Nucleophiles  
To identify the protein structural factors that affect the reactivity of Ser, Thr, and 
Tyr residues, we considered SASA and microenvironment effects such as polar and 
hydrophobic interactions. SASAs of the side chains were calculated using GETAREA,42 
and insight into the local microenvironment around each side chain was obtained from the 
protein’s 3D structure using the molecular visualization program PyMOL.46 SASA is 
typically considered an important criteria for residue reactivity in CL-MS, but we find a 
relatively poor correlation between SASA and Ser, Thr, and Tyr reactivity. Typically, side 
chains with %SASA below 20% are considered buried;42, 47 however, we do not see a 
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significant difference in the number of Ser, Thr, and Tyr residues having %SASA values 
above 20% between the sets of labeled and unlabeled residues in the three proteins. Indeed, 
of the 18 Ser, Thr, and Tyr residues labeled in the proteins, only 11 (or 61%) have SASA 
percentages above 20%, whereas in the unlabeled Ser, Thr, and Tyr residues, 34 of the 44 
(or 77%) have SASA percentages above 20% (Figure 2.10). Hence, solvent accessibility 
does not significantly influence the reactivity of these weakly nucleophilic residues, which 
is consistent with the previously observed poor correlation between SASA and reactivity 
of these residues.16,19,27,29 We also considered if protein secondary structure affects the 
reactivity of these side chains, but we do not find a preference for -helix, -strand, or 
random coil structure among the residues that are found to be labeled (see Tables A.1 to 
A.3). 
 
Figure 2.10: Flow chart summarizing the covalent labeling results and the structural 
features of weakly nucleophilic residues in 2m, ubiquitin, and hGH.  
The numbers of these residues that are found to be labeled or unlabeled in (a) intact proteins 
and (b) peptide fragments are shown in the chart. Structural features that could affect the 
labeling reactivity of these residues, such as the presence of nearby hydrophobic residues 
or charged residues and the solvent accessible surface area (SASA) above 20%, are 
indicated in (c). The fraction of labeled or unlabeled residues that have each specific 
structural feature is shown in the chart. For the unlabeled Ser, Thr, and Tyr residues, 
structural features are investigated for 44 out of 49 residues as 5 of the residues in hGH are 
not resolved in the crystal structure (PDB ID: 1HGU).45 
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The microenvironment of a side chain can influence the acid/base characteristics of 
side chains because of polar interactions (charge-charge interactions, charge-dipole 
interactions, dipole-dipole interactions)32, 33 or hydrophobic effects (i.e. Born or 
desolvation effect).32, 34-37 In chemical labeling experiments conducted with 
monofunctional NHS esters, O-acylation of Ser, Thr, and Tyr was suggested to be 
dependent on protein/peptide conformation and intramolecular interactions.33, 48-50 
Hydrogen bonding and other non-covalent interactions can cause changes in a side chain’s 
protonation state and thus affect its nucleophilicity.33, 51, 52 To explore this possible effect, 
we examined adjacent charged residues (Arg, Lys, Asp, Glu) and hydrogen bonding 
interactions between these residues and Ser, Thr, and Tyr. Nearby positively-charged 
residues (Arg, Lys) can presumably stabilize deprotonated forms of these weak 
nucleophiles, increasing their nucleophilicity, and negatively-charged residues (Asp, Glu) 
that form an ionic hydrogen bond with the hydroxyl group of Ser, Thr, and Tyr side chains 
might also increase their nucleophilicity (Figure 2.11). Only interactions between these 
acidic and basic groups and Ser, Thr, or Tyr residues within 4 Å were considered as this is 
a common distance over which such interactions typically have an effect.53-56 From our 
results, though, there seems to be very little correlation between nearby charged residues 
and Ser, Thr, and Tyr labeling in proteins. Only 28% of the labeled Ser, Thr, and Tyr 
residues have nearby charged polar contacts, which is very similar to the 20% of the 
unlabeled residues that have nearby charged residues (Figure 2.10). Perhaps, the charged 
polar contacts cannot sufficiently tune the nucleophilicity of Ser, Thr, and Tyr residues to 
a degree that it can enhance reactivity of these side chains.  
 
76 
 
 
 
Figure 2.11: Molecular schemes showing how both positively-charged and negatively-
charged residues could affect Ser, Thr, and Tyr.  
(a) Deprotonated forms of these weak nucleophiles can presumably be stabilized by nearby 
positively-charged residues (Arg, Lys), increasing their nucleophilicity, and (b) the 
hydroxyl group of Ser, Thr, and Tyr side chains can form an ionic hydrogen bond with 
nearby negatively-charged residues (Asp, Glu), which might also increase their 
nucleophilicity. 
The presence of nearby hydrophobic residues was also considered as such groups 
might increase the local concentration of DEPC, thereby enhancing the reactivity of Ser, 
Thr, and Tyr residues towards chemical labeling.33, 39 Even though DEPC is readily soluble 
in aqueous solutions at moderate concentrations (up to 40 mM) which is useful for labeling 
proteins,57 this molecule is quite hydrophobic and has limited solubility in water (~ 0.1%). 
We hypothesized that perhaps the hydrophobicity of a protein’s local structure may 
77 
 
enhance Ser, Thr, and Tyr reactivity by increasing DEPC’s local concentration. To study 
the potential influence of a hydrophobic microenvironment, we searched for the presence 
of hydrophobic side chains (Ala, Ile, Leu, Met, Pro, Val) and aromatic sidechains (Phe, 
Trp, Tyr) within 6 Å. A distance of 6 Å was chosen because of the molecular dimensions 
of DEPC, which is a symmetrical molecule having two electrophilic carbonyls, one of 
which could be positioned close enough to the hydroxyl group of Ser, Thr, or Tyr if it 
interacted with a hydrophobic group 6 Å away (Figure 2.12). Interestingly, each of the 
Ser, Thr, and Tyr residues that are found to be labeled in these model proteins sits close to 
at least one hydrophobic side chain (Figures 2.10 and 2.13). In contrast, only half of the 
unlabeled Ser, Thr, and Tyr residues have nearby hydrophobic residues (Figure 2.10). 
These results strongly suggest that hydrophobicity is an important factor that enhances the 
labeling reactivity of Ser, Thr, and Tyr residues in intact proteins. We propose that elevated 
local DEPC concentrations near these hydrophobic groups explain this enhanced reactivity. 
An analogous idea was suggested by Zenobi et al. to explain the enhanced cross-linking 
reactivity of Ser, Thr, and Tyr with bifunctional NHS esters to nearby Lys or His residues.33 
They argued that the high local concentration of the NHS cross-linker after formation of 
an N-acylated intermediate at His or Lys would allow the O-acylation of weak nucleophiles 
to occur at higher reaction yield. Similarly, a recent study performed by Tetin and 
coworkers suggested that a fluorescent label AlexaFluor488 was predominantly conjugated 
to Lys residues located in the proximity of Trp and Tyr residues.39 
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Figure 2.12: Mechanism of the nucleophilic substitution at the carbonyl group for 
DEPC covalent labeling.  
Our study indicates that hydrophobicity contributes to the higher labeling reactivity of 
certain Ser, Thr, and Tyr residues, due to the increase in local concentration of DEPC near 
these residues. 
 
 
Figure 2.13: Ser, Thr, and Tyr residues that are found to be labeled by DEPC in the 
proteins (a) 2m, (b) ubiquitin, and (c) hGH.  
Side chains of the labeled residues are shown in green. Dotted spheres represent the nearby 
hydrophobic side chains that contribute to the higher DEPC labeling reactivity of these 
residues. 
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To further investigate the idea that the increased local DEPC concentration can 
drive the reactivity of Ser, Thr, and Tyr residues, we labeled 2m, ubiquitin, and hGH 
peptides at 10-fold higher DEPC concentrations (i.e. 50:1 DEPC:peptide). Whereas only 
two Ser, Thr, or Tyr residues out of 67 are labeled at low DEPC concentration (i.e. 4:1 or 
5:1 DEPC:peptide), we find seven residues are modified at the higher DEPC concentration 
(Table 2). Obviously, this number of labeled Ser, Thr, and Tyr residues is still lower than 
in intact proteins, suggesting that the environment of the folded protein is still probably 
important for forming the necessary hydrophobic microenvironment to increase the DEPC 
local concentration sufficiently. 
The importance of nearby hydrophobic groups for enhancing Ser, Thr, or Tyr 
reactivity may explain why the SASA of side chains does not correlate well with extent of 
reactivity for these residues. This fact can be illustrated by considering the distribution of 
%SASA values for both labeled and unlabeled Ser, Thr, and Tyr residues in the three 
proteins (Figure 2.14). Most of the labeled residues have SASA percentages between 5% 
and 45%, and only 17% of the residues have SASA values above 45%. In contrast, almost 
half of the unlabeled residues have SASA above 45%. As expected, we see a decrease in 
the average number of nearby hydrophobic sites when SASA increases (red bars in Figure 
2.14). Between SASA values of 25% and 45%, there is a ‘sweet spot’ where many Ser, 
Thr, and Tyr residues are found to be labeled. In this range, the Ser, Thr, and Tyr residues 
have enough nearby hydrophobic sites, yet are still solvent accessible enough for DEPC to 
react with them. The unlabeled side chains are too exposed to the aqueous environment, 
and lack nearby hydrophobic groups to enhance their reactivity. Together, our findings 
indicate that a hydrophobic microenvironment influences Ser, Thr, and Tyr reactivity 
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towards DEPC labeling in intact proteins more than SASA. Additional studies are needed 
to further verify this effect, but the reactivity of specific Ser, Thr, and Tyr residues could 
be used to provide insight into the local microenvironment around these residues and could 
be useful in CL-MS based protein structural prediction. For example, the reactivity of 
specific Ser, Thr, and Tyr residues could indicate the presence of nearby hydrophobic 
residues, and this information could be used to improve confidence in certain structural 
models.  
 
Figure 2.14: %SASA values and the average number of nearby hydrophobic sites for 
both labeled and unlabeled Ser, Thr, and Tyr residues in the three proteins 
Histograms illustrating the distribution of %SASA values for both labeled (green) and 
unlabeled (blue) Ser, Thr, and Tyr residues in the proteins 2m, ubiquitin, and hGH. (See 
left axis.) Also included is the distribution of the average number of nearby hydrophobic 
sites (red) per Ser/Thr/Tyr residue in each bin of SASA values. (See right axis.)  
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Table 2.2: DEPC modification percentages of weakly nucleophilic residues in intact 
proteins and peptide fragments of 2m, ubiquitin, and hGH.  
DEPC to protein/peptide molar ratios used in the study are specified in the column headers. 
Each experiment was performed in triplicate or quadruplicate (n = 3 or 4). Error bars shown 
in a table are standard deviations. 
 
Residue DEPC modification (%) 
Intact protein 
(CL at 4X/5X 
molar excess) 
Peptide fragments 
(CL at 4X or 5X 
molar excess) 
Peptide fragments 
(CL at 50X 
molar excess) 
β-2-microglobulin (β2m) 
T4 59 ± 5 
(N-term & T4) 
N.D. ǂ 0.02 ± 0.01 
Y10 15 ± 2 N.D. 3.9 ± 0.8 
S11 3.0 ± 0.5 N.D. 0.02 ± 0.01 
S20 N.D. 2.6 ± 0.6 N.D. 
S33 1.6 ± 0.4 N.D. N.D. 
S55 0.6 ± 0.3 N.D. N.D. 
S57 1.8 ± 0.9 N.D. N.D. 
S61 10 ± 1 N.D. N.D. 
Y63 0.3 ± 0.2 N.D. N.D. 
Y66 0.3 ± 0.2 N.D. N.D. 
Y67 N.D. N.D. 1.3 ± 0.6 
Ubiquitin 
T7 13 ± 2 N.D. N.D. 
S65 2.4 ± 0.2 N.D. N.D. 
Human growth hormone (hGH) 
T28 1.3 ± 0.6 N.D. N.D. 
Y29 0.2 ± 0.1 N.D. N.D. 
Y36 0.4 ± 0.3 N.D. N.D. 
S56 0.02 ± 0.01 N.D. N.D. 
S58 64 ± 4 N.D. N.D. 
S107 N.D. N.D. 0.2 ± 0.1 
T136 0.15 ± 0.09 0.1 ± 0.1 0.08 ± 0.02 
Y144 0.66 ± 0.05 N.D. 0.02 ± 0.03 
 
ǂ N.D. = not detected (less than DEPC labeling threshold of 0.01%19) 
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2.4 Conclusion 
DEPC is capable of modifying weakly nucleophilic residues such as Ser, Thr, and 
Tyr in intact proteins, allowing for higher structural resolution. The same reagent, however, 
is essentially unreactive with Ser, Thr, and Tyr residues in small peptides, suggesting that 
the 3D context of the protein’s structure is able to tune the reactivity of these residues with 
DEPC. By comparing the DEPC reactivity of three intact proteins and their proteolytic 
fragments, we are able to identify the chemical environments that most influence the 
reactivity of these side chains in intact proteins. Interestingly, we find evidence that the 
presence of nearby hydrophobic residues increases the DEPC reactivity of Ser, Thr, and 
Tyr residues in intact proteins. This finding suggests that the reactivity of certain Ser, Thr, 
and Tyr residues could be used to indicate the presence of nearby hydrophobic groups and 
thus could be used as constraints in protein structure prediction.   
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CHAPTER 3 
 
COVALENT LABELING AND MASS SPECTROMETRY REVEAL SUBTLE 
HIGHER ORDER STRUCTURAL CHANGES FOR ANTIBODY 
THERAPEUTICS 
This chapter is part of a research article published as: Limpikirati, P.;  Hale, J. E.;  
Hazelbaker, M.;  Huang, Y.;  Jia, Z.;  Yazdani, M.;  Graban, E. M.;  Vaughan, R. C.; 
Vachet, R. W., Covalent labeling and mass spectrometry reveal subtle higher order 
structural changes for antibody therapeutics. mAbs 2019, 11 (3), 463-476. 
3.1 Introduction 
Monoclonal antibodies (mAbs) are among the fastest growing categories of 
therapeutics in the pharmaceutical industry.1-3 By 2020, around 70 mAb products are 
anticipated to be available on the market and their global sales are predicted to be nearly 
$125 billion, representing 15% of total pharmaceutical sales.1, 4 Unlike small molecule 
drugs, the higher-order structure (HOS) of mAbs contributes to the greater binding 
specificity towards drug targets, resulting in higher therapeutic efficacy and less adverse 
effects. Changes in HOS upon storage or mishandling, e.g., protein misfolding and 
aggregation, however, can lead to reduced stability, loss of efficacy, unwanted actions, or 
possible immunogenicity.5, 6 Monitoring HOS is thus essential to ensure efficacy and safety 
of mAb therapeutics throughout a product life cycle – from drug manufacturing to dose 
administration.6-9 Any new, structurally-informative method could be useful for biologics 
license applications (BLAs) because HOS characterization is required in the stability, lot-
to-lot comparability, and biosimilar studies of antibody therapeutics.6, 9, 10  
Detecting HOS changes of mAbs is challenging given their size and the 
multidomain nature. The current toolbox for HOS analysis of protein therapeutics has 
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limitations.5, 6, 8  X-ray crystallography and nuclear magnetic resonance (NMR) 
spectroscopy can provide atomic-level resolution of protein structure, but these methods 
are time- and sample-consuming, and not amenable to all proteins. In contrast, biophysical 
techniques such as differential scanning calorimetry (DSC), dynamic light scattering 
(DLS), fluorescence spectroscopy, infrared (IR) spectroscopy, and circular dichroism (CD) 
spectroscopy are rapid, but provide only low-resolution ensemble averages of protein 
global conformation. These low-resolution methods still are commonly used to 
characterize HOS of mAb therapeutics,11-19 even though they do not provide information 
about small localized conformational changes, some of which may be potentially 
significant for drug efficacy and safety. Hence, there is a growing need for rapid and 
sample-efficient analytical tools with moderate resolution that can characterize HOS of 
therapeutic mAbs at the amino acid level. Current regulatory guidelines do not specify what 
method(s) should be used in characterizing HOS of biologics,20-26 allowing for the 
development of novel analytical techniques.  
Mass spectrometry (MS) has become one of the most powerful methods for the 
analysis of proteins. From a recent evaluation of BLAs, the use of MS to characterize 
primary structure and HOS of protein therapeutics has increased in recent years.27 
Characterizing HOS using MS requires that a protein’s structural information is encoded 
into the mass of that protein. Commonly-used MS-based approaches for studying protein 
structure include hydrogen/deuterium exchange (HDX) and covalent labeling.6, 8, 10 In 
HDX-MS, information regarding solvent accessibility and dynamics of backbone amides 
can be obtained from the exchange of hydrogens by deuteriums, thereby increasing the 
mass in a structurally informative manner. HDX-MS has been successfully used to 
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investigate structural changes and identify aggregation sites in mAbs obtained from 
different storage or stress conditions.28-30 Although this technique has been commonly used 
in HOS analysis of mAb therapeutics,31-33 an analytical challenge is the accuracy of HDX 
measurements due to the transient nature of deuterium labeling that can lead to back 
exchange and scrambling. In addition, specialized robotic equipment and software are 
required to obtain optimal results.  
Covalent labeling (CL) can also be used with MS to study protein HOS, but unlike 
HDX, CL is generally not subject to back exchange and scrambling. CL approaches use 
reagents to irreversibly modify solvent-exposed amino acid side chains, encoding 
structural information into the mass of the protein. CL along with MS detection (CL-MS), 
especially when used with bottom-up tandem MS (MS/MS), provides information about 
solvent accessibility of amino acid side chains, making it complementary to HDX.34-38 As 
an example, site-specific carboxyl group footprinting has been applied for the structural 
characterization of glycosylated therapeutic mAbs39, 40 and for epitope-paratope 
mapping.41, 42 A localized conformation change of mAbs as induced by deglycosylation 
was also identified using this technique.43 However, the reagent pair of 1-ethyl-3-(3-
(dimethylamino)propyl)-carbodiimide hydrochloride (EDC) and glycine ethyl ester (GEE) 
that was used in the study can monitor only Glu and Asp residues, limiting its structural 
resolution. Using a more non-specific reagent capable of modifying a range of amino acid 
side chains simultaneously can allow protein structure to be probed with greater 
resolution.38 Hydroxyl radical footprinting (HRF), in which hydroxyl radicals (●OH) are 
generated and non-selectively label solvent accessible residues,44 has been used for the 
structural analysis of mAbs.40 HRF with MS detection has been used to identify epitopes 
90 
 
and paratopes for antigen-antibody interactions41, 45-47 and to determine dimer interfaces in 
formulated mAbs.48 However, specialized instrumentation such as a laser or a synchrotron 
source is needed for ●OH radical production. Moreover, data interpretation is complicated 
because ●OH radicals can generate over 50 different modification types on proteins.44 For 
day-to-day structural analysis of biotherapeutics, a less expensive and simpler 
experimental design and workflow is needed.  
Diethylpyrocarbonate (DEPC) is a commercially-available reagent that can react 
with a range of nucleophilic side chains and N-termini of proteins, resulting in excellent 
protein structural coverage.38, 49 Unlike radical reagents, no specialized instrumentation is 
required because DEPC can readily modify proteins once added to solution. DEPC labeling 
reactions also result in only one type of product, allowing very low levels of labeling to be 
straightforwardly identified and further increasing analytical sensitivity and structural 
coverage.34, 38 CL-MS methods based on DEPC have been extensively developed by our 
group,35, 50, 51 and have been used to obtain insight into protein-ligand and protein-protein 
interactions as changes in side chain solvent accessibility at binding sites can be probed.35, 
52-56        
Here, we extend the applicability of DEPC-based CL-MS to study protein 
conformational changes that occur upon heating. Using rituximab as a model mAb 
therapeutic, we demonstrate the ability to site-specifically detect subtle HOS changes at 
the temperatures far below the melting point of the mAb therapeutic, changes that are not 
detected by common biophysical methods. Sites of these structural changes are revealed at 
the amino-acid level using MS/MS and are validated by activity assays. Overall, given the 
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simplicity, sensitivity, and straightforwardness of DEPC CL-MS, we predict that this 
method will be amenable to the structural investigations of other antibody therapeutics. 
3.2 Experimental Section 
3.2.1 Materials 
Rituximab formulation (Rituxan 100 mg/10 mL vial, lot# 3209283, Genentech) 
was ordered from Myoderm. Diethylpyrocarbonate (DEPC) (#D5758), imidazole 
(#I5513), iodoacetamide (#I6125), tris(2-carboxyethyl)phosphine (TCEP) (#C4706), and 
trypsin (#T1426) were obtained from Sigma-Aldrich. Urea (#AC424581000) was 
purchased from Acros Organics. Sodium phosphate monobasic monohydrate (#S0710-1) 
was obtained from EM Science. Sodium phosphate dibasic anhydrous (#S374-500), 
LC/MS-grade formic acid (#A117-50), acetonitrile (#A998-4), and water (#W7-4) were 
purchased from Fisher Scientific.  
3.2.2 Heat Treatments 
Samples were aliquoted (5 μL) from a rituximab formulation stored at 4 °C. Control 
samples were incubated at 37 °C for 5 min prior to DEPC labeling. For thermal treatments, 
the samples were incubated at 45 °C, 55 °C, and 65 °C for 4 h in a temperature-controlled 
water bath. The samples were cooled to 37 °C prior to labeling. 
3.2.3 DEPC Labeling Reactions 
Rituximab samples (10 mg/mL, 69.5 μM) in formulation with only minor dilution 
(to 58 μM) were reacted with DEPC. The reagent was first diluted in acetonitrile to make 
an intermediate solution, and the final solution of DEPC was then prepared in water. 
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Labeling of rituximab was performed at 37 °C for 5 min at a DEPC to protein molar ratio 
of 4 to 1. The reaction was quenched by the addition of imidazole at a 1:50 DEPC to 
imidazole molar ratio. For each thermal treatment, at least three replicates were performed 
on the rituximab samples. 
3.2.4 Proteolytic Digestion 
Following quenching the labeled samples were added into a urea-containing tube 
and diluted in 50 mM phosphate buffer at pH 7.4. The resulting mixture contained 8 M 
urea for protein denaturation. L-methionine was added at the final concentration of 2 
mg/mL to minimize oxidation during protein digestion. To achieve complete digestion of 
rituximab, TCEP was added at the final concentration of 25 mM to reduce the disulfide 
bonds. Iodoacetamide (25 mM) was simultaneously added to alkylate the reduced Cys 
residues. The samples were kept in the dark at room temperature for 20 min. Tween 80 
was then removed from the samples using DetergentOUT™ Tween® Micro spin columns 
(#786-214, G-Biosciences). Subsequently, trypsin was added to the resulting samples at a 
1:10 (w/w) enzyme to substrate, and the labeled protein was digested overnight at 37 °C. 
Following digestion, an Amicon centrifugal filter with a 10 kDa molecular weight cutoff 
(#UFC501096, Millipore) was used to remove trypsin from the resulting rituximab 
peptides. The flow-through was collected, flash-frozen in liquid nitrogen, and stored at -20 
°C until LC-MS/MS analysis. 
3.2.5 HPLC Separation 
Online LC-MS/MS analyses were performed on all rituximab digests. A sample 
containing approximately 2 μg rituximab peptides was loaded on an Easy-NanoLC 1000 
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system (Thermo Scientific). A flow rate of 300 nL/min was used. Samples were first 
trapped and desalted on an Acclaim™ PepMap™ C18 trap column (2 cm x 75 μm ID, 3 
μm; Thermo Scientific). Separation of rituximab peptides was then performed using a 
FortisBIO C18 nanocolumn (15 cm x 75 μm ID, 1.7 μm; Fortis Technologies). LC/MS-
grade water (solvent A) and acetonitrile (solvent B), each containing 0.1% formic acid, 
were used as mobile phases. A shallow gradient was utilized to achieve sufficient 
separation of peptides on analytical column. A linear gradient of solvent B was increased 
from 0% B to 50% B over 90 min. The LC column was then flushed by elevating the mobile 
phase composition to 95% B over 15 min and holding at 95% B for another 20 min. 
3.2.6 Mass Spectrometry 
Mass spectra were acquired on a Thermo Scientific Orbitrap Fusion mass 
spectrometer. The nano-electrospray ionization source was operated in the positive mode 
using a needle voltage of 2,000 V. The ion transfer tube temperature was set to 300 °C. 
The resolution of Orbitrap was set to 60,000 and the MS1 AGC target and maximum 
injection time were optimized and set to 1 x 106 ions and 100 msec, respectively. Tandem 
mass spectrometry (MS/MS) was performed on linear quadrupole ion trap for the most 
abundant peptide ions, with ion abundances above 5,000. The precursor ions were selected 
using a quadrupole mass filter at an isolation width of 2.0, and the MS2 AGC target and 
maximum injection time were set to 5 x 104 ions and 100 msec, respectively. Tandem mass 
spectra were generated using collisional-induced dissociation with a normalized collision 
energy of 35%. To avoid a biased selection of high-abundance ions, a dynamic exclusion 
of 60 sec was activated after 5 spectra were acquired for any given precursor ion within 5 
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sec. Mass detection during MS and MS/MS was done in centroid mode to ease the data 
analysis. 
3.2.7 Peptide Identification and Peak Quantification 
A custom software pipeline described previously56 and specifically designed for protein 
CL-MS studies was used to identify and quantify labeling sites. Raw mass spectral data 
files from the LC-MS/MS analyses were firstly converted to .mgf format using 
MSConvertGUI software.57, 58 SearchGUI was used to analyze the .mgf files for the peptide 
identification.59 The sequence of rituximab’s light and heavy chains were added to a 
sequence database constructed from the common Repository of Adventitious Proteins 
(cRAP database).60 Tandem mass spectra were searched against the custom database and 
its reverse, the decoy database. Several search engines (X!Tandem,61, 62 MS-GF+,63 
OMSSA,64 and MyriMatch65) were all used. The search parameters were set as follows: a 
precursor mass tolerance of 10 ppm, carbamidomethylation of Cys as a fixed modification, 
oxidation of Met as a variable modification, and DEPC modification of His, Lys, Ser, Thr, 
Tyr, and N-terminus as a user variable modification (mass addition of 72.0211). 
Nonspecific enzyme cleavage was selected to improve the sequence coverage of searches, 
accounting for nonspecific proteolytic digestion and degradation of rituximab peptides 
during sample preparation. Next, PeptideShaker was used to visualize the results from 
multiple search engines.66 False discovery rates were set at 1% and post-translational 
modifications were scored using the PhosphoRS algorithm. The peptide identification 
results were reformatted and exported to a .csv file and processed to contain only rituximab 
features, which were to be used as a custom database for LC-MS peak identification. 
MZmine was used to analyze the raw LC-MS data files for peptide peak quantification.67, 
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68 Mass detection was performed at the MS1 level. Chromatograms were reconstructed and 
deconvoluted using m/z and ion abundances data, and peak areas were quantified. 
Deconvoluted chromatograms from multiple samples were aligned using the Join Aligner 
algorithm. The quantified, identified, and aligned data were finally exported in .csv format. 
DEPC modification levels (L) of each labeled residue were calculated as follows. 
(Equation 3.1)                     
                𝐿 =  % 𝐷𝐸𝑃𝐶 𝑙𝑎𝑏𝑒𝑙𝑖𝑛𝑔 =  
∑ ∑ 𝐴𝑖,𝑧
𝑚𝑜𝑑𝑖𝑚
𝑧=1
𝑛
𝑖=1
∑ ∑ 𝐴𝑖,𝑧
𝑚𝑜𝑑𝑖𝑚
𝑧=1
𝑛
𝑖=1 + ∑ ∑ 𝐴𝑖,𝑧
𝑢𝑛𝑚𝑜𝑑𝑖𝑚
𝑧=1
𝑛
𝑖=1
 × 100                  (3.1) 
where 𝐴𝑖,𝑧
𝑢𝑛𝑚𝑜𝑑𝑖 is the peak area of unmodified peptide that has a sequence containing the 
residue of interest (i) and possesses a certain charge state (z) in the mass spectrum, and  
𝐴𝑖,𝑧
𝑚𝑜𝑑𝑖 is the peak area of peptide in which the residue of interest is modified.  A pictorial 
representation of this calculation can be found in Figure 3.1. 
Note that the DEPC modification extents calculated by Equation 3.1 are only used 
for the relative quantitation, i.e., comparing the protein of interest under different 
conditions (control vs. stressed). The label levels do not reflect the absolute quantitation of 
modified species as the addition of a carbethoxyl group to the modified peptide and 
different LC solvent conditions during elution of peptides lead to different ionization 
efficiency of the unmodified and modified peptides.   
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Figure 3.1: Illustration of how the DEPC modification levels are calculated.  
After DEPC labeling and proteolytic digestion, (a) LC-MS analysis of the digested 
rituximab is performed. During LC-MS, peptides are subjected to CID MS/MS in a linear 
quadrupole ion trap for identication, while peptide ion abundances measured by the 
Orbitrap  are used for peak area quantification. Peak areas of (b) unlabeled and (c) labeled 
peptides in a chromatogram are used to calculate the labeling percent (see Equation 3.1). 
CID tandem spectra of (d) unlabeled and (e) labeled peptides obtained at specific retention 
time are used for peptide sequencing and identification of DEPC labeled site. Two LC 
peaks for the labeled peptide in (c) are observed because the His side chain has two 
nitrogens that are separately labeled to produce isomers that can be separated by LC. 
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3.2.8 Biophysical Characterization 
3.2.8.1 Intrinsic Fluorescence Spectroscopy 
Tryptophan fluorescence measurements were performed on a Photon Technology 
International Quantamaster‐4SE spectrofluorometer. Rituximab samples were diluted to 1 
μM in 50 mM phosphate buffer at pH 7.4 prior to analysis. Heated samples were then 
cooled to 37 °C prior to a measurement. A 200-μL solution of 1 μM rituximab sample was 
transferred to a quartz cuvette. Fluorescence spectra were acquired at room temperature 
using an excitation wavelength of 285 nm with a slid width of 1 nm and an emission scan 
range of 310 – 440 nm with a slit width of 0.2 nm.  
3.2.8.2 Circular Dichroism (CD) Spectroscopy 
Far-UV CD analyses were performed on a Jasco J-1500 spectropolarimeter. CD 
spectra were recorded at room temperature over a scan range of 250 to 195 nm. Rituximab 
samples were diluted to 1 μM in 50 mM phosphate buffer at pH 7.4 prior to analysis. Heated 
samples were cooled to 37 °C prior to a measurement. A 200-μL solution of 1 μM rituximab 
sample was then transferred to a quartz cuvette. The CD spectrometric parameters were set 
as follows: a scan resolution (data pitch) of 0.5 nm, a scan rate of 20 nm/min, a band width 
of 2 nm, and a digital integration time of 1 sec. Triplicate measurements were performed 
for each sample at room temperature. After background subtraction, raw CD outputs (θ, 
degree) were converted into mean residue ellipticity using Equation 3.2.69  
[Ɵ]𝑀𝑅  (𝑑𝑒𝑔𝑟𝑒𝑒 𝑐𝑚2𝑑𝑚𝑜𝑙−1) =
100 × Ɵ  (𝑚𝑖𝑙𝑙𝑖𝑑𝑒𝑔𝑟𝑒𝑒)
𝐶 (𝑚𝑜𝑙 𝐿−1) × 𝑁 ×𝑙 (𝑐𝑚)
                          (3.2) 
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where [θ]MR is mean residue ellipticity in deg cm2 dmol-1, θ is raw signal output in mdeg, 
C is rituximab concentration in molar, N is the number of amino acid residues in a protein, 
and l is path length of a cuvette in cm.  
3.2.8.3 Dynamic Light Scattering (DLS) 
Hydrodynamic radii of native and thermally-stressed rituximab were measured at 
room temperature using a Malvern Zetasizer ZSP – DLS system. Rituximab samples were 
diluted to 1 μM in 50 mM phosphate buffer at pH 7.4 prior to analysis. Heated samples 
were cooled to 37 °C prior to a measurement. A 1-mL solution of 1 μM rituximab sample 
was transferred to a plastic cuvette. Back scattering was detected at a measurement angle 
of 173ᴼ, and volume particle size distribution of the sample was recorded. Five replicate 
measurements were performed for each sample at room temperature. Measurement 
duration was set according to the preset levels (automatic mode). 
3.2.8.4 Size-Exclusion Chromatography (SEC) 
SEC separation of rituximab after heating was performed at room temperature on 
an Agilent 1260 Infinity HPLC system using a TSKgel SuperSW3000 column (30 cm x 
7.8 mm ID, 5 μm particle size; Tosoh Bioscience LLC). Rituximab samples were diluted 
to 1 mg/mL in 50 mM phosphate buffer at pH 8.0 prior to analysis. Heated samples were 
cooled to 37 °C prior to a chromatographic run. A sample containing approximately 50 μg 
rituximab was loaded on an SEC column. The mobile phase (pH 6.5) comprises 50 mM 
sodium phosphate, 400 mM sodium perchlorate, and 10% isopropanol, and an isocratic 
flow rate of 0.5 mL/min was used. A variable wavelength UV detector set at 280 nm was 
used for detection. 
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3.2.9 Determination of the Labeling Limits of Quantitation (LOQ) through Peptide 
Spiking Experiments  
Model peptide H2N-VVSVLTVLHQDWLNGK, which comes from the rituximab 
sequence (HC peptide with amino acids 306-321), was custom synthesized (AnaSpec Inc.). 
A variety of DEPC-modified species (with different modification sites) were generated 
from a covalent labeling of the model peptide (10 μM) at a DEPC to protein molar ratio of 
10 to 1 at 37°C for 5 min, which resulted in labels at N-terminus, H314, and K321. Labeled 
sites were identified and modification percentages were determined by LC-MS/MS. A 
mixture of DEPC-labeled peptides were spiked into a digest of unlabeled rituximab (2.57 
μM matrix) at varying concentrations, and the resulting solutions were subsequently 
analyzed by LC-MS/MS. Signals of the spiked peptide, as measured by LC-MS, were used 
to estimate the LOQ based on signal-to-noise ratio of response.  
3.2.10 Activity Assays 
3.2.10.1 Alamar Blue Assay 
A range of stress temperatures were used in this study. Rituximab samples were 
incubated at 37°C (control), 50°C, 60°C, and 68°C prior to an assay. The conditions used 
for this assay were derived from Zhang et al70. Briefly, Raji cells (ATCC CLL-86) were 
grown in a T75 flask using RPMI media supplemented with fetal bovine serum (FBS). 
Once confluent, cells were washed with phosphate-buffered saline (PBS) and diluted to 1 
x 106 cells/mL in RPMI media. 90 μL of cells were delivered into a 96 well plate, and 10 
μL of control or heat-treated rituximab diluted in RPMI media was added at the 
concentrations indicated (4 ng/mL rituximab). Plates were then incubated for 30 min at 37 
°C, then each well was supplemented with 10% InvitrogenTM normal human serum 
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(#31876, Thermo Fisher Scientific). Plates were returned to 37 °C for 4 h, then 11 μL of 
InvitrogenTM Alamar Blue reagent (#DAL1025, Thermo Fisher Scientific) was added per 
manufacturer's specifications. After 1 hour, fluorescence signal was read using an 
excitation wavelength of 560 nm and emission of 590 nm. Data was generated on a Synergy 
H1 microplate reader (BioTek) and results were exported to Microsoft Excel for analysis. 
Each sample was generated in triplicate, and independently generated to confirm trends 
were the same. 
3.2.10.2 Rituximab Bridging ELISA 
Custom rituximab ELISA plates were generated and used as previously described 
in Cragg et al71 and Hampson et al72 with some modifications. Briefly, anti-human capture 
antibody (clone SB2H2 recognizing the Fc region of human antibody, #MCA2531, Biorad) 
was diluted 1 to 1000 in coating buffer (15 mM sodium carbonate, 28.5 mM sodium 
bicarbonate, pH 9.6), and 100 μL was added to each well of a 96 well NUNC MaxiSorp 
flat-bottom plate (#44-2404-21, Thermo Fisher Scientific). Plates were then incubated 
overnight at 4 °C, then blocked with 200 μL of 1% bovine serum albumin (BSA) in PBS 
for 2 h. Plates were washed three times with PBST prior to use. For the rituximab 
quantitation and standard curve generation, samples were diluted in phosphate-buffered 
saline with Tween 20 (PBST) at the concentrations indicated (1 to 500 ng/mL rituximab). 
For the binding assay, 10 ng/mL rituximab was used in the experiment. Rituximab samples 
were incubated at 37°C (control), 45°C, 55°C, and 65°C prior to an assay. 100 μL of sample 
was added to each well and incubated for 1 h at room temperature. Wells were then washed 
five times with PBST, and the horseradish peroxidase (HRP) – labeled anti-rituximab 
detection antibody (clone MB2A4 anti-idiotypic antibody, #MCA2260P, Bio-Rad) was 
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added at a 1: 60,000 dilution in blocking buffer. Samples were incubated for 90 minutes, 
then washed five times with PBST. Plates were then developed using 100 μL of HRP 
substrate for 45 min and stopped with the addition of 50 μL of 3 M sulfuric acid. Data was 
generated on a Synergy H1 microplate reader (BioTex) measuring absorbance at 450 nm 
and normalized against the absorbance at 630 nm to clear up any background signal, and 
the results were exported to Microsoft Excel for analysis. Each sample was generated 
independently in triplicate.  
3.2.10.3 Raji Cell Pull-Down Assay 
A range of stress temperatures were used in this study. Rituximab samples were 
preheated at 37°C (control), 50°C, 60°C, and 68°C. Control and heat-treated rituximab was 
diluted to 200 ng/mL in PBS and mixed 1:1 with either Raji cells (1 x 106 cells/mL) in 
PBS, or PBS alone was used as a control. The total concentration of rituximab in the 
experiment was 100 ng/mL. Free rituximab was then quantified using the ELISA plates, 
and normalized against the control wells. Absolute quantitation was performed using 
standard curves generated from each heat-treated sample independently to confirm 
quantitation was in the linear part of the standard curve.  
3.3 Results  
3.3.1 Biophysical Characterization of Rituximab HOS after Storage at Mild to 
Moderate Stress 
Before studying heat-stressed rituximab by covalent labeling, we used CD 
spectroscopy, fluorescence spectroscopy, and dynamic light scattering (DLS) to identify 
any structural perturbations upon heating. 
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Figure 3.2: Biophysical characterization of rituximab at 37 °C (native, black) and 
thermally-stressed conditions, after incubation of the rituximab formulation at 45 °C 
for 4 h (red), 55 °C for 4 h (blue), and 65 °C for 4 h (green).  
Techniques used in structural characterization were (a) tryptophan fluorescence 
spectroscopy, (b) far-UV circular dichroism spectroscopy, and (c) dynamic light scattering. 
The essentially identical overlap of the spectra of the native and 45 °C and 55°C heat-
stressed samples indicate that these techniques do not detect any structural changes to 
rituximab after preheating to these temperatures. Upon heating at 65 °C, however, 
structural changes and aggregation occur. 
 
When heating rituximab for 4 h at temperatures below its melting point, we find 
that the three techniques are not able to detect any significant structural changes at 45 °C 
or 55 °C and reveal only mild changes at 65 °C (Figure 3.2). Upon heating at 65 °C, 
rituximab undergoes changes in its HOS, as indicated by intrinsic fluorescence and CD 
spectroscopy (Figure 3.2a and b), and unfolds to some extent as indicated by DLS (Figure 
3.2c). These classical biophysical techniques provide only the weighted average structure 
of a global conformation, so the locations of any structural changes are unknown. 
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3.3.2 DEPC Labeling with MS Detection as a Tool for HOS Analysis of Rituximab 
DEPC-based covalent labeling together with MS detection was used to identify any 
structural changes undergone by rituximab that could not be detected by CD, fluorescence, 
or DLS. DEPC is a reactive electrophile that can modify solvent accessible nucleophilic 
side chains (Cys, His, Lys, Thr, Tyr, Ser) and N-termini of proteins (Figure 3.3a and b). 
The resulting carbethoxylated products of these residues have a mass shift of +72.021 Da, 
and the specific protein modification sites can be identified and semi-quantified after 
proteolytic digestion, liquid chromatographic separation of the resulting peptides, and 
tandem MS analysis (Figure 3.4). Any changes to the extent of covalent labeling at 
particular residues can be used to probe HOS changes to proteins upon comparing one 
condition (e.g. native) to another (e.g., heated). During the labeling conditions, the DEPC 
to protein molar ratio is limited at 4 to 1 to minimize labeling-induced structural 
perturbations to a protein during the labeling reaction, while at the same time providing 
sufficient labeling extents to identify the modified sites.35 CD and intrinsic fluorescence 
spectroscopy confirm that the DEPC-modified rituximab undergoes no significant 
structural changes, as compared to the spectra of unlabeled rituximab (Figure 3.5). 
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Figure 3.3: DEPC CL-MS as a tool for structural analysis of rituximab.  
In an MS-based approach for structural analysis, a protein’s structural properties are 
encoded into the mass of protein via DEPC covalent labeling. This figure shows (a) 
chemical structure of DEPC, (b) reactions of amino acid residues that are modified in 
covalent labeling with DEPC, and (c) workflow for DEPC covalent labeling combined with 
bottom-up MS analysis via proteolytic digestion and LC-MS/MS to identify labeled sites 
and determine label levels at each modified residue. Peptide identification and peak area 
quantification were performed using a custom software pipeline developed by QuarryBio 
Inc.56 
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Figure 3.4: Scheme showing DEPC labeling with MS detection for the structural 
analysis of antibody therapeutics.  
DEPC reagent modifies solvent accessible amino acids. The modified protein is subjected 
to proteolytic digestion and the modified peptides are analyzed using LC–MS/MS. Sites of 
protein conformational changes can be revealed by changes in the extent of labeling at 
specific residues 
 
 
Figure 3.5: Controlling DEPC to rituximab molar ratio to minimize structural 
perturbations of rituximab during the labeling reaction.  
The DEPC to rituximab molar ratio is limited at 4 to 1 in order to minimize structural 
perturbations of rituximab during the labeling reaction. Previous studies on a variety of 
proteins indicate that a 4 to 1 ratio is appropriate to minimize labeling-induced structural 
changes.35, 55, 56 The structural integrity of rituximab after covalent labeling can be 
confirmed via: (a) tryptophan fluorescence spectra and (b) circular dichroism spectra 
obtained from rituximab samples under native (black), DEPC-labeled (red), and heated at 
70 °C for 15 min (blue) conditions. Heated rituximab was used to indicate spectral changes 
due to the structural change. The essentially identical overlap between the spectra of the 
native and DEPC-labeled rituximab samples indicates that covalent labeling has only little 
or no effect on the structural perturbation of rituximab. 
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To obtain the extent of labeling at a residue level, the DEPC-labeled rituximab was 
subjected to “bottom-up” analysis via proteolytic digestion and LC-MS/MS (Figures 3.1 
and 3.3c). Peptide identification and peak area determination were performed using 
custom-designed software described previously,56 as described in Section 3.2.7. A 
rituximab sequence coverage of over 90% was obtained in the tryptic peptide mapping, 
allowing almost the entire structure of the protein to be probed. Upon DEPC labeling, up 
to 47 residues are found to be modified in each light chain (LC) while 107 residues are 
modified in each heavy chain (HC), which together corresponds to 23% of the residues in 
rituximab. Considering the average distance between adjacent DEPC modification sites,50 
the effective resolution for probing rituximab’s structure using DEPC is  8 Å. Some 
DEPC-modified residues could be reliably detected down to levels as low as 0.001%, 
however a more conservative labeling threshold of 0.01% was used for all peptides. 
Detection of peptides at these labeling levels together with the excellent structural coverage 
allows us to monitor subtle structure changes to the protein upon heat treatment. The limits 
of quantitation (LOQ) were experimentally determined by spiking experiments of a model 
synthetic tryptic peptide (rituximab HC peptide with amino acids 306-321; DEPC-labeled 
at different sites), into a digest of unlabeled rituximab at varying concentrations (Figures 
3.6 and 3.7).  
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Figure 3.6: Representative extracted ion chromatograms (XICs) used to estimate the 
labeling LOQ for a DEPC-labeled model peptide (H2N-VVSVLTVLHQDWLNGK*). 
This peptide, which comes from the rituximab sequence, was synthesized and DEPC 
labeled before spiking into a digest of unlabeled rituximab at varying concentrations. 
Shown above are the XICs for peptide labeled at the Lys residue. Peak heights of the spiked 
peptide, as measured by LC-MS, are used to estimate the the LOQ based on signal-to-noise 
ratio of response. When the blank analysis gives a result with a nonzero signal-to-noise 
ratio, the LOQ is defined as the analyte concentration corresponding to a signal-to-noise 
ratio that is 10 times the blank signal-to-noise ratio (see Equation 3.3 below).73, 74 From 
the data in this figure, we find that the LOQ is 2.82 nM, which is equivalent to a labeling 
level of 0.001%. These experiments were repeated three times. 
 
Calculation of LOQ for the K labeled peptide (H2N-VVSVLTVLHQDWLNGK*) 
Blank measurement 
Peak height  Hbl  = 5,101 (noise) 
 
LOQ determination for H2N-VVSVLTVLHQDWLNGK* 
LOQ is defined as the analyte concentration corresponding to the signal-to-noise ratio of 
10, hence the peak height  HLOQ =  10Hbl                                    (3.3) 
                                                 HLOQ =  (10 × 5,101) = 51,010  
The closest data point that yield signal above HLOQ from our surrogate peptide experiment 
is at  XLOQ = 2.82 𝑛𝑀 
Using peak areas to calculate a labeling level: 
Peak area of this DEPC-modified peptide at 2.82 nM spiked = 20,250.23 
Total peak area of unmodified and modified peptides at 2.82 nM spiked = 1,640,538,555.33 
 The LOQ is at a labeling level = 
20,250.23
1,640,538,555.33
 × 100 = 0.001% 
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Figure 3.7: Representative extracted ion chromatograms (XICs) used to estimate the 
labeling LOQ for a DEPC-labeled model peptide (H2N*-VVSVLTVLHQDWLNGK). 
From the data in this figure, we find that the LOQ is 183 nM, which is equivalent to a 
labeling level of 0.03%. These experiments were repeated three times. 
 
Calculation of LOQ for the N-terminally labeled peptide (H2N*-
VVSVLTVLHQDWLNGK) 
Blank measurement 
Peak height  Hbl  = 56,723 (noise) 
 
LOQ determination for H2N*-VVSVLTVLHQDWLNGK 
LOQ is defined as the analyte concentration corresponding to the signal-to-noise ratio of 
10, hence the peak height  HLOQ =  10Hbl           
                                                 HLOQ =  (10 × 56,723) = 567,230  
The closest data point that yield signal above HLOQ from our surrogate peptide experiment 
is at XLOQ = 183 𝑛𝑀 
Using peak areas to calculate a labeling level: 
Peak area of this DEPC-modified peptide at 183 nM spiked = 433,880.64 
Total peak area of unmodified and modified peptides at 183 nM spiked = 1,644,219,196.06 
 The LOQ is at a labeling level = 
433,880.64
1,644,219,196.06
 × 100 = 0.03% 
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To identify regions of rituximab that undergo subtle structural changes upon 
heating, DEPC modification levels at individual amino acid residues of heat-treated 
rituximab were compared to the modification levels of the un-treated protein. For each 
stress condition, unpaired student t-tests were used to determine if the labeling levels are 
significantly different at a 95% confidence level. For strongly nucleophilic residues, like 
His and Lys, changes in labeling extent are determined by the absolute difference in DEPC 
label levels (Equation 3.4). 
                           𝐴𝑏𝑠𝑜𝑙𝑢𝑡𝑒 𝑑𝑖𝑓𝑓𝑒𝑟𝑒𝑛𝑐𝑒 =  ∆𝐿 =  𝐿𝑠𝑡𝑟𝑒𝑠𝑠𝑒𝑑 −  𝐿𝑛𝑎𝑡𝑖𝑣𝑒                        (3.4) 
where 𝐿𝑠𝑡𝑟𝑒𝑠𝑠𝑒𝑑 and 𝐿𝑛𝑎𝑡𝑖𝑣𝑒 are the average % DEPC modification of a given residue in the 
stressed and native proteins, respectively. (See Equation 3.1 for a calculation of % DEPC 
modification.)  For weakly nucleophilic residues, such as Tyr, Ser, and Thr, modification 
extents are much smaller than for His and Lys residues due to their lower intrinsic reactivity 
with DEPC. Thus, a ratio difference, which is more sensitive to a small modification 
changes, is used to determine labeling changes for Tyr, Ser, and Thr residues (Equation 
3.5). 
             𝑅𝑎𝑡𝑖𝑜 𝑑𝑖𝑓𝑓𝑒𝑟𝑒𝑛𝑐𝑒 (%) =  
𝐿𝑠𝑡𝑟𝑒𝑠𝑠𝑒𝑑− 𝐿𝑛𝑎𝑡𝑖𝑣𝑒
𝐿𝑛𝑎𝑡𝑖𝑣𝑒
 × 100                                        (3.5) 
3.3.3 DEPC CL-MS for Probing Subtle Structural Changes of Rituximab 
In Table 3.1 the number of DEPC-modifiable residues in each rituximab domain 
that undergo significant changes in modification extent after heating for 4 h at 45 °C is 
graphically depicted. The sites that undergo statistically significant labeling changes are 
binned into three groups – low, medium, and high – based on the extent of the labeling 
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change. These bins were obtained upon plotting the DEPC modification extents, from all 
stress temperatures, on a single histogram and finding that they distribute into three ranges 
(see Table 3.1 for details). Relatively few changes in DEPC labeling levels are found in 
rituximab samples stressed at 45 °C. Most of these changes are increases in labeling, as 
might be expected when the protein is heated and undergoes unfolding. In addition, the 
variable regions have far fewer changes than the constant domains. More than 70% of the 
labeling changes occur at Tyr, Ser, and Thr residues, and the labeling changes that occur 
at His and Lys residues are always less than 20%. While the extent of labeling of both sets 
of residues are influenced by changes in solvent accessibility, labeling of the weakly 
nucleophilic Tyr, Ser, and Thr residues is more sensitive to changes in local 
microenvironment. Thus, labeling changes predominantly in these residues suggests that 
the structural changes at 45 °C are primarily changes in the local microenvironment instead 
of large structural changes that lead to significant differences in solvent accessibility. 
Consistent with this idea is the fact that the labeling changes are scattered throughout the 
protein structure rather than clustered in certain regions of the protein (Figure 3.8a). DEPC 
labeling sites and levels for rituximab under native and the lower temperature thermally-
stressed conditions (45 °C and 55 °C) are listed in full in Tables B.1 and B.2 in Appendix 
B, respectively. 
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Table 3.1: Changes in DEPC modification extents after the heat stress at 45 °C for 4 
h.  
The pie charts indicate the fraction of modified residues that undergo statistically 
significant labeling changes within each domain of rituximab. Red represents labeling 
increases while blue represents decreases. The bar charts for each domain indicate the 
number of residues whose extent of covalent labeling (CL) change falls within low (L), 
medium (M), and high (H) bins.  
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Figure 3.8: Sites on rituximab that undergo significant labeling changes after heat 
stress at (a) 45 °C for 4 h and (b) 55 °C for 4 h, as compared to non-stressed rituximab.  
Spheres represent residues that undergo significant changes in label levels (p < 0.05). Red 
represents labeling increases while blue represents decreases. Note that, for clarity, only 
one asymmetric unit of rituximab structure is labeled in this figure. As no full-length 
structures of rituximab are available in a protein data bank (PDB), we used existing Fab and 
Fc crystal structures of rituximab to generate a molecular model for the entire rituximab 
molecule. A full-length human IgG1 model, from which atomic coordinates were generated 
using PDBs 2IG2 (Fc) and 1FC2 (Fab) with a hinge region and other details theoretically 
modeled75, 76, was used as a template. Fc (PDB 4W4N) and  Fab (PDB 4KAQ) structures of 
rituximab were then aligned to the template, using the molecular visualization system 
PyMOL. 
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Activity assays were conducted to determine if the DEPC labeling changes reflect 
significant enough structural changes to affect rituximab activity and thus validate the 
DEPC labeling results. Three types of activity assays were performed: (a) rituximab 
bridging ELISA, (b) Alamar blue assay, and (c) Raji cell pull-down assay (Figure 3.9). 
The bridging ELISA assay was used to evaluate binding of the Fc region, thereby reporting 
on the structural integrity of Fc region. In addition, complement-dependent cytotoxicity 
(CDC) activity of the Fc region was assessed using an Alamar blue assay.
70, 77  The 
structural integrity of Fab region was evaluated using CD20-positive Raji B cells as part of 
a pull-down assay.  These activity assays were conducted at different temperatures 
spanning the range of temperatures studied by DEPC labeling. Results from the bridging 
ELISA show that there is no significant change in Fc binding activity of rituximab after 
preheating to 45 °C (Figure 3.10a). CDC activity of Fc region is also estimated to remain 
unchanged after heat stress at 45 °C (Figure 3.10b). Similarly, the Fab binding activity of 
rituximab stressed at 45 °C is estimated not to differ from control samples (Figure 3.10c). 
Together, these activity assays are consistent with the idea that the protein does not undergo 
significant structural changes at 45 °C, as indicated by the DEPC labeling experiments. 
The number of residues undergoing labeling changes is relatively small in both the Fab and 
Fc regions and consists primarily of Tyr, Ser, and Thr residues that are more sensitive to 
local microenvironment changes. Moreover, the modification sites are scattered throughout 
the protein (Figure 3.8a), suggesting little effect on the conformation of the Fab and Fc 
regions, as confirmed by the activity assays.  
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Figure 3.9: Schematics of three types of activity assays used in this study.  
(a) The pharmacokinetic bridging format of the ELISA was used to evaluate binding of the 
Fc region to a capture antibody. The Fc of rituximab was first bound to an anti-human 
capture antibody, and the Fab was then bound to an anti-rituximab detection antibody. (b) 
Complement-dependent cytotoxicity (CDC) activity of the Fc region was assessed using an 
Alamar blue assay. In this assay, Raji B cells were incubated with control or stressed 
rituximab. Rituximab binds to CD20 antigen expressed of cell surface, and cytotoxicity 
can be exerted by Fc after a normal human serum complement is added. CDC activity was 
then measured via a cell viability assay, allowing it to act as a functional indicator of the 
HOS of the Fc region. (c) The functional activity of Fab binding to its antigen CD20 was 
measured using a Raji cell pull-down assay. A study has shown that rituximab is bound to 
the surface of CD20 cells in vitro.71 In this experiment, CD20-positive Raji B cells were 
treated with control or stressed rituximab without human serum added, and the unbound 
rituximab was then quantified using ELISA This assay could measure binding activity of 
the Fab region to its CD20 antigen on the cell surface.   
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Figure 3.10: Structural changes revealed from DEPC CL-MS experiments are 
validated using rituximab activity assays.  
The structural integrity of the Fc region is evaluated by (a) a rituximab bridging ELISA that 
measures Fc binding to a capture antibody and (b) an Alamar blue assay that measures 
complement dependent cytotoxicity (CDC). The structural integrity of the Fab region is 
assessed by (c) a Raji cell pull-down assay that measures Fab binding to CD-20 antigen on 
B cells. For each temperature condition, the means of two groups i.e. stressed vs. control 
(37 °C) were compared using student t-test at 95% confidence level. Each assay was 
performed in triplicate (n = 3). 
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More residues undergo significant changes in modification extent after heating at 
55 °C for 4 h, and these changes can be found in all rituximab domains, particularly in the 
VH and VL domains of the Fab region (Table 3.2). Most of the changes in each domain are 
increases in labeling, with an exception of the VH and CL domains where there is a similar 
number of labeling decreases. Almost twice as many labeling changes occur at His and Lys 
residues upon heating to 55 °C compared to heating at 45 °C, although most of the changes 
are characterized as low or medium changes. Most of the labeling changes at Tyr, Ser, and 
Thr are characterized as medium or high changes. Overall, these results indicate likely 
changes in protein topology, although the moderate labeling changes at His and Lys 
residues suggest somewhat modest structural changes. In contrast to the heat stress at 45 
°C, after heating at 55 °C, the sites whose label levels undergo significant changes are 
found to cluster in the Fab region of the protein, especially in VH, VL, and CL domains 
(Figure 3.8b). Such clustering suggests localized structural changes in the Fab region of 
rituximab. Similar clustering of residues undergoing labeling changes are not observed in 
the Fc region (Figure 3.8b). 
Further insight into the meaning of the labeling data can be obtained via comparison 
to the activity assays. A small, but statistically significant, change in Fc binding activity 
from the bridging ELISA is measured at 55 °C (Figure 3.10a), but the CDC activity of the 
Fc region does not change significantly after heating at 55 °C (Figure 3.10b). The lack of 
consistency in the Fc-related assays might correlate with the lack of clustering of labeled 
residues in the Fc as seen in the DEPC labeling experiments (Figure 3.10c). One possible 
explanation is that the conformational changes in the Fc region are significant enough to 
influence the ELISA but too subtle to affect the Alamar blue assay. A significant change 
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in Fab binding activity is observed from the Raji cell pull-down assay for rituximab 
preheated at 55 °C (Figure 3.10c). This result is very consistent with the observed labeling 
changes in the Fab region that show significant clustering of residues that undergo labeling 
changes (Figure 3.8b).   
Table 3.2: Changes in DEPC modification extents after the heat stress at 55 °C for 4 
h.  
The pie charts indicate the fraction of modified residues that undergo statistically 
significant labeling changes within each domain of rituximab. Red represents labeling 
increases while blue represents decreases. The bar charts for each domain indicate the 
number of residues whose extent of covalent labeling (CL) change falls within low (L), 
medium (M), and high (H) bins.  
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3.3.4 Investigation of Conformation Change upon Higher Heat Stress  
As indicated earlier, heating at 65 °C leads to greater changes in the fluorescence, 
CD, and DLS data. In fact, heating at this temperature for 4 h results in a cloudy sample, 
and DLS data suggest the formation of small protein aggregates, as indicated by a small 
percentage of species at 100 nm (Figure 3.2c). Additional support for this conclusion is 
also found from size-exclusion chromatography (SEC) measurements (Figure 3.11), 
which reveal the presence of high molecular weight species upon heating at 65 °C and not 
upon heating at 45 °C or 55 °C.  Upon applying our DEPC CL-MS method to rituximab 
thermally-stressed at 65 °C, we find significant labeling changes in all rituximab domains 
(Table 3.3 and Table B.3). Most notably, many more decreases in labeling are observed 
than increases in labeling, which is likely explained by protein aggregation. Significant 
decreases in labeling are found in both the Fab and Fc regions, while only a few residues in 
the Fab region undergo increases in labeling. Around 30% of the labeling changes at 65 °C 
are found at His and Lys residues, and most of these can be characterized as medium or 
high changes in labeling extent.  For Tyr, Ser, and Thr residues, most sites undergo medium 
or high extents of labeling changes.  Overall, these results suggest more profound changes 
in the solvent accessibility and the local microenvironment for many sites in the protein 
upon heating at 65 °C. When the residues that undergo changes in labeling are mapped on 
the rituximab structure, clusters of residues are found in the CH3 domain of Fc region and 
the variable domains of the Fab region (Figure 3.12).  
The labeling changes are consistent with activity assays that indicate changes in the 
Fab and Fc regions. Results from the bridging ELISA show that there is a significant change 
in Fc binding after heating to 65 °C (Figure 3.10a). CDC activity of the Fc region (Figure 
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3.10b) and Fab binding activity (Figure 3.10c) are also significantly different from control 
samples. The activity assay results are consistent with the DEPC labeling results, indicating 
significant structural changes to rituximab in both Fab and Fc regions.  
 
Figure 3.11: Size-exclusion chromatography (SEC) of rituximab at 37 °C (native, 
black) and thermally-stressed conditions, after incubation of the rituximab 
formulation at 45 °C for 4 h (red), 55 °C for 4 h (blue), and 65 °C for 4 h (green).  
After heating at 65 °C, the chromatogram of the stressed rituximab indicates the significant 
formation of high molecular weight species (i.e. Mn), whereas the other temperatures show 
almost exclusively monomeric rituximab (i.e. M). 
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Table 3.3: Changes in DEPC modification extents after the heat stress at 65 °C for 4 
h.  
The pie charts indicate the fraction of modified residues that undergo statistically 
significant labeling changes within each domain of rituximab. Red represents labeling 
increases while blue represents decreases. The bar charts for each domain indicate the 
number of residues whose extent of covalent labeling (CL) change falls within low (L), 
medium (M), and high (H) bins.  
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Figure 3.12: Sites on rituximab that undergo significant (a) increases and (b) 
decreases in DEPC modification after heat stress at 65 °C for 4 h, as compared to non-
stressed rituximab.  
Spheres represent residues that undergo significant changes in label levels (p < 0.05). Red 
represents labeling increases while blue represents decreases. Note that, for clarity, only 
one asymmetric unit of rituximab structure is labeled in this figure. (See Figure 3.8 for 
more details about rituximab’s molecular model.)   
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3.4 Discussion 
In this study, we have shown the applicability of DEPC CL-MS as an analytical 
tool to provide site-specific information about changes in the HOS of protein therapeutics. 
Sites of the structural changes are revealed from differences in DEPC modification levels 
compared to a control sample. The full meaning of the quantitative changes in labeling is 
not fully understood at this stage, but labeling increases often suggest greater unfolding in 
a given region and labeling decreases imply burial of side chains usually from aggregation. 
Changes in the solvent-accessible surface area (SASA) of a given residue is a primary 
factor that governs side chain reactivity,36-38 but changes in reactivity can also be caused 
by changes in local tertiary structure around a given residue (e.g., microenvironment).38 
Previous studies have identified the melting temperatures (Tm) for different 
domains of rituximab to be 71 °C, 74 °C, and 83 °C for the CH2, Fab, and CH3 domains, 
respectively.78 We stressed the rituximab samples at temperatures far below these Tm 
values as we were interested in studying the protein under mild to moderate thermal stress 
to see if DEPC CL-MS could report on any subtle structural changes. These lower 
temperatures more realistically mimic stresses that protein therapeutics may undergo.79 
Results from DEPC CL-MS after heating at 45 °C suggest that no significant structural 
changes occur at this temperature, which is consistent with fluorescence, CD, and DLS 
measurements as well as the activity assays. Even though a few residues undergo 
statistically significant labeling changes, the number of labeling changes that occur at His 
and Lys residues, which are the better reporters of SASA changes, is relatively small. Most 
of the labeling changes occur at Tyr, Ser, and Thr residues (Table 3.1), which are sites that 
are more sensitive to local microenvironment changes such as changes in H-bonding or 
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nearby electrostatic interactions. While the extent of DEPC modification of both sets of 
residues are influenced by SASA, the labeling changes that occur at the weakly 
nucleophilic Tyr, Ser, and Thr residues are much less correlated with the changes in 
SASA.38 Similar observations are made in HRF experiments, where the primary structure 
and HOS more significantly influence residues with poor intrinsic reactivity.36  The 
predominance of labeling changes at Tyr, Ser, and Thr residues suggests that any HOS 
changes at 45 °C are changes in the local microenvironment instead of significant unfolding 
that would dramatically change the SASA of residues. Moreover, the labeling changes are 
scattered throughout the protein structure rather than clustered at certain regions of the 
protein (Figure 3.8a), again implying very local effects. The data from the activity assays 
(Figure 3.10) are in agreement with this idea.  
A greater number of labeling changes occur upon heating rituximab to 55 °C than 
at 45 °C, and these labeling changes are clustered in the Fab domain of the protein. This 
extent and localized nature of labeling changes indicate that CL-MS is revealing structural 
perturbations, changes that are not measurable by fluorescence, CD, and DLS. Around 30% 
of the labeling changes at 55 °C occur at His and Lys residues, and these changes are mostly 
moderate or high increases in labeling (Table 3.2), indicating that the protein is unfolding 
in these regions. As alluded to earlier, the reactivity of the more nucleophilic His and Lys 
residues is better correlated with SASA, and thus the labeling of these residues are more 
sensitive to local unfolding events that would expose them to a greater extent.35 It is 
important to note that most of the His and Lys labeling changes at 55 °C are classified as 
moderate, meaning there is less than a 20% increase in labeling. While we have not 
established a quantitative relationship between labeling extents and SASA, the fact that the 
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biophysical techniques do not detect any structural changes suggests that any structural 
changes that do occur after heating to 55 °C are subtle. A larger number of Tyr, Ser, and 
Thr residues also undergo labeling changes after stressing at 55 °C than at 45 °C, and most 
are moderate or high increases (Table 3.2). Again, these residues are less correlated with 
SASA changes, but the significant number of labeling changes to these residues also 
suggests a structural change.  
The locations of the structural changes after heating to 55 °C are worth noting. The 
most significant and clustered labeling changes are found in the Fab region, which is 
reported to be the most sensitive region to heat stress in IgG1 molecules.80 Our results 
would seem to contrast with DSC data for rituximab obtained by Andersen et al. in which 
the CH2 domain is found to have the lowest Tm of 71 °C;
78 however, this difference is 
almost certainly due to differences in the nature of our labeling experiments and the DSC 
experiments. In our experiments, the protein reaches a thermal equilibrium after 4 h of 
heating at 55 °C before being cooled and analyzed, whereas the DSC experiment involves 
a temperature ramp where the protein is exposed to a given temperature for only a minute 
without associated cooling.78 Because different protein domains can change structures at 
different rates and re-fold to different extents upon cooling, one might not expect there to 
be a strong correlation between our heat-stress experiments and DSC experiments. Very 
telling is the fact that several residues that undergo significant labeling changes cluster in 
the variable domains, VH and VL, where the complementarity-determining regions (CDRs) 
for CD-20 are located (Figure 3.8b and Table 3.2).81 Among the residues undergoing 
significant labeling changes at 55 °C are Thr91 on the LC, located in the middle of CDR 
L3, His33 on the LC and His35 and Lys74 on the HC, which are located close to CDRs 
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L1, H1, and H2, respectively (Figure 3.13b). Structural changes near these residues, as 
indicated by the labeling changes, are nicely consistent with the decreased Fab binding that 
was found in the activity assay (Figure 3.10c). To the best of our knowledge, our CL-MS 
technique is the first to report a subtle HOS change of a therapeutic mAb at the temperature 
as low as 55 °C. 
 
Figure 3.13: Illustration of rituximab’s Fab domain highlighting structural changes 
that may affect CDRs after heat stress at (a) 45 °C for 4 h and (b) 55 °C for 4 h.  
Red represents the increase in label level while blue represents the decrease in label level. 
Six CDRs of rituximab (H1-H3 in heavy chain and L1-L3 in light chain) have been 
previously reported in Du et al.,81 and they are highlighted in magenta. Thr91 (light chain), 
His33 (light chain), His35 and Lys74 (heavy chain) which sit in or nearby CDRs are found 
to undergo significant changes in labeling after heat stress at 55 °C. (PDB accession code 
4KAQ)   
 
Heating at 65 °C more significantly alters the conformation of rituximab, as 
revealed by biophysical measurements, activity assays, and CL-MS. Indeed, some fraction 
of the protein aggregates upon heating for 4 h at this temperature, which is consistent with 
the propensity of rituximab to transiently unfold at temperatures below its Tm.
60 
Aggregation is also indicated by the fact that most of the measured changes in CL-MS are 
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moderate or high labeling decreases (Table 3.3). It may seem surprising that the 65 °C data 
does not have a more even mix of labeling increases and decreases because the protein 
probably unfolds to some degree in addition to aggregating. It should be noted, though, 
that our technique is inherently much more sensitive to aggregation events than unfolding 
events. The amino acids that are labeled by DEPC are primarily polar residues that are 
more likely to reside on the protein surface anyway. Consequently, protein unfolding 
events only mildly increase their SASA and DEPC reactivity, while aggregation events 
completely bury these normally exposed residues, dramatically changing their SASA and 
DEPC reactivity. If a given residue is more exposed in some protein molecules but buried 
in other protein molecules, the decrease in labeling due to residue burial will likely 
counterbalance any labeling increase due to increased solvent exposure. 
This greater sensitivity to aggregation events gives us excellent insight into regions 
of the protein that self-associate, as we have shown previously for other proteins.52, 53, 56 
Clusters of residues that undergo decreases in labeling are found in both Fab and Fc regions 
(Figure 3.12). Structural changes in the Fab region are consistent with a reduction in Fab 
binding to CD20 (Figure 3.10c), and many labeling changes are found near the CDRs. 
Among the labeling changes are Tyr70 on the LC and His35, Lys67, and Lys74 on the HC, 
which sit close to CDRs L2, H1, H2 and H2, respectively (Figure 3.14a). Labeling changes 
in the Fc region, particularly the CH3 domain are also confirmed by a reduction in Fc binding 
and CDC activity (Figure 3.10). Clusters of residues that undergo decreases in DEPC 
labeling in the CH3 domain of Fc (Ser258, Ser428, His439, and Tyr440) and the variable 
domains of Fab (Ser5, Tyr70, and Tyr101 on the LC and Thr118 and Ser120 on the HC) 
suggest these regions as the likely aggregation interfaces (Figure 3.14b).  
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Figure 3.14: Illustration of rituximab structure highlighting structural changes that 
may affect CDRs and the possible aggregation sites after heat stress at 65 °C for 4 h.  
(a) Cartoon representation of the Fab domain after the heat stress. Red represents the 
increase in label level while blue represents the decrease in label level. Six CDRs of 
rituximab (H1-3 in heavy chain and L1-3 in light chain) have been previously reported in 
Du et al.,81 and they are highlighted in magenta. Tyr70 (light chain), His35, Lys67, and 
Lys74 (heavy chain), which sit nearby CDRs, are found to undergo significant changes in 
labeling after heat stress at 65 °C. (PDB accession code 4KAQ) (b) Cartoon representation 
of possible aggregation sites in the Fab and Fc regions. Only decreases in labeling are shown 
in this figure. Those residues cluster to each other with a distance less than 12 Å. Note that 
only one asymmetric unit of rituximab structure is labeled in this figure. (See Figure 3.8 
for more details about rituximab’s molecular model.)   
 
Our DEPC CL-MS technique compares favorably to other MS-based structural 
techniques (e.g., HDX,28-30 HRF,48 and dimethyl labeling82) that have been used recently 
to study HOS changes or identify aggregation interfaces of mAbs. Most of the previous 
studies used harsh stress conditions (freeze-thaw, UV light, or temperature around the Tm) 
to induce conformation changes to the mAbs under study. Consistent with the results 
reported in our work here, most aggregation sites in mAbs are found to be in the Fab region, 
particularly in the variable domains,28, 30, 48, 56, 82 although there is at least one example of 
aggregation involving the Fc region.
29 To our knowledge, there are no published 
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experimental studies that report the aggregation interface for rituximab upon heating. 
Nevertheless, computational tools have predicted aggregation prone regions83-85 in Fab and 
Fc regions, of which many are located close to the sites found to decrease in labeling, such 
as Ser5 (LC),  Thr118 and Ser120 (HC, Fab) and Ser258 (HC, Fc).  
From a methodological perspective, CL-MS using DEPC has some advantages over 
other MS-based techniques, especially for revealing aggregation interfaces. In HDX-MS, 
reduced deuterium exchange along a protein backbone is used to identify aggregation sites, 
even though protein-protein interactions are primarily mediated by side chain interactions. 
DEPC labeling reports on the SASA of side chains, thereby providing a more direct 
indication of aggregation sites. CL-MS also does not require specialized equipment like 
HDX-MS, thereby simplifying the overall approach. HRF is another side-chain labeling 
technique that has been used for studying mAb interactions and structure, but HRF 
techniques also require specialized lasers41, 45, 46, 86, 87 or synchrotron40, 48 sources to 
generate the radicals. In addition, radicals generate multiple reaction products, as opposed 
to a single one with DEPC, which can decrease the sensitivity of the technique.  
3.5 Conclusion 
In conclusion, we demonstrate here the ability of DEPC CL-MS to investigate HOS 
of antibody therapeutics. DEPC directly probes solvent accessibility and the 
microenvironment of side chains, and any changes in DEPC reactivity are indicative of 
changes in protein conformation. With a broad spectrum of modifiable residues coupled 
with the sensitivity of MS, the structural resolution and sensitivity of our DEPC labeling 
technique is high enough for probing subtle protein conformational changes. We have 
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shown that DEPC CL-MS can reveal subtle HOS changes in rituximab at the temperatures 
below the Tm (e.g., 55 °C), temperatures at which classical biophysical techniques are not 
sensitive enough to detect any changes. The results from DEPC labeling are validated via 
activity assays. At higher heat stress (e.g., 65 °C), HOS changes and aggregation are 
apparent from clusters of residues that undergo decreases in labeling in both Fab and Fc 
regions. These results are confirmed by complementary biophysical and activity 
measurements. With its structural resolution, sensitivity, and simplicity, DEPC CL-MS 
should be amenable to the structural investigations of other antibody therapeutics. Future 
work will demonstrate its applicability to HOS characterization of other therapeutic 
antibodies and antibody-antigen complexes.  
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CHAPTER 4 
 
COVALENT LABELING/MASS SPECTROMETRY OF MONOCLONAL 
ANTIBODIES WITH DIETHYLPYROCARBONATE: REACTION KINETICS 
FOR ENSURING STRUCTURAL INTEGRITY 
4.1 Introduction 
Mass spectrometry (MS) has emerged as one of the leading techniques used for the 
routine structural analysis of antibody therapeutics to ensure the quality, efficacy and safety 
throughout a product life cycle.1-4 Higher-order structure (HOS) is one of the quality 
attributes of therapeutic monoclonal antibody (mAb) that has to be characterized as 
changes in HOS can cause decrease in therapeutic efficacy, reduced stability, or possible 
immunogenicity.5-7 In addition, identifying specific residues involved in antigen-antibody 
interactions, i.e. epitope/paratope mapping, is particularly useful to evaluate epitope 
novelty, predict immunogenicity, and assess and optimize binding characteristics.8, 9 The 
wider use of MS-based methods to probe protein’s HOS results from (a) an ability to obtain 
residue-level structural information that optical spectroscopy cannot provide, and (b) a 
more rapid, sensitive, and sample-efficient analysis compared to X-ray crystallography and 
NMR spectroscopy.  
The two most commonly used MS-based tools for studying mAb HOS are 
hydrogen-deuterium exchange (HDX) and covalent labeling (CL). HDX has been 
extensively used to investigate HOS changes and aggregation of mAbs during drug 
development.10-14 Epitope mapping and comparability studies are also examples of how 
HDX-MS has been used.14-18 CL of amino acid side chains is another technique that can be 
used to encode a protein’s structural properties into the mass of protein, allowing 
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information about a protein’s structure in solution to be read-out through MS-based 
bottom-up approaches.19-22 CL-MS has more recently been applied to study mAb higher 
order structure. Compared to hydrogen-deuterium exchange (HDX), CL benefits from 
limited label loss and scrambling due to the irreversible nature of the labeling reaction. 
Non-specific reagents (e.g., hydroxyl radicals, carbenes, and diethylpyrocarbonate) can 
simultaneously probe a range of different side chains, allowing excellent structural 
resolution to be obtained. Hydroxyl radical footprinting (HRF) has been used to 
characterize the conformations and dimer interfaces of mAb therapeutics and to perform 
epitope mapping for various antigen-antibody interactions.23-27 Carboxyl group 
footprinting has also been used to characterize the HOS of mAbs and was found to provide 
complementary information to HRF.28  
Our group has developed and used diethylpyrocarbonate (DEPC) as a labeling 
reagent because it is simple to use, commercially available, and labels a range of 
nucleophilic residues and the N-terminus of proteins once added into a solution. DEPC 
CL-MS has been used to reveal aggregation sites and HOS changes for heat-stressed 
murine IgG1 and rituximab, providing structural information for up to 30% of the residues 
in these mAbs.29, 30  An important principle of CL-MS experimental design is that a 
protein’s structure must not be perturbed during the labeling reaction, so that the probe can 
correctly report accurate structural information.19, 31 There are at least three general ways 
to assess a protein’s structural integrity upon CL. One way is to use a complementary 
measurement, such as CD spectroscopy, fluorescence spectroscopy, or an activity assay, to 
monitor any HOS change after labeling.30-32 These techniques are typically not sensitive 
enough to detect local structural perturbations. A second way is to ensure that the labeling 
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reaction occurs faster than any label-induced HOS change can happen, guaranteeing a 
protein’s HOS is not affected during CL. This approach only works for fast labeling 
chemistries, e.g. HRF and carbene labeling, that require laser or synchrotron sources.33-36  
 A third method, which is more reliable and effective, is to monitor labeling reaction 
kinetics. By plotting the unmodified fraction of a protein (or better, each of its peptide 
fragments) as function of reagent concentration, any labeling-induced structural 
perturbations can be revealed by deviations from the proper reaction order kinetics, e.g. 
pseudo first-order kinetics for HRF and second-order kinetics for DEPC CL.31, 37-39 Such 
dose-response plots of an intact protein are less useful than plots of peptide fragments as 
intact protein plots are ensemble averages, much like CD measurements, and do not 
provide site-specific information. Dose-response plots for proteolytic fragments obtained 
from bottom-up analysis of a labeled protein have been shown to be much more sensitive 
and reliable probes of possible protein structural perturbations as they provide information 
about any local structural perturbations caused by either nearby or distant modifications.31 
Deviations in the kinetics allow the researcher to identify the highest reagent dose to use 
while still ensuring the structural integrity of the protein. Using the highest dose, while 
preventing structural perturbations, maximizes the labeling extent and thus the structural 
resolution of the method. Kinetic measurements via dose-response plots have been 
effective for ensuring the reliability of the structural information for proteins ranging from 
cytochrome c to lysozyme to gelsolin.37-39 These measurements, however, have only been 
used for, single-domain proteins, and so an interesting question is whether they are 
beneficial for multi-domain proteins like mAbs. Moreover, it would be valuable to know 
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if CL on a residue in one domain of a protein (e.g. variable light chain in a mAb) can affect 
the structure and labeling of a distant domain (e.g. constant heavy chain in a mAb). 
In this work, we have acquired DEPC labeling dose-response plots for proteolytic 
fragments of different mAbs to: (a) test the applicability of this method for ensuring the 
structural integrity of multi-domain mAbs during CL-MS-based structural analyses, (b) 
identify if a common DEPC molar excess might be suitable for DEPC-based CL-MS 
analyses of mAbs, and (c) evaluate the extent to which a multi-domain protein’s structure 
is sensitive to multiple DEPC modifications. Results suggest that multi-domain proteins 
can withstand many more than 1 DEPC label without being perturbed structurally, which 
allows a more sensitive and higher resolution measure of structure because more 
modifications can be detected. In addition, based on the limited set of mAbs studied here, 
there seems to be a common DEPC molar ratio that can be used without worrying about 
structural perturbations.  
4.2 Experimental Section 
4.2.1 Materials 
Rituximab (Rituxan® 100 mg/10 mL vial, lot#3209283, Genentech) and the NIST 
Monoclonal Antibody Reference Material 8671 (NISTmAb 10 mg/mL vial, lot#14HB-D-
002) were ordered from Myoderm (Norristown, PA) and the National Institute of Standards 
and Technology (NIST, Gaithersburg, MD), respectively. Diethylpyrocarbonate (DEPC) 
(#D5758), imidazole (#I5513), iodoacetamide (#I6125), tris(2-carboxyethyl)phosphine 
(TCEP) (#C4706), and trypsin (#T1426) were all purchased from Sigma-Aldrich (St. 
Louis, MO). Sodium phosphate monobasic monohydrate (#S0710) was ordered from EM 
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Science (Darmstadt, Hesse, Germany). Sodium phosphate dibasic anhydrous (#S374), 
LC/MS-grade formic acid (#A117), acetonitrile (#A998), and water (#W7) were obtained 
from Fisher Scientific (Fair Lawn, NJ). All reagents used in this study have no known 
potential hazards. 
4.2.2 Sample Preparation and DEPC Labeling Reactions 
Rituximab was used as is in its formulation, which contains 10 mg/mL rituximab, 
0.7 mg/mL polysorbate 80, 7.35 mg/mL sodium citrate dihydrate and 9 mg/mL sodium 
chloride in water at pH 6.5. For the NISTmAb formulation, L-histidine was removed from 
the formulation using PD SpinTrap G-25 spin columns (#28918004, GE Healthcare Life 
Sciences, Marlborough, MA) to prevent this amino acid from interfering with the DEPC 
reaction. The NISTmAb was then buffer exchanged in 50 mM phosphate buffer at pH 6.0, 
which is the pH of the formulation before L-histidine removal. Aliquots of rituximab and 
the NISTmAb (10 mg/mL, 70 μM) with only minor dilution (to 60 μM) were reacted with 
DEPC. Stock solutions of DEPC (69 mM) were freshly prepared in acetonitrile, and the 
final solution of DEPC was then prepared in water. Labeling of each mAb was performed 
for 5 min at 37 °C and was initiated by adding various molar excesses of DEPC, from 2-
fold up to 30-fold). The reaction was quenched by the addition of imidazole at a 1:50 DEPC 
to imidazole molar ratio. For experiments at each DEPC concentration, at least three 
replicates were performed on the rituximab and NISTmAb samples. 
4.2.3 Proteolytic Digestion 
After quenching, the labeled mAb samples were diluted in 50 mM phosphate buffer 
at pH 7.4 and added into a urea-containing tube. The resulting mixture contained 8 M urea 
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for protein denaturation at room temperature. TCEP was added at the final concentration 
of 25 mM to reduce the disulfide bonds, and iodoacetamide was simultaneously added at 
the same final concentration to alkylate the reduced Cys residues. The samples were then 
kept in the dark at room temperature for 20 min. For rituximab samples, DetergentOUT™ 
Tween® Micro spin columns (#786–214, G-Biosciences, St. Louis, MO) were used to 
remove Tween® 80 from the samples. Subsequently, overnight digestion at 37 °C was 
performed with trypsin at a 1:10 (w/w) enzyme to substrate ratio. Following digestion, 
trypsin was removed from the resulting rituximab or NISTmAb peptides through 
ultrafiltration using an Amicon® centrifugal filter with a 10 kDa molecular weight cutoff 
(#UFC501096, Millipore, Burlington, MA). The flow-through was collected, flash-frozen 
in liquid nitrogen, and stored at −20 °C until LC-MS/MS analysis. 
4.2.4 HPLC Separation 
Online LC-MS/MS analyses were performed on all rituximab and NISTmAb 
digests. A sample containing approximately 5 μg of the digested protein was loaded on a 
Thermo Scientific Dionex Ultimate 3000 HPLC system (Waltham, MA). The separation 
of peptides was performed on a Thermo Scientific Acclaim™ PepMap™ RSLC C18 
column (15 cm x 300 μm, 2 μm particle size, 100 Å pore size) with a flow rate of 4 μL/min. 
LC/MS-grade water (solvent A) and acetonitrile (solvent B), each containing 0.1% formic 
acid, were used as mobile phases. Desalting was performed at 5% B during the first 5 min 
after sample injection. A linear gradient of solvent B was increased from 5% B to 35% B 
over 65 min. The gradient was finally elevated to and held at 95% B to flush the column. 
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4.2.5 Mass Spectrometry 
Mass spectra were acquired on a Thermo Scientific Orbitrap Fusion mass 
spectrometer (Waltham, MA). The electrospray needle voltage was kept at 4 kV (positive 
mode), and the ion transfer tube temperature was set to 275 °C. Tandem mass spectrometry 
(MS/MS) was conducted on a set of selected mAb peptides. The precursor ions 
(unmodified or modified peptide ions) were selected using a quadrupole mass filter at an 
isolation width of 2.0. The AGC target and maximum injection time were set to 5 × 104 
ions and 50 msec, respectively. Collision induced dissociation (CID) was performed in a 
linear quadrupole ion trap with a normalized collision energy of 35%. Mass spectra of 
product ions were acquired on an Orbitrap analyzer with a resolution of 30,000. 
4.2.6 Dose-Response Plots 
DEPC can modify His, Lys, Ser, Thr, Tyr, and N-termini, and the labeling results 
in a single type of modification product with a mass addition of 72.02 Da (Figure 4.1a). 
Under the conditions used in this study, the reaction of DEPC with a specific site in the 
protein follows second order kinetics.31  
Nucleophilic side chain (P) + DEPC (X) → Carbethoxylated P + CO2 + CH3CH2OH 
If the reaction follows second order kinetics, the rate is defined by:  
𝑅𝑎𝑡𝑒 =  −
𝑑[𝑃]
𝑑𝑡
= 𝑘[𝑃][𝑋]                 (4.1) 
where [P] is the concentration of unmodified mAb at time t, [X] is the DEPC concentration 
at time t, and k is the second-order rate coefficient. 
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Let     𝑎 = 𝑟𝑒𝑎𝑐𝑡𝑖𝑜𝑛 𝑝𝑟𝑜𝑔𝑟𝑒𝑠𝑠 =  [𝑃]0 − [𝑃] =  [𝑋]0 − [𝑋]                              (4.2) 
where [P]0 is the initial concentration of unmodified mAb, [X]0 is the initial concentration 
of DEPC 
−
𝑑[𝑃]
𝑑𝑡
=
𝑑𝑎
𝑑𝑡
=  𝑘([𝑃]0 −  𝑎)([𝑋]0 −  𝑎)                                      (4.3)  
𝑑𝑎
([𝑃]0− 𝑎)([𝑋]0− 𝑎) 
= 𝑘 𝑑𝑡                                                                       (4.4)                                                                               
  ∫
𝑑𝑎
([𝑃]0− 𝑎)([𝑋]0− 𝑎) 
𝑎
0
= 𝑘 ∫ 𝑑𝑡
𝑡
0
                                                                  (4.5)                                                                                   
1
[𝑋]0− [𝑃]0 
 [ln
[𝑃]0
[𝑃]0− 𝑎
−  ln
[𝑋]0
[𝑋]0− 𝑎
] = 𝑘𝑡                                                                          (4.6)  
1
[𝑋]0− [𝑃]0 
 [ln
[𝑃]0[𝑋]
[𝑃][𝑋]0
] = 𝑘𝑡                                                                         (4.7)  
                                       ln(
[𝑋]0[𝑃]
[𝑋][𝑃]0
) = −𝑘𝑡[𝑋]0 + 𝑘𝑡[𝑃]0                          (4.8) 
 
For each specific labeling site, a plot between ln(
[𝑋]0[𝑃]
[𝑋][𝑃]0
) and [X]0 was produced for 
a given peptide from LC-MS/MS data of that peptide. [P]/[P]0 is the ratio of the peak area 
for the unmodified peptide to the sum of the peak areas for the modified and unmodified 
peptide, and [X] is determined by the difference between the [P] and [P]0 values. A 
hypothetical dose-response plot for a second order reaction is shown in Figure 4.1b.  
A custom software pipeline specifically designed for protein CL-MS studies with 
DEPC29, 30 was used for the initial identification of the peptides that were chosen for 
MS/MS. Assignments of b and y ions from CID tandem mass spectra were performed with 
a mass tolerance of 0.5 Da. From the LC-MS/MS analyses on a set of selected mAb 
peptides, Thermo Scientific Xcalibur™ software was used to reconstruct product ion 
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chromatograms of unmodified and modified peptides. Peptide identification and peak 
quantification were performed using tandem spectra and mass spectral peak areas, 
respectively.  
 
Figure 4.1: The reaction of DEPC with a specific site in protein  
(a) DEPC labeling of nucleophilic side chains (His, Lys, Tyr, Ser, and Thr) in the 
antibodies. (b) A hypothetical dose-response plot for a given peptide fragment can be used 
to identify any labeling-induced structural perturbation to the protein in the region 
represented by the measured peptide. In this example, a break in linearity is indicative of a 
structural perturbation at a high DEPC concentration. 
4.2.7 LC-MS Analysis of DEPC-Labeled Light and Heavy Chains of the mAbs 
Aliquots of rituximab and the NISTmAb (10 mg/mL, 70 μM) were reacted with 
DEPC. Information about sample preparation and DEPC labeling reaction conditions can 
be found in Section 4.2.2. After labeling and quenching, TCEP was added to the DEPC-
labeled samples at a 500:1 TCEP:mAb molar ratio to reduce the disulfide bonds of the 
mAb and yield heavy and light chains. The resulting mixtures were diluted in 50 mM 
phosphate buffer at pH 7.4 to a final concentration of 0.15 mg/mL.  
Online LC-MS analyses were performed on the TCEP-reduced samples. A sample 
containing approximately 2 μg protein was loaded on a Thermo Scientific Ultimate 3000 
HPLC system (Waltham, MA). The separation was performed on a Waters Acquity UPLC 
Protein BEH C4 column (50 mm x 2.1 mm, 1.7 μm particle size, 300 Å pore size; Milford, 
MA) with a flow rate of 200 μL/min. LC/MS-grade water (solvent A) and acetonitrile 
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(solvent B), each containing 0.1% formic acid, were used as mobile phases. Desalting was 
performed at 5% B during the first 4 min after sample injection. A linear gradient of solvent 
B was increased from 5% B to 100% B over 12 min. The gradient was held at 95% B for 
additional 3 min to flush a column. 
Mass spectra were acquired on a Thermo Scientific Orbitrap Fusion mass 
spectrometer (Waltham, MA). The electrospray needle voltage was kept at 4 kV (positive 
mode), and the ion transfer tube temperature was set to 330 °C. In-source activation energy 
was applied at 35 V to help remove water and other adducts from protein ions. Mass spectra 
were acquired on an Orbitrap analyzer, with a resolution of 15,000. The AGC target and 
maximum injection time were set to 1 × 106 ions and 100 msec, respectively. 
Measurements were conducted in the high mass range mode with 3 microscans per 
spectrum.  
4.3 Results and Discussion 
4.3.1 Dose-Response Plots as Indicators of Antibody Structural Changes upon DEPC 
Labeling 
Reliable information about the HOS of mAbs can be obtained from CL-MS 
experiments only when the protein’s structural integrity is preserved during the labeling. 
Under the conditions that DEPC is normally used for labeling, its reaction with a specific 
site in a protein follows second order kinetics.31 Deviations from these kinetics at high 
reagent concentrations can indicate a structural perturbation, as the labeling kinetics are 
sensitive to any structural changes that affect the reactivity of a given residue. We have 
shown in previous work with DEPC that breaks in linearity in dose-response plots are 
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indicators of labeling-induced structural perturbations in small proteins, such as 
cytochrome c and myoglobin.31 In addition, other investigators have used dose-response 
plots to measure structural changes during HRF and carboxyl group footprinting.28, 38 
Because DEPC can hydrolyze in water over time, the DEPC reactions are conducted at a 
constant reaction time t,  and a rate constant can be determined from a dose-response plot. 
Changes in local structural features like solvent accessibility and microenvironment19, 31, 40 
that can occur at higher DEPC concentrations lead to breaks in the linearity of the plot, 
indicating these structural perturbations (Figure 4.1b). Dose-response plots for individual 
proteolytic fragments of the labeled protein provide a sensitive measure of structural 
perturbations as they report on local changes. The experimental workflow to generate dose-
response plots for proteolytic fragments is shown in Figure 4.2. 
 
 
Figure 4.2: The experimental workflow used to generate dose-response plots for 
selected proteolytic fragments of the mAbs studied here.  
The mAb reacts with DEPC at different reagent concentrations. The labeled mAb is 
subjected to proteolytic digestion, and the labeled peptides are analyzed using LC–MS/MS. 
Peak areas of unmodified and modified species are used to generate a dose-response plot. 
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The antibodies rituximab and NISTmAb were reacted with a range of DEPC 
concentrations, and dose-response plots were generated for a set of representative peptides 
with labeled sites spread throughout the antibody structure (Figure 4.3). One to two 
peptides per domain were selected, and these peptides (a) had no post-translational 
modifications, and (b) were generated with no missed cleavages during the tryptic 
digestion. Several of the peptides that are reported here include residues in the 
complementarity-determining regions (CDRs), which makes them critically important for 
the antibody’s structure and function. Examples of tandem mass spectra and label site 
identifications of these representative peptides can be found in Figures 4.4 and 4.5. 
 
Figure 4.3: Labeling sites (orange sphere) from a set of representative peptides that 
were selected from different domains throughout the antibody structures.  
(a) Rituximab - Fab (PDB 4KAQ) and Fc (PDB 4W4N) structures of rituximab are aligned 
to the human IgG1 model, using the molecular visualization system PyMOL.29,41 Note that, 
for clarity, only one asymmetric unit of rituximab structure is labeled in this figure. (b) 
NISTmAb Fab (PDB 5K8A) and (c) NISTmAb Fc (PDB 4W4N) 
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Figure 4.4: MS/MS assignments for DEPC-labeled peptides from each of the six 
antibody domains in heavy chain (HC) and light chain (LC) of rituximab, (a) VH, (b) 
CH1, (c) CH2, (d) CH3, (e) VL, and (f) CL 
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Figure 4.5: MS/MS assignments for DEPC-labeled peptides from each of the six 
antibody domains in heavy chain (HC) and light chain (LC) of NISTmAb, (a) VH, (b) 
CH1, (c) CH2, (d) CH3, (e) VL, and (f) CL 
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4.3.2 Dose-response plots can be used to reveal labeling-induced structural 
perturbations for antibodies, which are multi-domain proteins 
Dose-response plots for selected proteolytic fragments of rituximab are shown in 
Figure 4.6. For all of the peptides, linear relationships are observed at low DEPC 
concentrations, suggesting that the protein’s HOS in different domains is maintained 
during the DEPC labeling at these concentrations. Breaks in linearity of the dose-response 
plots were determined from R2 values and standard errors of regression (sy/x).
42, 43 
Specifically, R2 values above 0.95 and sy/x below 30% were used as cutoffs for assessing 
linearity. The 30% value for sy/x was chosen because we found that the average %RSD for 
all the data for rituximab and NISTmAb is around 30%. One conclusion from the rituximab 
results is that the linearity of the dose-response plots is maintained for at least up to 6-fold 
DEPC in all cases, and for some residues it is maintained up to 10- or 15-fold DEPC [Table 
4.1 and Figure 4.6 (j) to (p)]. This observation means that rituximab’s HOS can be reliably 
maintained at DEPC:protein molar ratios of 6-fold. An almost identical conclusion is made 
from the dose-response plots for proteolytic fragments of NISTmAb (Figure 4.7). The 
dose-response plots maintain linearity up to 6-fold for all peptides, while some peptides 
retain linearity at DEPC:protein ratios as high as 15-fold [Table 4.1 and Figure 4.7 (f) to 
(o)]. The fact that deviations in linearity occur at higher than 6-fold DEPC for both 
antibodies suggests that this might be a DEPC:protein ratio that could be commonly used 
for mAbs without worry of structural perturbations. Indeed, because therapeutic mAbs 
have the same overall fold and tend to have identical Fc domains, the results obtained here 
are probably transferrable to all mAbs; however, more studies would likely be needed to 
more thoroughly evaluate this observation. 
 
156 
 
Table 4.1: A summary of the dose-response data for residues in rituximab and the 
NISTmAb.  
 
Antibody Residuea Secondary structure Linearity  
up to 
Rate coefficient kb 
(M-1 s-1) 
Rituximab 
LC S170/T171/Y172c -sheet & random coil 6X 7.4 ± 0.8 x 10
-1
 
HC H289/K292c Random coil 10X 3.1 ± 0.2 x 10
-1
 
HC Y282 -sheet  6X 1.6 ± 0.1 x 10
-1
 
LC H33 -sheet  6X 1.0 ± 0.1 x 10
-1
 
HC S25/Y27c Random coil 10X 7.2 ± 0.6 x 10
-2
 
LC Y48 Random coil 15X 4.9 ± 0.3 x 10
-2
 
HC Y395/K396c -sheet  10X 2.2 ± 0.1 x 10
-2
 
HC T254 -sheet  6X 2.1 ± 0.4 x 10
-2
 
HC Y377 Random coil 6X 1.34 ± 0.02 x 10
-2
 
HC S258 Random coil 6X 1.31 ± 0.06 x 10
-2
 
HC Y153 Random coil 6X 8.5 ± 0.1 x 10
-3
 
HC Y52 -sheet  6X 3.6 ± 0.2 x 10
-3
 
HC Y60/K63c Random coil 6X 3.5 ± 0.2 x 10
-3
 
HC S185/S187/S188c -sheet 15X 2.5 ± 0.1 x 10
-3
 
HC S161 -sheet 10X 2.5 ± 0.2 x 10
-3
 
LC T108 Random coil 10X 2.2 ± 0.1 x 10
-3
 
 
NISTmAb 
HC K58/K59c -sheet & random coil 6X 8.0 ± 0.2 x 10
-1
 
HC Y281 -sheet  10X 3.6 ± 0.1 x 10
-1
 
HC H288/K291c Random coil 10X 3.5 ± 0.1 x 10
-1
 
HC K13 Random coil 8X 3.2 ± 0.2 x 10
-1
 
LC Y31 Random coil 15X 4.3 ± 0.5 x 10
-2
 
LC H33 -sheet  15X 2.3 ± 0.2 x 10
-2
 
LC T50/S51/K52c -sheet & random coil 6X 1.22 ± 0.04 x 10
-2
 
LC S170/T171/Y172c -sheet & random coil 10X 1.22 ± 0.09 x 10
-2
 
HC Y376 Random coil 10X 1.1 ± 0.1 x 10
-2
 
HC T253 -sheet  6X 4.7 ± 0.5 x 10
-3
 
HC Y152 -sheet 10X 4.5 ± 0.3 x 10
-3
 
HC S127 -sheet  6X 3.6 ± 0.1 x 10
-3
 
HC S257 Random coil 6X 3.1 ± 0.2 x 10
-3
 
HC S134/S135/K136c -helix 10X 2.9 ± 0.2 x 10
-3
 
LC T108 Random coil 8X 2.2 ± 0.1 x 10
-3
 
a LC refers to light chain, and HC refers to heavy chain. 
b The k values are obtained by dividing the measured slope by the reaction time (see Equation 4.8). Error 
bars are calculated from the standard error of the slope. 
c Tandem mass spectrometry does not enable the precise modification site to be definitively identified. 
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Figure 4.6: Dose-response plots for selected proteolytic fragments of rituximab after 
labeling with DEPC at different concentrations varying from 2- to 30-fold DEPC to 
protein molar ratio (2X to 30X).  
The plots of reactive residues from different antibody domains (VH, CH1, CH2, CH3, VL, 
and CL) in heavy chain (HC) and light chain (LC) are shown here. From all of the 
representative peptides, linear relationships are observed between the unmodified fraction 
𝐥𝐧(
[𝑿]𝟎[𝑷]
[𝑿][𝑷]𝟎
) and the DEPC concentrations at low reagent concentrations up to 6X [plots (a) 
to (i)] or beyond 6X [plots (j) to (p)]. The rate coefficient (k) values in M-1 s-1 are obtained 
by dividing the measured slopes by the reaction time (see Equation 4.8), and the error bars 
are calculated from standard error of slope. 
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Figure 4.7: Dose-response plots for selected proteolytic fragments of NISTmAb after 
labeling with DEPC at different concentrations varying from 2- to 30-fold DEPC to 
protein molar ratio (2X to 30X).  
The plots of reactive residues from different antibody domains (VH, CH1, CH2, CH3, VL, 
and CL) in heavy chain (HC) and light chain (LC) are shown here. From all of the 
representative peptides, linear relationships are observed between the unmodified fraction 
𝐥𝐧(
[𝑿]𝟎[𝑷]
[𝑿][𝑷]𝟎
) and the DEPC concentrations at low reagent concentrations up to 6X [plots (a) 
to (e)] or beyond 6X [plots (f) to (o)]. The rate coefficient (k) values in M-1 s-1 are obtained 
by dividing the measured slopes by the reaction time (see Equation 4.8), and the error bars 
are calculated from standard error of slope. 
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A closer look at the labeling data reveals that some antibody domains are more 
susceptible to labeling-induced structural changes than others (Table 4.1 and Figure 4.8). 
Most notably, the Fab has a greater percentage of sites (60%) whose linearity goes beyond 
6-fold DEPC. In contrast, the CH2 domain has a smaller percentage (38%) of sites that 
maintain linearity past 6-fold DEPC. These observations are consistent with the known 
stability differences of the Fab and CH2 domains. Previous studies have identified the 
melting temperatures (Tm) to be 71°C and 74°C for the CH2 and Fab domains of rituximab, 
respectively, and  69°C and 83°C for those of the NISTmAb.44, 45 The CH2 domains of both 
antibodies have lower Tm values than that of Fab domains, which may explain why the CH2 
domain is more sensitive to labeling-induced structural perturbations. Upon comparing the 
Fab sites in each antibody, the NISTmAb has higher number of sites whose linearity goes 
beyond 6-fold DEPC (70%) than rituximab (50%). Perhaps the higher overall stability of 
NISTmAb’s Fab explains why it has higher number of sites whose linearity goes beyond 6-
fold DEPC. 
 
 
Figure 4.8: Trends of structural perturbations with regard to different antibody 
domains.  
The Fab has a greater percentage of sites whose linearity goes beyond 6X (60%, 12 out of 
20 sites) whereas CH2 has a smaller percentage of sites whose linearity goes beyond 6X 
(38%, 3 out of 8 sites). Considering the number of Fab sites in each antibody, NISTmAb 
has higher number of sites whose linearity is beyond 6X (70%, 7 out of 10 sites) while 
rituximab has lower number (50%, 5 out of 10 sites). 
 
 
162 
 
4.3.3 Labeling rate coefficients can be determined from dose-response plots 
DEPC modification rate coefficients (k) range from 2.2 x 10-3 to 8.0 x 10-1 M-1 s-1 
(Table 4.1). These are ‘apparent’ rate coefficients because differences in ionization 
efficiencies between the labeled and unlabeled peptides make it difficult to obtain real rate 
coefficients from the experiments. The reaction rate coefficients tend to be higher for His 
and Lys residues than for Ser, Thr, and Tyr residues. Around 85% of His/Lys residues have 
k values greater than 1 x 10-2 M-1 s-1, while about 50% of the Ser/Thr/Tyr residues have k 
values greater than 1 x 10-2 M-1 s-1. These results are consistent with our previous studies 
that His and Lys side chains have higher intrinsic reactivities towards DEPC labeling than 
Ser, Thr, and Tyr side chains.19, 31, 40  
Because the two mAbs have the same constant domain sequences, and presumably 
similar/ structures in these regions, we also can compare DEPC labeling rate coefficients 
for eight common residues in these constant regions (CL, CH1, and Fc) to understand how 
the formulation affects the labeling rates. Upon comparing the common residues, we find 
that H289/K292 (H288/K291) and Y377 (Y376) in the heavy chain and T108 in the light 
chain have essentially the same rate coefficients for the two mAbs. Note that the 
NISTmAb’s residue numbers are shown in parentheses as its heavy chain has one less 
residue at the N-terminus than rituximab. In contrast, the rate coefficients for Y153 (Y152), 
Y282 (Y281), T254 (T253), and S258 (S257) in the heavy chain change by a factor of 2 to 
4, and the rate coefficient for S170/T171/Y172 in the light chain changes by a factor of 
almost 60. The difference in labeling rate coefficients for these residues can be ascribed to 
(a) differences in the rituximab and NISTmAb formulations and/or (b) changes in the 
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microenvironment around these residues due to the formulation differences or non-
identical local structures in the constant regions of these mAbs.  
The key differences of the rituximab and NISTmAb formulations are pH (6.5 and 
6.0, respectively) and the presence of polysorbate 80 in the former. The residues Y153, 
Y282, T254 have nearby acidic residues (within 4 Å distance). The difference in the pH of 
the two mAb formulations could affect the protonation states of these adjacent acidic 
residues, thereby influencing the nucleophilicity and thus the DEPC reactivity of these Tyr, 
Ser, and Thr residues.19 In contrast, there are no acidic residues adjacent to H289/K292, 
Y377, and T108, perhaps explaining why the rate coefficients for these residues are almost 
the same for the two mAbs. Interestingly, S170 has a nearby acidic residue in the 
NISTmAb, but in rituximab an Arg residue is close, perhaps explaining why 
S170/T171/Y172 is 60-fold more reactive in rituximab. Moreover, the microenvironment 
around these residues in each mAb is quite different in terms of nearby hydrophobic 
residues and other polar residues. 
4.3.4 Multi-domain antibodies can be labeled with more than one DEPC molecules 
before being structurally perturbed 
The ‘single hit rule’ in CL indicates that the addition of subsequent covalent labels 
after the first will necessarily occur to a chemically perturbed protein and should thus be 
avoided. We were interested, though, to see how many DEPC labels a multi-domain protein 
could accommodate before structural changes actually occurred, as evidenced by changes 
in the reaction kinetics. Because the dose-response plots for both antibodies were still linear 
up to a 6-fold excess of DEPC, we separately reacted each antibody with this level of DEPC 
and then measured the extent of labeling on the intact light and heavy chains using LC-MS 
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We find that the weighted average numbers of labels on the light chains of rituximab and 
NISTmAb are 0.6 and 0.7, respectively, whereas the weighted average number of labels 
on the two heavy chains of rituximab and NISTmAb are 2.3 and 2.7, respectively (Figure 
4.9). Note that the heavy chain’s spectra are complicated by N-glycan heterogeneity. 
Enzymatic removal of the glycoform to reduce spectral complexity is possible, but we did 
not perform this because we wanted to limit any possible hydrolysis of the DEPC labeled 
sites during the relatively long enzymatic reaction time. Because each protein has two light 
chains, the total extent of labeling is 3.5 for rituximab and 4.1 for NISTmAb.  
The fact that both antibodies can accommodate 3 or 4 labels before any structural 
perturbation is observed suggests that the ‘single hit rule’ is not relevant to such large multi-
domain proteins such as antibodies. Previous work in our group on relatively small (< 30 
kDa) single-domain proteins showed that modification conditions that lead to 0.8 to 1.2 
labels per protein on average can maintain the structural integrity of these proteins during 
the labeling.31, 46, 47 Being able to add more than one label per mAb is beneficial for CL-
MS studies, as it allows a more sensitive measure of structure because more modifications 
are detected. It is perhaps not surprising that multi-domain proteins such as mAbs are 
capable of accommodating more than one label, as the multi-domain structure of these 
proteins likely make them less readily perturbed when modifications are occurring at 
distant sites (e.g. different domains). This explanation is supported by the success of 
therapeutic antibody-drug conjugates (ADCs) that have hydrophobic drugs attached. 
Conjugation of these drugs, often at multiple sites, do not significantly perturb the structure 
and function of the multi-domain antibody.48-51 While up to 4 DEPC modifications can be 
accommodated by the mAbs studied here, these proteins do have 12 domains, so 
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modification-induced structural changes still do occur across domains. Overall, our 
findings indicate that multi-domain antibodies can be labeled with more than one DEPC 
molecule before being structurally perturbed, thus improving the CL-MS resolution 
substantially compared to the single-hit rule. In addition, these results could be helpful for 
understanding the extent to which ADCs could be conjugated with drug molecules before 
structural perturbations are observed. 
 
Figure 4.9: Mass spectra obtained from LC-MS analyses of DEPC-labeled mAbs, 
showing the extent of modification for the light and heavy chains of (a) rituximab and 
(b) NISTmAb after labeling at 6-fold DEPC:protein molar ratio.  
COEt refers to a carbethoxy group that is the product upon modification with DEPC. 
Because of glycan heterogeneity on the heavy chain (HC) and signal overlap with the light 
chain (LC), only the G1F/G1F glycoform of a non-reduced heavy chain (2HC) is shown. 
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4.4 Conclusion 
Measuring the kinetics of DEPC CL reactions can reveal the DEPC concentrations 
at which labeling-induced structural perturbations occur for antibodies. For two separate 
antibodies that have different formulations, we find that a 6-fold molar excess of DEPC 
can be used without perturbing the protein’s structure, suggesting that this is a reliable 
DEPC concentration for CL studies of antibodies. This practical finding should avoid the 
need for time-consuming optimization of DEPC CL conditions for antibodies. Moreover, 
at these DEPC:mAb labeling ratios, up to four DEPC modifications can be added, 
indicating that these multi-domain proteins can accommodate more than one label without 
being structurally perturbed.  Interestingly, most of the domains in the NISTmAb maintain 
their structural integrity at higher DEPC concentrations than rituximab, which is consistent 
with the greater stability of this mAb. This observation may suggest that more thermally 
stable proteins could accommodate even higher levels of labeling, allowing a more 
sensitive measure of HOS by DEPC CL.  Overall, these studies improve our ability to use 
DEPC CL to study the HOS of protein therapeutics. 
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CHAPTER 5 
 
SUMMARY AND FUTURE DIRECTIONS 
5.1 Summary 
This dissertation has described the use of a diethylpyrocarbonate (DEPC-based 
covalent labeling (CL) method combined with mass spectrometry (MS) to characterize the 
higher-order structure (HOS) of proteins and protein therapeutics. DEPC is a simple to use, 
commercially-available CL reagent.  From reactions of amino acid side chains with DEPC, 
a protein’s structural properties can be encoded into the mass of protein, and the site-
specific identification of modified residues can be performed by MS. This dissertation aims 
to address the need in pharmaceutical industry, specifically the protein therapeutics field. 
Characterizing HOS of monoclonal antibodies (mAbs) is challenging given their size and 
the multidomain nature. As one of the non-specific reagents, DEPC can readily react with 
a range of residues in proteins, allowing for higher structural resolution to obtain insight 
into conformational changes of therapeutic proteins. 
In Chapter 2, we studied the effect of residue microenvironment on DEPC labeling 
reactivity of weakly nucleophilic residues (Ser, Thr, and Tyr). We find that in intact 
proteins Ser, Thr, and Tyr can be modified by DEPC in addition to other residues such as 
His and Lys, which allows for higher structural resolution to obtain insight into 
conformational changes of therapeutic proteins. Our findings indicate that a hydrophobic 
microenvironment influences Ser, Thr, and Tyr reactivity toward DEPC labeling in intact 
proteins more than solvent accessibility. Meanwhile, His and Lys are less likely to be 
affected by a hydrophobic microenvironment because they are inherently much more 
reactive than Ser, Thr, and Tyr, so they do not need high local concentrations of DEPC to 
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be modified. Additional studies are needed to further verify the hydrophobic 
microenvironment effect, but the reactivity of specific Ser, Thr, and Tyr residues could be 
used to provide insight into the local microenvironment around these residues and could 
be useful in CL-MS-based protein structural prediction. For example, the reactivity of 
specific Ser, Thr, and Tyr residues in proteins could indicate the presence of nearby 
hydrophobic residues, and this information could be used to improve confidence in certain 
structural models. In protein-ligand complexes, we anticipate that if a ligand is 
hydrophobic enough, the labeling reactivity of close-by Ser, Thr, and Tyr residues should 
reveal the presence of ligand binding sites. 
In Chapter 3, we demonstrated the use of DEPC-based CL-MS to detect 
conformational changes caused by heat stress of therapeutic mAbs. Our DEPC CL-MS 
technique compares favorably to other MS-based structural techniques (e.g., hydrogen-
deuterium exchange [HDX],1-3 hydroxyl radical footprinting [HRF],4 and dimethyl 
labeling5) that have been used recently to study HOS changes or identify aggregation 
interfaces of mAbs. To the best of our knowledge, our CL-MS technique is the first to 
report a subtle HOS change of a therapeutic mAb at the temperature far below the antibody 
melting temperature, changes that are not detected by common characterization techniques. 
At higher stress temperature, conformational changes and aggregation sites are also 
identified.  
CL-MS using DEPC offers some advantages over other MS-based techniques, 
especially for revealing protein aggregation interfaces and protein-ligand binding sites. In 
HDX-MS, reduced deuterium exchange along a protein backbone is used to identify 
binding interfaces, even though protein-protein and protein-ligand interactions are 
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primarily mediated by side chain interactions. DEPC labeling reports on side chains, 
thereby providing a more direct indication of binding interfaces. Decreased labeling at 
specific residues can be used to determine the binding interfaces because protein 
aggregation and ligand binding decrease the solvent accessibility of the side chains 
involved in a binding event. CL-MS also does not require specialized equipment like HDX-
MS, thereby simplifying the overall approach. HRF is another side-chain labeling 
technique, but HRF techniques also require specialized lasers or synchrotron sources to 
generate the radicals. In addition, radicals generate multiple reaction products which can 
complicate the analyses, as opposed to a single one with DEPC. However, DEPC CL has 
the slower labeling time scale than HDX and HRF, which should make it only sensitive to 
changes in solvent accessibility and insensitive to changes in protein dynamics. Thus, 
changes in protein dynamics at allosteric sites upon protein-protein and protein-ligand 
interactions are likely not to be reported by DEPC CL-MS. 
In Chapter 4, we evaluated applicability of DEPC reaction kinetics to ensure site-
specific or local structural integrity of multi-domain mAbs during labeling as reliable 
information about HOS of mAbs can be obtained only when the protein’s structural 
integrity is preserved during the labeling. We find that multi-domain mAbs can withstand 
many more than one label, which contrasts to previously studied single-domain proteins. 
This more extensive labeling provides a more sensitive measure of structure, making 
DEPC-based CL-MS suitable for the HOS analyses of mAbs. However, we do not expect 
that all big proteins can withstand more than one label per protein because different 
proteins have different folding and thermal stability. Structure of big proteins with limited 
stability may be perturbed even after having only one label per protein. In addition, even 
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though big proteins are likely less perturbed when modifications occur at distant sites, an 
allosteric effect might be induced by a first label and results in a conformation change at a 
distant site.   
For protein-ligand systems, measuring the kinetics of DEPC CL reactions should 
be able to reveal the DEPC concentrations at which labeling-induced structural 
perturbations occur for a protein, ensuring that there is no ligand dissociation upon labeling. 
If more than one labels on average per protein molecule is possible for the protein-ligand 
complex, the increased structural resolution can improve the identification of ligand 
binding sites and allosteric sites.  
5.2 Future Directions 
The following sections discuss possible future improvements to the covalent 
labeling method and the structural characterization of protein therapeutics.  
5.2.1 Residue Microenvironment Effect on DEPC Covalent Labeling 
5.2.1.1 Microenvironment Investigations of DEPC Covalent Labeling Data Obtained 
from Other Proteins 
In Chapter 2, we find evidence that the presence of nearby hydrophobic residues 
increases the DEPC reactivity of Ser, Thr, and Tyr residues in intact proteins.6 However, 
the examination of the structural features was performed for only three different proteins, 
β-2-microglobulin (2m), ubiquitin, and human growth hormone (hGH) (Tables A.1, A.2, 
and A.3 in Appendix A). In order to get more evidence to support that the nearby 
hydrophobic residues are essential for the enhanced reactivity of certain Ser, Thr, and Tyr 
residues, we should expand the microenvironment investigations to DEPC labeling results 
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of Ser, Thr, and Tyr residues in other proteins. In this dissertation, we have used DEPC 
CL-MS data7 recently obtained from bovine carbonic anhydrase (BCA), equine holo-
myoglobin (MYG), and hen egg-white lysozyme (LYZ) intact proteins. Structural features 
and DEPC modification percentages for nucleophilic residues in these proteins are shown 
in Tables A.4, A.5, and A.6. Adding data from these three proteins to the data from three 
proteins in Chapter 2, altogether, the total number of Ser, Thr, and Tyr residues in six 
different proteins is 139 of which 55 residues are found to be labeled by DEPC in these 
proteins. Interestingly, almost 90% of the labeled Ser, Thr, and Tyr residues that sits close 
to at least one hydrophobic side chain (Figure 5.1). In contrast, only half of the unlabeled 
Ser, Thr, and Tyr residues have nearby hydrophobic residues (Figure 5.1). This additional 
evidence can emphasize the importance of nearby hydrophobic groups for 
enhancing Ser, Thr, or Tyr reactivity.    
 
Figure 5.1: Flow chart summarizing the covalent labeling results and the structural 
features of weakly nucleophilic residues in six different proteins.  
 
However, we do not see evidence that the presence of nearby hydrophobic residues 
can enhance the DEPC reactivity of Ser, Thr, and Tyr residues in rituximab. Around 70% 
of both the labeled and the unlabeled Ser, Thr, and Tyr residues have nearby hydrophobic 
residues. Because a full crystal structure for rituximab is not available, the comparison may 
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have flaws. Another explanation is based on the rituximab formulation (10 mg/mL 
rituximab) which contains 0.7 mg/mL polysorbate 80 (Tween® 80). As a molar ratio of 
polysorbate 80 to rituximab is more than 7,000-fold, and the concentration of polysorbate 
80 is above its critical micellar concentration (13 to 15 mg/L),8 we hypothesize that 
polysorbate 80 may form a micelle around rituximab which may affect the 
microenvironment effect from hydrophobic residues. To investigate the microenvironment 
effect regarding the presence of nearby hydrophobic residues without a micelle, labeling 
experiments should be performed on (a) rituximab with polysorbate 80 removal or (b) 
NISTmAb whose formulation does not contain any surfactant.  
Additionally, because the microenvironment investigations described herein were 
performed on PDB atomic coordinate of each protein in a manual manner, it is very time 
consuming to expand the investigations into the larger proteins such as mAbs. A computer 
script should be written and programmed to identify and determine the number of 
hydrophobic neighboring residues around Ser, Thr, and Tyr residues from atomic 
coordinates of the 3D structures of proteins. The computer script will allow further 
investigations of the microenvironment effect on DEPC covalent labeling of proteins. 
Ultimately, we expect that the reactivity of certain Ser, Thr, and Tyr residues could be used 
to indicate the presence of nearby hydrophobic groups and thus could be used as constraints 
in protein structure prediction and to improve confidence in certain structural models.   
5.2.1.2 Quantitative correlation between DEPC Labeling Extent and the Distance of 
the Close-by Hydrophobic Residues 
Investigations of the microenvironment around Ser, Thr, and Tyr residues in intact 
proteins indicate that hydrophobicity is important for labeling rather than solvent 
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accessibility or polar interactions. However, we still have no evidence of a quantitative 
correlation between DEPC labeling extent and the distance of the close-by hydrophobic 
residues. This lack of a quantitative correlation could be for many reasons. One reason 
could be the structures we use for determining the distance of the hydrophobic residues. 
Some of the structures come from X-ray crystallography, and therefore do not take into 
account of protein dynamics. One might expect that the distances might vary to some extent 
as the protein undergoes local motion. In order to address this issue, simulation of the 
molecular dynamics of proteins should be performed to investigate the distance between 
the hydrophobic residues and Ser, Thr, and Tyr residues. We expect to obtain a quantitative 
correlation between the distance of the nearby hydrophobic residues and the DEPC 
modification percentage of these residues. 
Another reason for the lack of quantitative correlation could be the fact that we do 
not measure an absolute level of labeling extent, but instead we measure a relative extent 
of labeling. The modification levels here do not reflect the absolute quantitation of 
modified species as the addition of a carbethoxyl group to the modified peptide and the 
different LC solvent conditions during gradient elution of peptides result in different 
ionization efficiencies for the unmodified and modified peptides. If possible, we might be 
able to correct for the ionization efficiency differences between the labeled and unlabeled 
peptides and thus get a more accurate measurement of the modification percentage.  
5.2.1.3 Structure-Reactivity Relationship of Reagent’s Functional Group and the 
Labeling Reactivity at Weakly Nucleophilic Side Chains 
Despite the successful use of DEPC, their chemical tunability and/or amino acid 
coverage could still be improved upon. As our study suggests that hydrophobicity may 
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contribute to higher labeling reactivity of weak nucleophiles due to the increase in local 
concentration of a CL reagent at protein’s surface,6 hydrophobicity can be one of the 
reagent properties to be considered for reagent development for the CL-based structural 
analysis of proteins and protein therapeutics. Recently, we have developed a new class of 
CL reagents having an α,β-unsaturated carbonyl (ABUC) scaffold (Figure 5.2) for 
studying protein HOS.9 ABUC reagents with hydrophobic functional group variations can 
be synthesized. Effect of hydrophobic moiety (e.g. R2 = H, Me, Et, n-Bu, t-Bu) on the 
labeling reactivity at weakly nucleophilic side chains should be evaluated using specific 
model peptides and proteins.  
 
Figure 5.2: Structure of the α,β-unsaturated carbonyl (ABUC) reagent 
(R1 = leaving group, R2 = hydrophobic functional group) 
We anticipate that the hydrophobic moiety of these CL reagents, if not limited by 
solubility, can contribute to the increase in CL reactivity of these residues. If tuning 
hydrophobicity does not significantly improve probing resolution of CL reagents, an 
alternate plan will focus on tuning stability of a leaving group (e.g. with a better leaving 
group as R1) and/or electrophilicity of a reaction site (e.g. with a more electron withdrawing 
group as R2) to accelerate the labeling reaction. Tuning functional groups of ABUC-
scaffold CL reagents will allow the development of novel CL reagents for HOS 
characterization of protein therapeutics with expanded structural coverage and good 
sensitivity to detect subtle structural changes. 
179 
 
5.2.2 Structural Characterization of mAb Therapeutics 
5.2.2.1 Synergistic Structural Information about Stressed Therapeutic Antibodies 
from Hydrogen Deuterium Exchange (HDX) and CL-MS 
In Chapter 3, we demonstrate the ability of DEPC CL-MS to investigate HOS of 
antibody therapeutics. DEPC can probe solvent accessibility and the microenvironment of 
side chains, and any changes in DEPC reactivity are indicative of changes in protein 
conformation. DEPC CL technique can provide structural information which is 
complementary to what can be obtained from HDX. HDX reports on the protein backbone 
structure and dynamics while DEPC CL reports on side chain accessibility. CL-MS 
experimental results can be compared with HDX-MS results to validate the consistency of 
structural characterization. In addition, because of the different labeling timescales of these 
two techniques, we predict that there might be synergy between HDX and CL data when 
studying HOS of mAbs. Using HDX to characterize structures of stressed rituximab after 
heating at different temperatures may offer further insights into the HOS of antibody 
undergoing from subtle to massive conformation changes. 
5.2.2.2 DEPC CL-MS for Epitope Mapping of Antigen-Antibody Interactions 
Covalent labeling techniques are emerging as powerful tools for epitope mapping 
of mAbs. Previously, hydroxyl radical footprinting (HRF) has been used to perform epitope 
mapping for various antigen-antibody interactions.10-12 To demonstrate the applicability of 
DEPC labeling for epitope mapping, DEPC CL-MS will be used to identify distinct three-
dimensional epitopes for adalimumab, infliximab, and golimumab on tumor necrosis factor 
alpha (TNF). We expect that the identified epitopes from CL-MS will be consistent with 
the epitopes obtained from the previously published crystal structures (PDB 3WD5, 5YOY, 
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and 4G3Y for TNF in complex with adalimumab, infliximab, and golimumab, 
respectively). In addition, HDX-MS can be used to provide complementary information to 
CL-MS regarding the epitope mapping. 
5.2.3 DEPC CL Reaction Kinetics for Ensuring Structural Integrity 
5.2.3.1 Determination of DEPC Labeling Reaction Order Using Kinetic Isolation 
Method 
The bimolecular reaction between DEPC and a specific site in protein should follow 
second order kinetics.9 In Chapter 4, we demonstrated that dose-response plots based on 
reaction kinetics of DEPC CL can be used to reveal labeling-induced structural 
perturbation for antibodies with an assumption that deviation from the second order 
kinetics can indicate structural perturbation of mAbs. However, the rate law does not 
necessarily reflect that stoichiometry of reaction for once the products or intermediates that 
have been generated might participate in the reaction and affect the rate.13 In addition, 
DEPC molecule is symmetric and has two reaction sites, hence we are concerned that the 
labeling reaction between DEPC and a nucleophilic site may not undergo the regular 
second order kinetics. Determination of DEPC labeling reaction order should be performed 
in order to get more understandings about the labeling kinetics. Kinetic isolation method 
can be used for the determination of the rate law.13 To reduce complexity of the study, we 
will use the model peptide sequence of Fmoc-DGXGG-amide (X = nucleophilic residue) 
which has only single modifiable site for DEPC labeling. The kinetic isolation method will 
be applied to assess reaction orders with regard to the model peptide and DEPC. 
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In the kinetic isolation method, the reaction between DEPC and a nucleophilic site 
in the model peptide is assumed to be under higher-order kinetics with a rate equation 
shown below (Equation 5.1). 
Peptide (P) + DEPC → Carbethoxylated P + CO2 + CH3CH2OH 
𝑅𝑎𝑡𝑒 =  −
𝑑[𝑃]
𝑑𝑡
= 𝑘[𝐷𝐸𝑃𝐶]𝑎[𝑃]𝑏              (5.1) 
where a and b are the reaction orders with regard to DEPC and the model peptide, 
respectively, [P] is the concentration of unmodified peptide at time t, [X] is the DEPC 
concentration at time t, and k is the labeling rate coefficient. 
➢ Reaction with excess [DEPC] 
Given  𝑘𝐷𝐸𝑃𝐶 =  𝑘[𝐷𝐸𝑃𝐶]
𝑎            (5.2) 
The rate equation is reduced to 𝑅𝑎𝑡𝑒 =  −
𝑑[𝑃]
𝑑𝑡
= 𝑘𝐷𝐸𝑃𝐶[𝑃]
𝑏                   (5.3) 
    log Rate =  log 𝑘𝐷𝐸𝑃𝐶 + 𝑏 log  [𝑃]                    (5.4) 
Initial rate method  log Rate0 =  log 𝑘𝐷𝐸𝑃𝐶 + 𝑏 log  [𝑃]0       (5.5) 
The initial rate (Rate0) can be measured during an infinitesimal time (t → 0), and we 
assume that 1-min labeling time is small enough. 
Rate0 = −
𝑑[𝑃]
𝑑𝑡
  −
[𝑃]
𝑡
     (5.6) 
Experimentally, the model peptide at different concentrations ([𝑃]0 = 25, 50, 75, 
100, 150 µM) is labeled with DEPC at a fixed excess concentration ([𝐷𝐸𝑃𝐶]0 = 150 µM) 
for 1 min, and the reaction is then quenched with imidazole. LC-MS is used to determine 
a DEPC modification percentage in order to obtain [𝑃] and calculate Rate0. Reaction 
order with regard to the model peptide (b) can be obtained from a slope of a plot between 
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log Rate0 and log [𝑃]0 (see Equation 5.5). Our study shows that in a reaction between 
DEPC and the model peptide Fmoc-DGYGG-amide, the reaction order with regard to the 
peptide is one. (Figure 5.3) 
 
Figure 5.3: Determination of the reaction order with regard to the model peptide 
using kinetic isolation method 
 
➢ Reaction with excess [P] 
Given  𝑘𝑃 =  𝑘[𝑃]
𝑏                        (5.7) 
The rate equation is reduced to 𝑅𝑎𝑡𝑒 = 𝑘𝑝[𝐷𝐸𝑃𝐶]
𝑎                               (5.8) 
    log Rate =  log 𝑘𝑃 + 𝑎 log  [𝐷𝐸𝑃𝐶]                    (5.9) 
Initial rate method  log Rate0 =  log 𝑘𝑃 + 𝑎 log  [𝐷𝐸𝑃𝐶]0                (5.10) 
Rate0 can be measured during an infinitesimal time (t → 0), and we assume that 1-min 
labeling time is small enough. 
Rate0 = −
𝑑[𝐷𝐸𝑃𝐶]
𝑑𝑡
  −
[𝐷𝐸𝑃𝐶]
𝑡
     (5.11) 
183 
 
Our experimental plan is as follows. The model peptide at a fixed excess 
concentration ([𝑃]0) is labeled with DEPC at different concentrations ([𝐷𝐸𝑃𝐶]0) for 1 
min, the second peptide (e.g. Cys-containing peptide) is then added to react with the 
remaining DEPC, and the reaction is finally quenched with imidazole. LC-MS is used to 
determine a DEPC modification percentage of the second peptide, and a concentration of 
the remaining DEPC can be obtained from a plot between DEPC concentration and 
modification percentage of the second peptide. [𝐷𝐸𝑃𝐶] and Rate0 can be calculated from 
the concentration of the remaining DEPC. Reaction order with regard to DEPC (a) can be 
obtained from a slope of a kinetic plot between log Rate0 and log  [𝐷𝐸𝑃𝐶]0 (see Equation 
5.10). 
5.2.3.2 Determination of DEPC Modification Rate Coefficients: Correction for the 
Ionization Efficiency Differences  
In Chapter 4, DEPC modification rate coefficients (k) determined from dose-
response plots are ‘apparent’ rate coefficients because differences in ionization efficiencies 
between the labeled and unlabeled peptides make it difficult to obtain real rate coefficients 
from the experiments. The ionization efficiency differences between the labeled and 
unlabeled peptides might be corrected in order to get a more accurate rate measurement. 
To accomplish this, the ion intensities of the labeled peptides should be plotted as a function 
of DEPC concentration up to the molar ratio at which deviation occurs. A plot for the 
unlabeled peptide should be separately prepared. The slopes of these plots would 
effectively be the sensitivities of the peptides, and the ratios of these sensitivities should be 
the ratio of the ionization efficiencies. We expect that this correction might work if the 
reproducibility of the data is good enough. 
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To see if there is any trend in the data with regard to rate coefficients, plotting the 
measured rates for a given residue type as a function of SASA and as a function of the 
number of nearby hydrophobic groups (or distance of hydrophobic groups or some 
combination of those factors) should be considered. 
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APPENDIX A 
STRUCTURAL FEATURES AND DEPC MODIFICATION PERCENTAGES 
FOR NUCLEOPHILIC RESIDUES IN DIFFERENT PROTEINS 
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Table A.1: DEPC modification percentages of nucleophilic residues in 2m intact protein and its proteolytic peptides.  
Each experiment was performed in triplicate or quadruplicate (n = 3 or 4). Error bars shown in a table are standard deviations. Listed 
along are structural features of each residue from PDB 1JNJ. ✔ and ✖ represent presence or absence of each structural element, 
respectively. (+) and (-) represent positively charged and negatively charged polar contacts, respectively.  
 
2m 
residue 
Secondary 
structure 
pKaǂ Solvent accessibility* Microenvironment % DEPC CL 
%SASA 
ratio 
> 20% 
Charged polar contact 
[within 4 Å] 
Hydrophobic 
neighbor 
[within 6 Å] 
Intact protein 
(DEPC:protein 
= 4:1) 
Peptide 
(DEPC:peptide 
= 4:1) 
Peptide 
(DEPC:peptide 
= 50:1) 
T4 Random 
coil 
N/Aa 81.5 
 
✔ ✖ 
- Overall: Uncharged, nothing 
✔ 
- OH close to P5, L87 
59  5 
(T4 & N-
term) 
N.D.c 0.02  0.01 
K6 -sheet 10.42 
 
79.6 
 
✔ ✖ 
-  H-bonding with backbone CO 
of D8 
- Overall: Uncharged, polar 
contact 
✖ 
 
41  5 
 
N/Ab N/A 
Y10 -sheet 10.98 
 
41.6 
 
✔ ✖ 
-  H-bonding with side chain 
CONH2 of N24 
- Overall: Uncharged, polar 
contact 
✔ 
- OH close to Y26, 
L65 
 
15  2 
 
N.D. 
 
3.9  0.8 
 
S11 -sheet N/A 10.3 
 
✖ 
 
✖ 
-  H-bonding with side chain 
aromatic amine of W95 
-  H-bonding with backbone CO 
of F22, R97, M99 
-  H-bonding with backbone NH 
of R12, D98, M99 
- Overall:  Uncharged, polar 
contact 
✔ 
- OH close to A15, 
L23, F70, M99 
 
 
3.0  0.5 
 
N.D. 
 
0.02  0.01 
H13 Random 
coil 
6.09 
 
47.7 
 
✔ ✖ 
- Overall: Uncharged, nothing 
✔ 
- imidazole amine 
close to F22  
30 ± 3 N/A N/A 
a N/A = not applicable; b N-terminal blocking using SNHSA also results in side reaction (acetylation) at Lys and His residues in free peptides, so they are not discussed here. 
c N.D. = not detected (less than DEPC labeling threshold of 0.01%1)  
* SASA calculated using GETAREA2, as explained in detail in Section 2.2.8; ǂ pKa calculated using PROPKA3 
188 
 
2m 
residue 
Secondary 
structure 
pKaǂ Solvent accessibility* Microenvironment % DEPC CL 
%SASA 
ratio 
> 20% 
Charged polar contact 
[within 4 Å] 
Hydrophobic 
neighbor 
[within 6 Å] 
Intact protein 
(DEPC:protein 
= 4:1) 
Peptide 
(DEPC:peptide 
= 4:1) 
Peptide 
(DEPC:peptide 
= 50:1) 
K19 Random 
coil 
10.42 
 
77.7 
 
✔ ✔ 
- Salt bridge with side chain 
COOH of E16  
-  H-bonding with backbone CO 
of S20, N21 
- Overall: Charged, (-) 
✖ 
 
30  2 N/A N/A 
S20 Random 
coil 
N/A 61.6 
 
✔ ✔ 
-  H-bonding with side chain OH 
of T71 
-  H-bonding with backbone CO 
of E69  
-  H-bonding with side chain 
COOH of E69  
- Overall: Charged, (-) 
✖ 
 
N.D. 
 
2.6 ± 0.6 
 
N.D. 
 
Y26 -sheet 10.20 
 
26.4 
 
✔ ✖ 
- Overall: Uncharged, nothing 
✔ 
- OH close to L65  
N.D. N.D. N.D. 
S28 -sheet N/A 18.2 
 
✖ 
 
✖ 
-  H-bonding with side chain 
CONH2 of Q8  
-  H-bonding with side chain OH 
of Y26  
-  H-bonding with backbone NH 
of G29  
- Overall: Uncharged, polar 
contact 
✔ 
- OH close to Y26  
N.D. N.D. N.D. 
H31 Random 
coil 
5.98 
 
33.5 
 
✔ ✖ 
- Overall: Uncharged, nothing 
✔ 
- imidazole amine 
close to I1  
5 ± 3 
 
N/A N/A 
S33 Random 
coil 
N/A 70.1 
 
✔ ✖ 
- Overall: Uncharged, nothing 
✔ 
- OH close to P32, 
F62  
1.6 ± 0.4 
 
N.D. N.D. 
K41 Random 
coil 
12.73 
 
12.4 
 
✖ 
 
✔ 
- Salt bridge with side chain 
COOH of E44, D76  
-  H-bonding with side chain OH 
of Y78  
-  H-bonding with backbone CO 
of E44  
- Overall: Charged, (-) 
✔ 
- NH2 close to I46  
 
1.7 ± 0.8 
 
N/A N/A 
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2m 
residue 
Secondary 
structure 
pKaǂ Solvent accessibility* Microenvironment % DEPC CL 
%SASA 
ratio 
> 20% 
Charged polar contact 
[within 4 Å] 
Hydrophobic 
neighbor 
[within 6 Å] 
Intact protein 
(DEPC:protein 
= 4:1) 
Peptide 
(DEPC:peptide 
= 4:1) 
Peptide 
(DEPC:peptide 
= 50:1) 
K48 Random 
coil 
10.62 
 
87.0 
 
✔ ✔ 
- Salt bridge with side chain 
COOH of E47 
- Overall: Charged, (-) 
✖ 
 
5  2 
 
N/A N/A 
H51 Random 
coil 
7.15 
 
57.5 
 
✔ ✔ 
- Salt bridge with side chain 
COOH of D53  
-  H-bonding with backbone NH 
of D53  
- Overall: Charged, (-) 
✔ 
- imidazole amine 
close to L64  
 
4  1 
 
N/A N/A 
S52 Random 
coil 
N/A 50.7 
 
✔ ✖ 
- H-bonding with side chain OH 
of Y67  
- H-bonding with backbone CO 
of D53, L65  
- H-bonding with backbone NH 
of D53, L65 
- Overall: Uncharged, polar 
contact 
✔ 
- OH close to L65, 
Y67  
N.D. N.D. N.D. 
S55 Random 
coil 
N/A 55.3 
 
✔ ✖ 
- H-bonding with backbone CO 
of S57  
- Overall: Uncharged, polar 
contact 
 
✔ 
- OH close to L54  
 
0.6 ± 0.3 
 
N.D. N.D. 
S57 Random 
coil 
N/A 34.9 
 
✔ ✔ 
- H-bonding with side chain 
COOH of D59  
- H-bonding with side chain OH 
of S61  
- H-bonding with backbone CO 
of F56, S61  
- H-bonding with backbone NH 
of K58, D59  
- Overall: Charged, (-) 
 
✔ 
- OH close to F56  
 
1.8 ± 0.9 
 
N.D. N.D. 
K58 Random 
coil 
10.29 
 
88.5 
 
✔ ✖ 
- Overall: Uncharged, nothing 
 
✔ 
- NH2 close to F56  
9 ± 2 
 
N/A N/A 
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2m 
residue 
Secondary 
structure 
pKaǂ Solvent accessibility* Microenvironment % DEPC CL 
%SASA 
ratio 
> 20% 
Charged polar contact 
[within 4 Å] 
Hydrophobic 
neighbor 
[within 6 Å] 
Intact protein 
(DEPC:protein 
= 4:1) 
Peptide 
(DEPC:peptide 
= 4:1) 
Peptide 
(DEPC:peptide 
= 50:1) 
S61 Random 
coil 
N/A 28.1 
 
✔ ✔ 
- H-bonding with side chain 
guanidinium of R3 
- H-bonding with backbone NH 
of G29, S57, F62  
- H-bonding with backbone CO 
of G29, F56, S57, D58 
- Overall: Charged, (+) 
✔ 
- OH close to F56, 
W60, F62, Y63 
10 ± 1 
 
N.D. N.D. 
Y63 Random 
coil 
9.54 
 
27.7 
 
✔ ✖ 
- H-bonding with side chain OH 
of Y26, S55 
- Overall: Uncharged, polar 
contact  
✔ 
- OH close to Y26, 
F56 
0.3  0.2 
 
N.D. N.D. 
Y66 -sheet 13.25 
 
7.5 
 
✖ ✖ 
- Overall: Uncharged, nothing 
✔ 
- OH close to V27, 
F30, I35, V37, L64 
0.3  0.2 
 
 
N.D. N.D. 
Y67 -sheet 10.46 
 
 
22.8 
 
✔ ✔ 
- H-bonding with side chain OH 
of S52  
- H-bonding with backbone CO 
of H51  
- H-bonding with side chain 
COOH of E50  
- Overall: Charged, (-) 
✔ 
- OH close to L65 
N.D. N.D. 1.3  0.6 
T68 -sheet N/A 0.1 
 
✖ ✔ 
- H-bonding with backbone CO 
of K48, backbone NH of E69  
- H-bonding with side chain 
COOH of E69  
- Overall: Charged, (-) 
✔ 
- OH close to L39, 
I46, V49, F70 
N.D. N.D. N.D. 
T71 Random 
coil 
N/A 29.8 
 
✔ ✖ 
- H-bonding with side chain OH 
of S20 
- H-bonding with backbone CO 
of E69 
- Overall: Uncharged, polar 
contact  
✖ 
 
N.D. N.D. N.D. 
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2m 
residue 
Secondary 
structure 
pKaǂ Solvent accessibility* Microenvironment % DEPC CL 
%SASA 
ratio 
> 20% 
Charged polar contact 
[within 4 Å] 
Hydrophobic 
neighbor 
[within 6 Å] 
Intact protein 
(DEPC:protein 
= 4:1) 
Peptide 
(DEPC:peptide 
= 4:1) 
Peptide 
(DEPC:peptide 
= 50:1) 
T73 Random 
coil 
N/A 63.9 
 
✔ ✔ 
- H-bonding with side chain 
COOH of D76  
- H-bonding with backbone NH 
of E74, K75, D76 
- Overall: Charged, (-) 
✖ 
 
N.D. N.D. N.D. 
K75 Random 
coil 
10.47 
 
100 
 
✔ ✔ 
- Salt bridge with side chain 
COOH of E74, E77 
- Overall: Charged, (-) 
✖ 
 
2.3 ± 0.9 
 
N/A N/A 
Y78 Random 
coil 
10.34 
 
 
5.1 
 
✖ 
 
✔ 
-  H-bonding with side chain 
NH2 of K41 
- H-bonding with backbone NH 
of T71 
- H-bonding with backbone CO 
of T71 
- Overall: Charged, (+) 
 
✔ 
- OH close to I46, F70 
 
N.D. N.D. N.D. 
H84 Random 
coil 
5.78 
 
0.0 
 
✖ 
 
✖ 
- H-bonding with backbone NH 
of T86 
- Overall: Uncharged, polar 
contact 
 
✔ 
- imidazole amine 
close to F30, V85 
2.0  0.3 N/A N/A 
T86 Random 
coil 
NA 9.2 
 
✖ 
 
✖ 
- H-bonding with backbone NH 
of L87  
- H-bonding with backbone CO 
of V85  
- Overall: Uncharged, polar 
contact 
 
✔ 
- OH close to V85, 
L87  
 
N.D. N.D. N.D. 
S88 Random 
coil 
NA 96.7 
 
✔ ✖ 
- H-bonding with backbone CO 
of V85  
- Overall: Uncharged, polar 
contact 
 
✔ 
- OH close to L87  
N.D. N.D. N.D. 
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2m 
residue 
Secondary 
structure 
pKaǂ Solvent accessibility* Microenvironment % DEPC CL 
%SASA 
ratio 
> 20% 
Charged polar contact 
[within 4 Å] 
Hydrophobic 
neighbor 
[within 6 Å] 
Intact protein 
(DEPC:protein 
= 4:1) 
Peptide 
(DEPC:peptide 
= 4:1) 
Peptide 
(DEPC:peptide 
= 50:1) 
K91 Random 
coil 
10.36 
 
71.3 
 
✔ ✖ 
- H-bonding with side chain 
CONH2 of Q89 
- H-bonding with backbone CO 
of I92 
- Overall: Uncharged, polar 
contact 
 
✔ 
- NH2 close to V93 
 
4  3 
 
N/A N/A 
K94 Random 
coil 
10.56 
 
80.3 
 
✔ ✔ 
- Salt bridge with side chain 
COOH of E77 
- H-bonding with backbone CO 
of W95  
- Overall: Charged, (-) 
 
✔ 
- NH2 close to I92, 
M99  
6  2 N/A N/A 
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Table A.2: DEPC modification percentages of nucleophilic residues in ubiquitin (Ub) intact protein and its proteolytic peptides.  
Each experiment was performed in triplicate or quadruplicate (n = 3 or 4). Error bars shown in a table are standard deviations. Listed 
along are structural features of each residue from PDB 1UBQ. ✔ and ✖ represent presence or absence of each structural element, 
respectively. (+) and (-) represent positively charged and negatively charged polar contacts, respectively.  
 
Ub 
residue 
Secondary 
structure 
pKaǂ Solvent accessibility* Microenvironment % DEPC CL 
%SASA 
ratio 
> 20% 
Charged polar contact 
[within 4 Å] 
Hydrophobic 
neighbor 
[within 6 Å] 
Intact protein 
(DEPC:protein 
= 4:1) 
Peptide 
(DEPC:peptide 
= 4:1) 
Peptide 
(DEPC:peptide 
= 50:1) 
K6 -sheet 10.37 
 
59.7 
 
✔ ✖ 
- Overall: Uncharged, nothing 
✖ 
 
0.8  0.6 N/Ab N/A 
T7 -sheet N/Aa 14.2 
 
✖ ✖ 
- H-bonding with backbone CO 
of T9, K11 
- H-bonding with backbone NH 
of T9, K11 
- Overall: Uncharged, polar 
contact 
✔ 
- OH close to L8  
 
13 ± 2 N.D.c N.D. 
T9 Random 
coil 
N/A 85.5 
 
✔ ✖ 
- H-bonding with side chain OH 
of T7 
- Overall: Uncharged, polar 
contact 
✖ 
 
N.D. N.D. N.D. 
K11 -sheet 11.02 
 
59.8 
 
✔ ✔ 
- Salt bridge with side chain 
COOH of E34 
- Overall: Charged, (-) 
✔ 
- NH2 close to I13  
 
N.D. N/A N/A 
T12 -sheet N/A 39.4 
 
✔ ✖ 
- Overall: Uncharged, nothing 
✖ 
 
N.D. N.D. N.D. 
T14 -sheet N/A 54.8 
 
✔ ✖ 
- Overall: Uncharged, nothing 
 
✖ 
 
N.D. N.D. N.D. 
S20 Random 
coil 
N/A 86.9 
 
✔ ✖ 
- Overall: Uncharged, nothing 
 
✔ 
- OH close to P19 
N.D. N.D. N.D. 
a N/A = not applicable; b N-terminal blocking using SNHSA also results in side reaction (acetylation) at Lys and His residues in free peptides, so they are not discussed here. 
c N.D. = not detected (less than DEPC labeling threshold of 0.01%1)  
* SASA calculated using GETAREA2, as explained in detail in Section 2.2.8; ǂ pKa calculated using PROPKA3 
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Ub 
residue 
Secondary 
structure 
pKaǂ Solvent accessibility* Microenvironment % DEPC CL 
%SASA 
ratio 
> 20% 
Charged polar contact 
[within 4 Å] 
Hydrophobic 
neighbor 
[within 6 Å] 
Intact protein 
(DEPC:protein 
= 4:1) 
Peptide 
(DEPC:peptide 
= 4:1) 
Peptide 
(DEPC:peptide 
= 50:1) 
T22 Random 
coil 
N/A 46.2 
 
✔ ✖ 
- H-bonding with backbone NH 
of N25 
- Overall: Uncharged, polar 
contact 
✖ 
 
N.D. N.D. N.D. 
K27 
 
 
-helix 10.53 
 
9.8 
 
✖ 
 
✔ 
- Salt bridge with side chain 
COOH of D52 
- H-bonding with backbone CO 
of Q41 
- Overall: Charged, (-) 
✔ 
- NH2 close to I23  
 
N.D. N/A N/A 
K29 -helix 
 
10.40 
 
37.3 
 
✔ ✖ 
- H-bonding with backbone CO 
of E16 
- Overall: Uncharged, polar 
contact 
✔ 
- NH2 close to V17  
 
N.D. N/A N/A 
K33 -helix 
 
10.27 
 
49.4 
 
✔ ✖ 
- H-bonding with backbone CO 
of T14 
- Overall: Uncharged, polar 
contact 
✔ 
- NH2 close to I13, 
L15  
20  6 N/A N/A 
K48 Random 
coil  
 
10.31 
 
56.1 
 
✔ ✖ 
- H-bonding with backbone CO 
of A46 
- Overall: Uncharged, polar 
contact 
✔ 
- NH2 close to A46  
 
11  4 N/A N/A 
T55 Random 
coil 
N/A 32.3 
 
✔ ✖ 
- H-bonding with side chain OH 
of S57 
- H-bonding with backbone NH 
of D58 
- Overall: Uncharged, polar 
contact 
✖ N.D. N.D. N.D. 
S57 -helix N/A 59.6 
 
✔ ✖ 
- H-bonding with side chain OH 
of T55, backbone CO of P19 
- Overall: Uncharged, polar 
contact 
✖ 
 
N.D. N.D. N.D. 
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Ub 
residue 
Secondary 
structure 
pKaǂ Solvent accessibility* Microenvironment % DEPC CL 
%SASA 
ratio 
> 20% 
Charged polar contact 
[within 4 Å] 
Hydrophobic 
neighbor 
[within 6 Å] 
Intact protein 
(DEPC:protein 
= 4:1) 
Peptide 
(DEPC:peptide 
= 4:1) 
Peptide 
(DEPC:peptide 
= 50:1) 
Y59 -helix 9.98 
 
12.9 
 
✖ ✖ 
- H-bonding with backbone NH 
of E51 
- Overall: Uncharged, polar 
contact 
✔ 
- OH close to L50  
 
 
 
N.D. N.D. N.D. 
K63 Random 
coil 
10.66 
 
74.3 
 
✔ ✖ 
- Overall: Uncharged, nothing 
✖ 0.31  0.08 N/A N/A 
S65 -sheet N/A 9.2 
 
✖ ✖ 
- H-bonding with backbone CO 
of Q62 
- H-bonding with backbone NH 
of Q62 
- Overall: Uncharged, polar 
contact 
✔ 
- OH close to F45, I61  
2.4 ± 0.2 N.D. N.D. 
T66 -sheet N/A 40.1 
 
✔ ✖ 
- Overall: Uncharged, nothing 
✔ 
- OH close to F4 
 
N.D. N.D. N.D. 
H68 -sheet 6.00 
 
49.1 
 
✔ ✖ 
- Overall: Uncharged, nothing 
 
✔ 
- NH close to I44  
 
2.7  0.5 N/A N/A 
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Table A.3: DEPC modification percentages of nucleophilic residues in hGH intact protein and its proteolytic peptides.  
Each experiment was performed in triplicate or quadruplicate (n = 3 or 4). Error bars shown in a table are standard deviations. Listed 
along are structural features of each residue from PDB 1HGU. ✔ and ✖ represent presence or absence of each structural element, 
respectively. (+) and (-) represent positively charged and negatively charged polar contacts, respectively.  
 
hGH 
residue 
Secondary 
structure 
pKaǂ Solvent accessibility* Microenvironment % DEPC CL 
%SASA 
ratio 
> 20% 
Charged polar contact 
[within 4 Å] 
Hydrophobic 
neighbor 
[within 6 Å] 
Intact protein 
(DEPC:protein  
= 5:1) 
Peptide 
(DEPC:peptide  
= 5:1) 
Peptide 
(DEPC:peptide 
= 50:1) 
T4 Random 
coil 
N/Aa 100 
 
✔ ✖ 
- Overall: Uncharged, nothing 
✔ 
- OH close to P3  
N.D.c N.D. N.D. 
S8 -helix N/A 40.3 
 
✔ ✖ 
- Overall: Uncharged, nothing 
✔ 
- OH close to V186  
N.D. N.D. N.D. 
H19 -helix 4.78 
 
37.2 
 
✔ ✖ 
- Overall: Uncharged, nothing 
✔ 
- imidazole amine 
close to M15 
1.3  0.8 
(H19/H22) 
N/Ab N/A 
H22 -helix 5.16 
 
24.0 
 
✔ ✖ 
- Overall: Uncharged, nothing 
✔ 
- imidazole amine 
close to F26, M171  
N.D. N/A N/A 
T28 -helix N/A 10.7 
 
✖ 
 
✔ 
- H-bonding with side chain 
COOH of D27 
- H-bonding with backbone CO 
of L24  
- Overall: Charged, (-) 
✔ 
- OH close to L24  
 
1.3  0.6 
 
N.D. N.D. 
Y29 -helix 13.59 
 
4.1 
 
✖ 
 
✔ 
- H-bonding with side chain NH2 
of K42 
- Overall: Charged, (+) 
✔ 
- OH close to Y161  
 
0.2  0.1 N.D. N.D. 
Y36 -helix 10.35 37.2 ✔ ✖ 
- Overall: Uncharged, nothing 
✔ 
- OH close to F32 
0.4  0.3 N.D. N.D. 
K39 No information from a crystal structure about this residue 
 
0.06  0.01 N/A N/A 
a N/A = not applicable; b N-terminal blocking using SNHSA also results in side reaction (acetylation) at Lys and His residues in free peptides, so they are not discussed here. 
c N.D. = not detected (less than DEPC labeling threshold of 0.01%1)  
* SASA calculated using GETAREA2, as explained in detail in Section 2.2.8; ǂ pKa calculated using PROPKA3 
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hGH 
residue 
Secondary 
structure 
pKaǂ Solvent accessibility* Microenvironment % DEPC CL 
%SASA 
ratio 
> 20% 
Charged polar contact 
[within 4 Å] 
Hydrophobic 
neighbor 
[within 6 Å] 
Intact protein 
(DEPC:protein  
= 5:1) 
Peptide 
(DEPC:peptide  
= 5:1) 
Peptide 
(DEPC:peptide 
= 50:1) 
K42 Random 
coil 
11.22 
 
 
36.2 
 
✔ ✖ 
- H-bonding with side chain OH 
of Y28 
- Overall: Uncharged, polar 
contact 
✖ 0.07  0.02 N/A N/A 
Y43 Random 
coil 
10.05 
 
87.7 
 
✔ ✖ 
- Overall: Uncharged, nothing 
✖ 
 
N.D. N.D. N.D. 
S44 Random 
coil 
N/A 37.0 
 
✔ ✖ 
- H-bonding with backbone CO 
of Q41 
- H-bonding with backbone NH 
of F45  
- Overall: Uncharged, polar 
contact 
✔ 
- OH close to F45, 
L46  
 
 
N.D. N.D. N.D. 
T51 No information from a crystal structure about this residue 
 
N.D. N.D. N.D. 
S52 Random 
coil 
N/A 65.5 
 
✔ ✖ 
- H-bonding with backbone CO, 
NH of L53 
- Overall: Uncharged, polar 
contact 
 
✖ 
 
 
 
 
 
N.D. N.D. N.D. 
S56 Random 
coil 
N/A 20.8 
 
✔ ✖ 
- H-bonding with backbone CO 
of L53 
- Overall: Uncharged, polar 
contact 
✔ 
- OH close to L53  
 
0.02  0.01 N.D. N.D. 
S58 Random 
coil 
N/A 3.3 
 
✖ 
 
✖ 
- H-bonding with backbone CO, 
NH of I59 
- H-bonding with backbone CO 
of F55 
- Overall: Uncharged, polar 
contact 
✔ 
- OH close to F177  
 
64  4 
 
N.D. N.D. 
T61 Random 
coil 
N/A 38.7 
 
✔ ✔ 
- H-bonding with side chain NH2 
of K73 
- Overall: Charged, (+) 
✔ 
- OH close to P62, 
F177  
 
N.D. N.D. N.D. 
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hGH 
residue 
Secondary 
structure 
pKaǂ Solvent accessibility* Microenvironment % DEPC CL 
%SASA 
ratio 
> 20% 
Charged polar contact 
[within 4 Å] 
Hydrophobic 
neighbor 
[within 6 Å] 
Intact protein 
(DEPC:protein  
= 5:1) 
Peptide 
(DEPC:peptide  
= 5:1) 
Peptide 
(DEPC:peptide 
= 50:1) 
S63 Random 
coil 
N/A 17.6 
 
✖ 
 
✖ 
- H-bonding with backbone CO 
of P62 
- Overall: Uncharged, polar 
contact 
✔ 
- OH close to F177  
 
N.D. N.D. N.D. 
T68 No information from a crystal structure about this residue 
 
N.D. N.D. N.D. 
K71 Random 
coil 
10.04 
 
27.1 
 
✔ ✖ 
- H-bonding with backbone CO 
of Q69 
- Overall: Uncharged, polar 
contact 
✔ 
- NH2 close to I59  
 
N.D. N/A N/A 
S72 Random 
coil 
N/A 32.2 
 
✔ ✖ 
- H-bonding with backbone NH 
of L74 
- Overall: Uncharged, polar 
contact 
✔ 
- OH close to L74  
 
N.D. N.D. N.D. 
S80 -helix N/A 0.5 
 
✖ 
 
✖ 
- H-bonding with backbone CO 
of L76 
- Overall: Uncharged, polar 
contact 
✔ 
- OH close to L83, 
V174, L178, 
N.D. N.D. N.D. 
S86 -helix N/A 0.1 
 
✖ 
 
✖ 
- H-bonding with backbone CO 
of Y144 
- Overall: Uncharged, polar 
contact 
✔ 
- OH close to F55, 
W87  
 
N.D. N.D. N.D. 
S96 Random 
coil 
N/A 49.7 
 
✔ ✖ 
- Overall: Uncharged, nothing 
✖ 
 
N.D. N.D. N.D. 
S101 Random 
coil 
N/A 33.4 
 
✔ ✖ 
- H-bonding with backbone CO 
of V103 
- Overall: Uncharged, polar 
contact 
✖ 
 
N.D. N.D. N.D. 
Y104 Random 
coil 
10.05 
 
82.5 
 
✔ ✖ 
- Overall: Uncharged, nothing 
 
✖ 
 
N.D. N.D. N.D. 
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hGH 
residue 
Secondary 
structure 
pKaǂ Solvent accessibility* Microenvironment % DEPC CL 
%SASA 
ratio 
> 20% 
Charged polar contact 
[within 4 Å] 
Hydrophobic 
neighbor 
[within 6 Å] 
Intact protein 
(DEPC:protein  
= 5:1) 
Peptide 
(DEPC:peptide  
= 5:1) 
Peptide 
(DEPC:peptide 
= 50:1) 
S107 Random 
coil 
N/A 26.1 
 
✔ ✔ 
- H-bonding with side chain 
guanidinium of R20 
- Overall: Charged, (+) 
✔ 
- OH close to L24  
 
N.D. N.D. 0.19  0.12 
 
S109 Random 
coil 
N/A 49.3 
 
✔ ✔ 
- H-bonding with sidechain 
COOH of D106 
- Overall: Charged, (-) 
✖ 
 
N.D. N.D. N.D. 
Y112 -helix 10.38 29.9 ✔ ✖ 
- Overall: Uncharged, nothing 
✖ N.D. N.D. N.D. 
K116 -helix 10.63 
 
40.9 
 
✔ ✖ 
- Overall: Uncharged, nothing 
✔ 
- NH2 close to L88, 
Y112 
N.D. N/A N/A 
T124 -helix N/A 47.2 
 
✔ ✖ 
- Overall: Uncharged, nothing 
✔ 
- OH close to L10  
N.D. N.D. N.D. 
S133 Random 
coil 
N/A 80.2 
 
✔ ✖ 
- H-bonding with backbone CO 
of G132 
- Overall: Uncharged, polar 
contact 
✖ 
 
N.D. N.D. N.D. 
T136 Random 
coil 
N/A 35.9 
 
✔ ✔ 
- H-bonding with side chain 
guanidinium of R78 
- Overall: Charged, (+) 
✔ 
- OH close to L74  
 
0.15  0.09 
 
0.1 ± 0.1 0.08  0.02 
 
K141 Random 
coil 
10.42 
 
90.5 
 
✔ ✖ 
- Overall: Uncharged, nothing 
✖ 
 
18  8 
 
N/A N/A 
T143 Random 
coil 
N/A 96.4 
 
✔ ✖ 
- Overall: Uncharged, nothing 
✔ 
- OH close to A145  
N.D. N.D. N.D. 
Y144 Random 
coil 
10.41 
 
31.1 
 
✔ ✖ 
- Overall: Uncharged, nothing 
✔ 
- OH close to L82  
 
0.66  0.05 N.D. 0.02  0.03 
S145 No information from a crystal structure about this residue 
 
N.D. N.D. N.D. 
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hGH 
residue 
Secondary 
structure 
pKaǂ Solvent accessibility* Microenvironment % DEPC CL 
%SASA 
ratio 
> 20% 
Charged polar contact 
[within 4 Å] 
Hydrophobic 
neighbor 
[within 6 Å] 
Intact protein 
(DEPC:protein  
= 5:1) 
Peptide 
(DEPC:peptide  
= 5:1) 
Peptide 
(DEPC:peptide 
= 50:1) 
K146 Random 
coil 
9.4 1.1 
 
✖ 
 
✖ 
- Overall: Uncharged, nothing 
✔ 
- NH2 close to L53, 
F55  
0.09  0.08 N/A N/A 
T149 No information from a crystal structure about this residue 
 
N.D. N.D. N.D. 
S151 Random 
coil 
N/A 56.7 
 
✔ ✖ 
- H-bonding with backbone CO 
of N150 
- Overall: Uncharged, polar 
contact  
✖ 
 
N.D. N.D. N.D. 
H152 Random 
coil 
6.38 
 
84.4 
 
✔ ✖ 
- Overall: Uncharged, nothing 
✖ 
 
N.D. N/A N/A 
K159 -helix 11.43 
 
 
70.9 
 
✔ ✔ 
- Salt bridge with sidechain 
COOH of E34 
- Overall: Charged, (-) 
 
✖ 
 
N.D. N/A N/A 
Y161 -helix 11.14 
 
10.0 
 
✖ 
 
✖ 
- Overall: Uncharged, nothing 
✔ 
- OH close to L46  
N.D. N.D. N.D. 
T165 No information from a crystal structure about this residue 
 
N.D. N.D. N.D. 
K169 -helix 10.00 
 
42.8 
 
✔ ✖ 
- Overall: Uncharged, nothing 
✖ 
 
N.D. N/A N/A 
K173 -helix 8.71 
 
1.4 
 
✖ 
 
✖ 
- H-bonding with backbone CO 
of K169 
- Overall: Uncharged, polar 
contact 
 
✔ 
- NH2 close to F55  
 
5.0  0.4 N/A N/A 
T176 -helix N/A 19.0 
 
✖ 
 
✔ 
- H-bonding with sidechain NH2 
of R179 
- H-bonding with backbone CO 
of D172 
- Overall: Charged, (+) 
 
✖ 
 
N.D. N.D. N.D. 
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hGH 
residue 
Secondary 
structure 
pKaǂ Solvent accessibility* Microenvironment % DEPC CL 
%SASA 
ratio 
> 20% 
Charged polar contact 
[within 4 Å] 
Hydrophobic 
neighbor 
[within 6 Å] 
Intact protein 
(DEPC:protein  
= 5:1) 
Peptide 
(DEPC:peptide  
= 5:1) 
Peptide 
(DEPC:peptide 
= 50:1) 
S185 Random 
coil 
N/A 24.0 
 
✔ 
 
✖ 
- H-bonding with backbone CO 
of V181 
- Overall: Uncharged, polar 
contact 
✔ 
- OH close to F11  
 
N.D. N.D. N.D. 
S189 Random 
coil 
N/A 96.1 
 
✔ 
 
✖ 
- Overall: Uncharged, nothing 
✖ 
 
N.D. N.D. N.D. 
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Table A.4: DEPC modification percentages of nucleophilic residues in bovine carbonic anhydrase (BCA) intact protein.  
Each experiment was performed in triplicate or quadruplicate (n = 3 or 4). Error bars shown in a table are standard deviations. Listed 
along are structural features of each residue from PDB 1V9E. ✔ and ✖ represent presence or absence of each structural element, 
respectively. (+) and (-) represent positively charged and negatively charged polar contacts, respectively.  
 
BCA 
residue 
Secondary 
structure 
pKaǂ Solvent accessibility* Microenvironment % DEPC CL 
%SASA 
ratio 
> 20% 
Charged polar contact 
[within 4 Å] 
Hydrophobic neighbor 
[within 6 Å] 
Intact protein 
(DEPC:protein 
= 10:1) 
S1 Random 
coil 
N/Aa 81.1 
 
✔ ✔ 
-  H-bonding with side chain NH2 of K168 
- Overall: Charged, (+) 
✖ 
 
N.D.b 
H2 Random 
coil 
4.54 
 
11.3 
 
✖ 
 
✖ 
 
✔ 
- imidazole amine close to W4 
N.D. 
H3 Random 
coil 
6.33 
 
81.0 
 
✔ ✖ 
 
✖ 
 
N.D. 
Y6 Random 
coil 
13.76 3.4 
 
✖ 
 
✖ 
-  H-bonding with backbone CO of N242 
✔ 
- OH close to W15 
15.4  0.6 
 
K8 Random 
coil 
10.40 
 
89.9 
 
✔ ✖ ✖ 13 ± 1 
H9 Random 
coil 
6.27 
 
84.7 
 
✔ ✖ ✖ 
 
6  1 
H14 -helix 5.95 42.6 
 
✔ ✖ 
-  H-bonding with backbone CO of K8 
✖ 
 
4  1 
H16 -helix 6.07 38.0 ✔ ✖ ✖ 
 
3  1 
K17 -helix 10.30 66.1 ✔ ✖ ✖ 
 
N.D. 
S28 Random 
coil 
N/A 0.0 ✖ 
 
✖ 
- H-bonding with side chain OH of Y192 
- H-bonding with side chain aromatic amine of 
W207 
-  H-bonding with backbone CO and NH of S195 
 
✔ 
- OH close to Y192, W207 
2  1 
a N/A = not applicable; b N.D. = not detected (less than DEPC labeling threshold of 0.01%1)  
* SASA calculated using GETAREA2, as explained in detail in Section 2.2.8; ǂ pKa calculated using PROPKA3 
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BCA 
residue 
Secondary 
structure 
pKaǂ Solvent accessibility* Microenvironment % DEPC CL 
%SASA 
ratio 
> 20% 
Charged polar contact 
[within 4 Å] 
Hydrophobic neighbor 
[within 6 Å] 
Intact protein 
(DEPC:protein 
= 10:1) 
T34 -helix N/A 40.7 ✔ ✔ 
- H-bonding with side chain COOH of D109 
- Overall: Charged, (-) 
 
✔ 
- OH close to V37, V108 
N.D. 
K35 -helix 10.67 100.0 ✔ ✖ ✖ 
 
N.D. 
K44 Random 
coil 
10.65 66.3 ✔ ✖ ✖ 
 
N.D. 
Y50 Random 
coil 
14.02 4.8 ✖ 
 
✖ 
- H-bonding with side chain aromatic amine of 
H121 
✔ 
- OH close to P179 
0.2  0.2 
T54 Random 
coil 
N/A 36.2 ✔ ✖ 
-  H-bonding with backbone CO of E52 
✔ 
- OH close to A53 
0.6  0.4 
S55 -sheet N/A 0.0 ✖ 
 
✖ ✔ 
- OH close to T54, Y69, P175 
0.02  0.02 
H63 Random 
coil 
1.74 17.3 ✖ 
 
✖ ✔ 
- imidazole amine close to W4, Y6 
23 ± 8 
S64 Random 
coil 
N/A 0.2 ✖ ✖ 
- H-bonding with side chain CONH2 of N61 
✔ 
- OH close to W96 
0.9  0.5 
Y69 -sheet 14.67 0.2 ✖ ✖ 
-  H-bonding with backbone CO of F177 
✔ 
- OH close to A53, V67, F92, F177 
0.52  0.06 
S72 Random 
coil 
N/A 74.8 ✔ ✖ ✖ 0.23  0.02 
K75 Random 
coil 
10.53 32.3 ✔ ✔ 
- H-bonding with side chain COOH of D70 
✖ 0.22  0.01 
K79 -sheet 10.49 48.4 ✔ ✖ ✖ 
 
3.4  0.3 
T84 Random 
coil 
N/A 100.0 ✔ ✖ ✖ 
 
N.D. 
T86 Random 
coil 
N/A 26.7 ✔ ✖ ✔ 
- OH close to V77 
0.008  0.002 
Y87 -sheet 12.20 2.1 ✖ ✖ 
- H-bonding with side chain CONH2 of N123 
 
✔ 
- OH close to L83 
0.02  0.01 
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BCA 
residue 
Secondary 
structure 
pKaǂ Solvent accessibility* Microenvironment % DEPC CL 
%SASA 
ratio 
> 20% 
Charged polar contact 
[within 4 Å] 
Hydrophobic neighbor 
[within 6 Å] 
Intact protein 
(DEPC:protein 
= 10:1) 
H93 -sheet -2.62 12.9 ✖ ✖ ✖ 
 
N.D. 
H95 -sheet -1.24 0.1 ✖ ✖ ✖ 
 
0.2  0.2 
S98 
 
Random 
coil 
N/A 48.5 ✔ ✖ ✔ 
- OH close to L240, A241 
0.02  0.01 
S99 
 
Random 
coil 
N/A 59.9 ✔ ✔ 
- H-bonding with side chain COOH of D101 
- Overall: Charged, (-) 
✖ 
 
N.D. 
S104 
 
Random 
coil 
N/A 0.0 ✖ ✖ 
-  H-bonding with backbone CO of H106 
-  H-bonding with backbone NH of Y113 
 
✖ 
 
N.D. 
H106 Random 
coil 
2.72 0.0 ✖ ✖ ✔ 
- imidazole amine close to P29, V30, 
W207, V209 
0.1  0.1 
T107 -sheet N/A 4.4 ✖ ✔ 
- H-bonding with side chain COOH of D31 
- Overall: Charged, (-) 
✔ 
- OH close to A246 
0.1  0.1 
K111 Random 
coil 
9.40 53.6 ✔ ✖ ✔ 
- NH2 close to Y113 
3.7  0.9 
K112 Random 
coil 
10.09 44.2 ✔ ✖ ✔ 
- NH2 close to W243 
0.2  0.2 
Y113 Random 
coil 
11.30 7.7 ✖ ✖ ✔ 
- OH close to P213 
N.D. 
H118 -sheet -5.13 1.4 ✖ ✖ ✔ 
- imidazole amine close to V141 
0.17  0.06 
H121 -sheet 3.50 0.0 ✖ ✖ ✔ 
- imidazole amine close to L119 
N.D. 
T124 Random 
coil 
N/A 23.7 ✔ ✖ 
-  H-bonding with backbone CO of T86 
✖ 
 
N.D. 
K125 Random 
coil 
12.41 55.5 ✔ ✔ 
- H-bonding with side chain COOH of D137 
- H-bonding with side chain OH of Y126 
- Overall: Charged, (-) 
 
✔ 
- NH2 close to Y126 
N.D. 
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BCA 
residue 
Secondary 
structure 
pKaǂ Solvent accessibility* Microenvironment % DEPC CL 
%SASA 
ratio 
> 20% 
Charged polar contact 
[within 4 Å] 
Hydrophobic neighbor 
[within 6 Å] 
Intact protein 
(DEPC:protein 
= 10:1) 
Y126 -helix 10.91 16.9 ✖ ✔ 
- H-bonding with side chain COOH of D137 
- H-bonding with side chain NH2 of K125 
✖ 
 
N.D. 
T131 -helix N/A 56.1 ✔ ✔ 
- H-bonding with side chain COOH of D128 
- Overall: Charged, (-) 
✖ 
 
N.D. 
K147 -sheet 10.31 59.0 ✔ ✖ ✔ 
- NH2 close to Y113, P213 
4  1 
K157 -helix 10.06 42.7 ✔ ✖ ✔ 
- NH2 close to F174, P175, F177 
0.9  0.3 
S164 
 
-helix N/A 43.4 ✔ ✖ ✔ 
- OH close to A161 
N.D. 
K166 Random 
coil 
10.47 29.3 ✔ ✖ 
-  H-bonding with backbone CO of T86 
✖ 
 
N.D. 
T167 Random 
coil 
N/A 21.2 ✔ ✖ ✔ 
- OH close to I165, A231 
N.D. 
K168 Random 
coil 
10.31 27.0 ✔ ✖ 
- H-bonding with side chain OH of S1 
✔ 
-  NH2 close to A231 
N.D. 
K170 Random 
coil 
10.45 53.7 ✔ ✖ ✖ N.D. 
S171 -sheet N/A 30.3 ✔ ✖ ✖ N.D. 
T172 -sheet N/A 32.7 ✔ ✖ ✔ 
- OH close to M58, I165 
N.D. 
S181 -helix N/A 30.0 ✔ ✖ ✔ 
- OH close to A154, F177, L182 
N.D. 
Y189 -sheet 12.63 0.0 ✖ ✖ 
-  H-bonding with backbone CO of K44 
✔ 
- OH close to L43, L46, P82 
N.D. 
T191 -sheet N/A 0.4 ✖ ✖ 
-  H-bonding with backbone CO of W207 
✔ 
- OH close to P82, Y189, W207 
N.D. 
Y192 -sheet 14.03 0.0 ✖ ✖ 
- H-bonding with side chain OH of S28 
✔ 
- OH close to V30 
N.D. 
S195 Random 
coil 
N/A 0.0 ✖ ✖ 
-  H-bonding with backbone CO of L196 
-  H-bonding with backbone NH of S28 
 
✖ N.D. 
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BCA 
residue 
Secondary 
structure 
pKaǂ Solvent accessibility* Microenvironment % DEPC CL 
%SASA 
ratio 
> 20% 
Charged polar contact 
[within 4 Å] 
Hydrophobic neighbor 
[within 6 Å] 
Intact protein 
(DEPC:protein 
= 10:1) 
T197 Random 
coil 
N/A 2.2 ✖ ✖ ✖ 0.03  0.02 
T198 Random 
coil 
N/A 18.1 ✖ ✖ 
-  H-bonding with backbone CO of P199 
✔ 
- OH close to P199 
0.014  0.003 
S204 Random 
coil 
N/A 2.1 ✖ ✖ 
-  H-bonding with backbone CO of A133 
✔ 
- OH close to L202, V205 
N.D. 
T206 -sheet N/A 23.1 ✔ ✖ ✔ 
- OH close to A140 
N.D. 
K211 Random 
coil 
10.74 23.0 ✔ ✖ 
-  H-bonding with backbone CO of K259 
✔ 
-  NH2 close to W190 
0.005  0.003 
S215 -sheet N/A 43.2 ✔ ✖ 
-  H-bonding with backbone CO of D150 
✔ 
- OH close to V216 
N.D. 
 
 
S217 -helix N/A 9.8 ✖ ✖ 
-  H-bonding with sidechain CONH2 of Q219 
-  H-bonding with backbone NH of Q220 
✔ 
- OH close to V216 
0.01  0.01 
S218 -helix N/A 54.7 ✔ ✔ 
- H-bonding with side chain COOH of D101 
- Overall: Charged, (-) 
✔ 
- OH close to V148 
N.D. 
 
K223 -helix 10.46 32.4 ✔ ✔ 
- H-bonding with side chain COOH of D163 
- Overall: Charged, (-) 
✔ 
-  NH2 close to L162 
N.D. 
 
T226 Random 
coil 
N/A 34.5 ✔ ✖ ✖ N.D. 
K250 Random 
coil 
10.72 29.2 ✔ ✔ 
- H-bonding with side chain COOH of E25 
-  H-bonding with backbone CO of N23, G24 
- Overall: Charged, (-) 
✔ 
-  NH2 close to P248 
14  4 
K259 Random 
coil 
10.47 92.7 ✔ ✖ ✖ 66  12 
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Table A.5: DEPC modification percentages of nucleophilic residues in equine holo-myoglobin (MYG) intact protein.  
Each experiment was performed in triplicate or quadruplicate (n = 3 or 4). Error bars shown in a table are standard deviations. Listed 
along are structural features of each residue from PDB 1DWR. ✔ and ✖ represent presence or absence of each structural element, 
respectively. (+) and (-) represent positively charged and negatively charged polar contacts, respectively.  
 
MYG 
residue 
Secondary 
structure 
pKaǂ Solvent accessibility* Microenvironment % DEPC CL 
%SASA 
ratio 
> 20% 
Charged polar contact 
[within 4 Å] 
Hydrophobic neighbor 
[within 6 Å] 
Intact protein 
(DEPC:protein 
= 4:1) 
S3 -helix N/Aa 63.8 
 
✔ ✖ 
-  H-bonding with backbone NH of E6 
✔ 
- OH close to L2 
39 ± 19 
(N-term/S3) 
K16 -helix 10.98 
 
22.1 
 
✔ ✔ 
- H-bonding with side chain COOH of D109 
- Overall: Charged, (-) 
✖ 
 
3 ± 2 
H24 -helix 5.75 
 
2.7 
 
✖ 
 
✖ 
 
✔ 
- imidazole amine close to V17, L115 
0.01 ± 0.02 
T34 -helix N/A 33.9 
 
✔ ✖ 
-  H-bonding with backbone CO of I30, R31 
✔ 
- OH close to I30 
1.1  0.5 
 
H36 -helix 5.90 
 
32.6 
 
✔ ✖ ✔ 
- imidazole amine close to L32, F106 
1.1  0.5 
 
K42 Random 
coil 
9.80 
 
33.0 
 
✔ ✖ 
-  H-bonding with backbone CO of K98 
✔ 
- NH2 close to P100 
0.7  0.4 
K45 Random 
coil 
10.74 54.9 
 
✔ ✔ 
- H-bonding with side chain COOH of D60 
- Overall: Charged, (-) 
 
✔ 
- NH2 close to F46 
0.8  0.7 
K47 Random 
coil 
Information from a crystal structure about this residue is not clear N.D.b 
H48 Random 
coil 
6.21 64.7 ✔ ✖ ✔ 
- imidazole amine close to F46, L49 
N.D. 
K50 Random 
coil 
10.46 83.4 ✔ ✖ 
-  H-bonding with backbone CO of K47 
 
✖ 0.3  0.3 
a N/A = not applicable; b N.D. = not detected (less than DEPC labeling threshold of 0.01%1)  
* SASA calculated using GETAREA2, as explained in detail in Section 2.2.8; ǂ pKa calculated using PROPKA3 
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MYG 
residue 
Secondary 
structure 
pKaǂ Solvent accessibility* Microenvironment % DEPC CL 
%SASA 
ratio 
> 20% 
Charged polar contact 
[within 4 Å] 
Hydrophobic neighbor 
[within 6 Å] 
Intact protein 
(DEPC:protein 
= 4:1) 
T51 -helix N/A 61.8 ✔ ✔ 
- H-bonding with side chain COOH of E54 
-  H-bonding with backbone NH of E54 
- Overall: Charged, (-) 
✔ 
- OH close to A53 
0.1  0.1 
K56 -helix 10.19 58.3 ✔ ✖ ✔ 
- NH2 close to I30 
0.1  0.1 
S58 
 
-helix N/A 9.1 ✖ ✖ 
-  H-bonding with backbone NH of L61 
✔ 
- OH close to L61 
0.2  0.3 
K62 -helix 10.65 48.0 ✔ ✖ ✖ 0.8  0.5 
K63 -helix 10.44 75.3 ✔ ✖ 
 
✖ 0.1  0.1 
H64 -helix 3.84 26.6 ✔ ✖ 
 
✔ 
- imidazole amine close to F46, L49 
0.02 ± 0.02 
T66 -helix N/A 40.2 ✔ ✖ 
-  H-bonding with backbone CO of K62 
✔ 
- OH close to I21, A22 
0.2  0.1 
T70 -helix N/A 71.8 ✔ ✖ 
-  H-bonding with backbone CO of T66 
✔ 
- OH close to I21 
N.D. 
K77 -helix 11.06 50.5 ✔ ✔ 
- H-bonding with side chain COOH of E18 
- Overall: Charged, (-) 
✔ 
- NH2 close to L11, W14 
7 ± 3 
K78 Random 
coil 
11.35 46.2 ✔ ✔ 
- H-bonding with side chain COOH of E85 
-  H-bonding with backbone CO of H81 
- Overall: Charged, (-) 
✖ 6 ± 3 
K79 Random 
coil 
10.47 53.6 ✔ ✖ 
 
✖ 3.1  0.4 
H81 Random 
coil 
6.47 89.1 ✔ ✖ 
 
✖ 1.0  0.5 
H82 -helix 6.42 4.9 ✖ 
 
✔ 
- H-bonding with side chain COOH of D141 
- Overall: Charged, (-) 
✔ 
- imidazole amine close to L86 
1.0  0.6 
K87 -helix 10.48 52.0 ✔ ✖ 
 
✖ 1.0  0.5 
S92 -helix Information from a crystal structure about this residue is not clear 
 
1 ± 1 
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MYG 
residue 
Secondary 
structure 
pKaǂ Solvent accessibility* Microenvironment % DEPC CL 
%SASA 
ratio 
> 20% 
Charged polar contact 
[within 4 Å] 
Hydrophobic neighbor 
[within 6 Å] 
Intact protein 
(DEPC:protein 
= 4:1) 
H93 -helix 2.32 35.3 ✔ ✖ 
-  H-bonding with side chain OH of S92 
- Coordination with Fe(II) of heme 
✔ 
- imidazole amine close to L89, I99, 
L104 
0.11  0.08 
T95 -helix N/A 76.2 ✔ ✖ 
 
✔ 
- OH close to L149 
0.3  0.2 
K96 -helix 10.38 84.2 ✔ ✖ 
 
✖ 1.2  0.9 
H97 Random 
coil 
4.46 43.3 ✔ ✔ 
- H-bonding with COOH of heme 
- Overall: Charged, (-) 
✔ 
- imidazole amine close to hydrocarbon 
chain of heme 
0.2  0.2 
K98 Random 
coil 
10.23 65.0 ✔ ✖ 
-  H-bonding with side chain OH of T95 
✖ 0.8  0.4 
K102 -helix 11.14 63.6 ✔ ✔ 
- H-bonding with side chain COOH of E105 
- Overall: Charged, (-) 
✔ 
- NH2 close to F106 
0.17  0.09 
Y103 -helix 11.10 15.2 ✖ ✖ 
 
✔ 
- OH close to P100 
0.24  0.08 
S108 -helix N/A 5.4 ✖ ✔ 
- H-bonding with side chain guanidinium of R139 
- H-bonding with backbone CO of L104 
- Overall: Charged, (+) 
✔ 
- OH close to I111 
0.16  0.05 
H113 -helix 5.52 43.2 ✔ ✔ 
- H-bonding with side chain guanidinium of R31 
- Overall: Charged, (+) 
✖ 2.7  0.8 
H116 -helix 6.02 43.9 ✔ ✖ 
 
✔ 
- imidazole amine close to I112 
0.9  0.5 
S117 -helix N/A 51.3 ✔ ✖ 
 
✖ 8 ± 4 
K118 -helix 11.44 23.5 ✔ ✔ 
- H-bonding with side chain COOH of E27 
- Overall: Charged, (-) 
✔ 
- NH2 close to V114 
1.7  0.7 
H119 -helix 5.26 20.0 ✔ ✖ 
 
✔ 
- imidazole amine close to L115 
3 ± 3 
T132 -helix N/A 45.8 ✔ ✖ 
- H-bonding with backbone CO of Q128 
✔ 
- OH close to I112, M131, L135 
N.D. 
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MYG 
residue 
Secondary 
structure 
pKaǂ Solvent accessibility* Microenvironment % DEPC CL 
%SASA 
ratio 
> 20% 
Charged polar contact 
[within 4 Å] 
Hydrophobic neighbor 
[within 6 Å] 
Intact protein 
(DEPC:protein 
= 4:1) 
K133 -helix 11.12 44.8 ✔ ✔ 
- H-bonding with side chain COOH of E6 
- H-bonding with backbone CO of G1 
- Overall: Charged, (-) 
✖ N.D. 
K145 -helix 11.64 16.4 ✖ ✔ 
- H-bonding with side chain COOH of E83 
- Overall: Charged, (-) 
✔ 
- NH2 close to L86 
2  1 
Y146 -helix 12.86 4.2 ✖ ✖ 
-  H-bonding with backbone CO of I99 
✔ 
- OH close to I142, F151 
0.5  0.2 
K147 -helix 10.45 97.0 ✔ ✖ 
 
✖ 3.1  0.7 
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Table A.6: DEPC modification percentages of nucleophilic residues in hen egg-white lysozyme (LYZ) intact protein.  
Each experiment was performed in triplicate or quadruplicate (n = 3 or 4). Error bars shown in a table are standard deviations. Listed 
along are structural features of each residue from PDB 1DWR. ✔ and ✖ represent presence or absence of each structural element, 
respectively. (+) and (-) represent positively charged and negatively charged polar contacts, respectively.  
 
LYZ 
residue 
Secondary 
structure 
pKaǂ Solvent accessibility* Microenvironment % DEPC CL 
%SASA 
ratio 
> 20% 
Charged polar contact 
[within 4 Å] 
Hydrophobic neighbor 
[within 6 Å] 
Intact protein 
(DEPC:protein 
= 4:1) 
K19 β-sheet 11.25 44.6 
 
✔ ✔ 
- H-bonding with side chain COOH of E25 
- Overall: Charged, (-) 
 
✔ 
- NH2 close to F21 
63  10 
 
K31 -helix 11.60 
 
42.1 
 
✔ ✔ 
- H-bonding with COOH of C-terminus 
- Overall: Charged, (-) 
✔ 
- NH2 close to L147 
10  3 
 
H33 -helix 6.42 
 
19.7 
 
✖ 
 
✖ 
- H-bonding with side chain OH of T89 
✔ 
- imidazole amine close to I106, V110 
0.17  0.09 
 
Y38 Random 
coil 
9.24 32.4 
 
✔ ✖ 
- H-bonding with side chain OH of S118 
✔ 
- OH close to V117 
N.D.b 
Y41 Random 
coil 
10.10 23.5 ✔ ✖ 
-  H-bonding with backbone NH of M123 
✔ 
- OH close to V117, M123 
0.04  0.02 
 
S42 Random 
coil 
N/Aa 41.2 ✔ ✖ 
-  H-bonding with backbone NH of G26 
✔ 
- OH close to L43 
0.06  0.03 
 
K51 -helix 10.15 33.7 ✔ ✖ 
- H-bonding with side chain CONH2 of N55 
✔ 
- NH2 close to F56 
9  5 
 
S54 Random 
coil 
N/A 0.0 ✖ 
 
✖ 
-  H-bonding with backbone NH of I73 
✔ 
- OH close to I73 
N.D. 
T58 Random 
coil 
N/A 0.8 ✖ 
 
✖ ✔ 
- OH close to I73 
N.D. 
T61 
 
β-sheet N/A 44.2 ✔ ✖ ✖ N.D. 
a N/A = not applicable; b N.D. = not detected (less than DEPC labeling threshold of 0.01%1)  
* SASA calculated using GETAREA2, as explained in detail in Section 2.2.8; ǂ pKa calculated using PROPKA3 
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LYZ 
residue 
Secondary 
structure 
pKaǂ Solvent accessibility* Microenvironment % DEPC CL 
%SASA 
ratio 
> 20% 
Charged polar contact 
[within 4 Å] 
Hydrophobic neighbor 
[within 6 Å] 
Intact protein 
(DEPC:protein 
= 4:1) 
T65 Random 
coil 
N/A 100 ✔ ✖ ✖ N.D. 
S68 β-sheet N/A 1.6 ✖ ✖ 
- H-bonding with side chain CONH2 of N64 
✖ N.D. 
T69 β-sheet N/A 5.4 ✖ ✖ ✔ 
- OH close to Y71 
N.D. 
Y71 
 
β-sheet 11.87 9.8 ✖ ✖ ✖ N.D. 
S78 
 
Random 
coil 
N/A 23.5 ✔ ✖ 
-  H-bonding with backbone NH of M123 
✔ 
- OH close to V117, M123 
0.04  0.02 
 
T87 Random 
coil 
N/A 0.0 ✖ ✖ 
-  H-bonding with side chain OH of T89 
- H-bonding with backbone CO, NH of T69 
✔ 
- OH close to Y71 
0.010  0.005 
 
S90 Random 
coil 
N/A 2.1 ✖ ✔ 
- H-bonding with side chain COOH of E84 
- Overall: Charged, (-) 
 
✔ 
- OH close to Y88 
0.31  0.08 
 
S99 -helix N/A 15.9 ✖ ✖ 
-  H-bonding with backbone CO of S78, T87 
✖ 0.04  0.02 
 
S103 Random 
coil 
N/A 85.5 ✔ ✖ 
-  H-bonding with side chain NH of A100 
✔ 
- OH close to P97 
0.19  0.04 
 
S104 Random 
coil 
N/A 53.7 ✔ ✖ 
-  H-bonding with side chain OH of T89 
- H-bonding with backbone CO, NH of D105 
✖ 0.03  0.01 
 
T107 -helix N/A 77.0 ✔ ✖ ✖ 0.03  0.01 
 
S109 -helix N/A 53.2 ✔ ✔ 
- H-bonding with side chain COOH of D105 
- Overall: Charged, (-) 
 
✔ 
- OH close to I106 
N.D. 
K114 -helix 10.15 2.0 ✖ ✖ 
-  H-bonding with backbone CO of L101 
✔ 
- OH close to I78, L101, I106 
0.15  0.02 
 
K115 Random 
coil 
10.45 27.3 ✔ ✖ 
-  H-bonding with backbone CO of H33 
 
✔ 
- NH2 close to V110 
5.7  0.5 
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LYZ 
residue 
Secondary 
structure 
pKaǂ Solvent accessibility* Microenvironment % DEPC CL 
%SASA 
ratio 
> 20% 
Charged polar contact 
[within 4 Å] 
Hydrophobic neighbor 
[within 6 Å] 
Intact protein 
(DEPC:protein 
= 4:1) 
S118 Random 
coil 
N/A 27.6 ✔ ✖ ✔ 
- OH close to V117 
0.21  0.06 
 
K134 Random 
coil 
10.17 51.7 ✔ ✖ 
- H-bonding with side chain CONH2 of N124 
✔ 
- NH2 close to W129 
0.6  0.1 
 
T136 Random 
coil 
N/A 50.4 ✔ ✖ 
-  H-bonding with backbone CO of C133 
✔ 
- OH close to V138 
20  5 
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APPENDIX B 
DEPC MODIFICATION PERCENTAGES FOR INDIVIDUAL RESIDUES OF 
RITUXIMAB UNDER NATIVE AND STRESSED CONDITIONS 
 
Table B.1: DEPC modification percentages for individual residues of rituximab 
under native conditions and after heating to 45 °C for 4 h.  
A difference was considered significant if the p‐value, calculated by performing an 
unpaired T‐test, was less than 0.05 (corresponding to a 95% confidence level, n = 4). Error 
bars shown in a table are standard deviations. Color coding of the cells (introduced below) 
indicates the extent of covalent labeling (CL) change which falls within low (L), medium 
(M), and high (H) bins. 
 
 
Residues 
 
Native Stressed 45 °C  
4 h 
Significant? Absolute difference 
(H, K) 
Ratio difference 
(S, T, Y) 
Light chain - VL domain 
S 5 0.03%  0.02% 0.03%  0.01% No   
S 7      
S 12 0.07%  0.02% 0.05%  0.03% No   
S 14 1.5%  0.7% 0.63%  0.30% No   
K18 0.17%  0.11% 0.09%  0.09% No   
T 20      
T 22      
S 26      
S 27 0.19%  0.10% 0.24%  0.29% No   
S 28 0.04%  0.04% 0.10%  0.10% No   
S 30      
Y 31 0.22%  0.13% 0.31%  0.32% No   
H 33 0.51%  0.42% 0.09%  0.10% No   
K 38 0.10%  0.06% 0.15%  0.08% No   
S 41 0.01%  0.02% 0.01%  0.01% No   
S 42 0.03%  0.02% 0.01%  0.01% No   
K 44 0.13%  0.06% 0.13%  0.05%  No   
Y 48 0.05%  0.03% 0.07%  0.04% No   
T 50 0.11%  0.05% 0.09%  0.07% No   
S 51 0.05%  0.03% 0.03%  0.02% No   
S 55 0.02%  0.02% 0.01%  0.00% No   
S 62 3.6%  2.6% 1.8%  1.4% No   
S 64 2.1%  1.8% 1.2%  1.0% No   
S 66 1.3%  1.2% 0.79%  0.32% No   
T 68 1.3%  1.2% 0.79%  0.32% No   
S 69 0.02%  0.02% 0.02%  0.01% No   
Y 70 0.02%  0.02% 0.02%  0.01% No   
S 71 50%  7% 30%  19% No   
T 73 7.5%  4.8% 5.3%  4.4% No   
S 75 7.6%  4.9% 5.5%  4.6%  No   
T 84 0.08%  0.04% 0.07%  0.04% No   
Y 85      
Y 86      
T 91      
S 92 1.7%  0.8% 3.7%  3.7% No   
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Residues 
 
Native Stressed 45 °C  
4 h 
Significant? Absolute difference 
(H, K) 
Ratio difference 
(S, T, Y) 
T 96 1.9%  0.8% 3.9%  3.7% No   
T 101      
K 102 0.00%  0.00% 0.00%  0.00% No   
K 106      
Light chain - CL domain 
T 108      
S 113 0.02%  0.01% 0.14%  0.11% No   
S 120      
K 125      
S 126 0.06%  0.10% 0.02%  0.01% No   
T 128      
S 130      
Y 139      
K 144      
K 148 1.3%  1.5% 1.3%  0.8% No   
S 155 4.5%  1.5% 9.3%  3.6% Yes +4.9%  3.9% +109%  95% 
S 158 4.5%  1.5% 9.3%  3.6% Yes +4.9%  3.9% +109%  95% 
S 161 4.5%  1.5% 9.3%  3.6% Yes +4.9%  3.9% +109%  95% 
T 163 0.61%  0.55% 0.89%  0.51% No   
S 167 0.64%  0.58% 0.99%  0.56% No   
K 168      
S 170      
T 171      
Y 172      
S 173      
S 175      
S 176      
T 177      
T 179 0.53%  0.96% 0.06%  0.06% No   
S 181 0.97%  0.52% 0.31%  0.06% Yes -0.67%  0.53% -68%  65% 
K 182 16%  3% 8.0%  5.3% No   
Y 185      
K 187 90%  4% 92%  4% No   
H 188 78%  9% 87%  10% No   
K 189 77%  9% 86%  9% No   
Y 191 3.4%  1.3% 6.1%  4.8% No   
T 196 3.4%  1.5% 4.9%  1.0% No   
H 197 3.7%  1.6% 5.3%  0.9% No   
S 201      
S 202      
T 205      
K 206 0.92%  0.39% 1.3%  0.6% No   
S 207      
Heavy chain – VH domain 
K 13 2.5%  1.7% 2.7%  1.2% No   
S 17 2.4%  1.6% 2.6%  1.2% No   
K 19 0.20%  0.06% 0.22%  0.07% No   
S 21      
K 23 0.82%  0.70% 2.5%  2.8% No   
S 25      
Y 27 43%  1% 44%  4% No   
T 28 41%  2% 44%  3% No   
T 30 21%  8% 17%  8% No   
S 31 0.30%  0.35% 0.52%  0.34% No   
Y 32 0.30%  0.35% 0.52%  0.34% No   
H 35 90%  5% 84%  7% No   
K 38 56%  17% 57%  13% No   
T 40      
Y 52 0.35%  0.11% 0.26%  0.17% No   
T 58      
S 59      
Y 60      
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Residues 
 
Native Stressed 45 °C  
4 h 
Significant? Absolute difference 
(H, K) 
Ratio difference 
(S, T, Y) 
K 63 1.64%  0.64% 1.11%  0.58% No   
K 65      
K 67 80%  11% 82%  15% No   
T 69 4.0%  2.2% 25%  18% No   
T 71 26%  5% 39%  21% No   
K 74 32%  5% 36%  17% No   
S 75      
S 76 26%  7% 6.5%  4.2% Yes -20%  8% -76%  38% 
S 77 14%  4% 2.3%  1.6% Yes -12%  4% -84%  38% 
T 78 0.55%  0.54% 0.45%  0.42% No   
Y 80 1.1%  1.0% 1.4%  0.6% No   
S 84 2.5%  0.4% 3.4%  5.8% No   
S 85      
T 87      
S 88 3.6%  0.8% 4.4%  1.6% No   
S 91      
Y 94 0.13%  0.08% 0.22%  0.12% No   
Y 95 2.8%  1.7% 3.4%  1.7% No   
S 99      
T 100      
Y 101      
Y 102      
Y 107      
T 115 0.11%  0.17% 0.57%  0.91% No   
T 116 0.11%  0.17% 0.57%  0.91% No   
T 118      
S 120 7.9%  4.4% 2.7%  0.9% No   
Heavy chain – CH1 domain 
S 123 9.5%  2.0% 5.6%  5.1% No   
T 124 14%  4% 7.5%  6.0% No   
K 125 42%  12% 25%  15% No   
S 128 
 
0.01%  0.01% 0.05%  0.03% No   
S 135 0.05%  0.02% 0.25%  0.17% No   
S 136 0.04%  0.02% 0.03%  0.02% No   
K 137 0.05%  0.02% 0.22%  0.12% Yes +0.17%  0.13  
S 138 1.4%  0.9% 1.3%  0.7% No   
T 139 0.03%  0.02% 0.02%  0.02% No   
S 140 0.33%  0.19% 0.06%  0.03% Yes -0.26%  0.20% -81%  77% 
T 143 0.30%  0.18% 0.07%  0.04% Yes -0.24%  0.19% -78%  78% 
K 151      
Y 153 0.01%  0.00% 0.01%  0.01% No   
T 159 4.6%  2.7% 2.8%  1.2% No   
S 161 1.8%  0.5% 0.7%  0.8% No   
S 164 14%  4% 8.2%  4.6% No   
T 168 7.9%  3.8% 4.9%  3.2% No   
S 169 0.38%  0.59% 0.53%  0.31% No   
H 172 35%  4% 35%  8% No   
T 173      
S 180 7.5%  1.6% 9.1%  10.6% No   
S 181 7.3%  1.7% 8.9%  10.6% No   
Y 184      
S 185      
S 187 0.86%  0.93% 1.2%  1.2% No   
S 188 1.4%  1.1% 1.4%  1.3% No   
T 191 1.5%  0.8% 0.39%  0.52%  No   
S 194 0.04%  0.02% 0.17%  0.10% Yes +0.13%  0.10% +313%  281% 
S 195 1.4%  0.7% 0.8%  0.5% No   
S 196 1.6%  1.1% 0.95%  0.47% No   
T 199      
T 201 0.55%  0.36% 2.4%  3.7% No   
Y 202 0.55%  0.36% 2.4%  3.7% No   
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Residues 
 
Native Stressed 45 °C  
4 h 
Significant? Absolute difference 
(H, K) 
Ratio difference 
(S, T, Y) 
H 208 1.5%  0.2% 1.0%  0.7% No   
K 209 7.8%  3.1% 6.4%  2.9% No   
S 211 0.00%  0.00% 0.00%  0.00% No   
T 213      
K 214 0.30%  0.26% 0.20%  0.18% No   
K 217 
     
K 218      
K 222 100%  0% 100%  0% No   
S 223 0.80%  0.56% 1.3%  0.8% No   
Heavy chain – Hinge region and CH2 domain 
K 226 39%  12% 73%  20% Yes +34%  23%  
T 227 0.07%  0.07% 0.14%  0.12% No   
H 228 16%  8% 14%  3% No   
T 229 16%  8% 14%  3% No   
S 243 0.06%  0.05% 0.04%  0.03% No   
K 250      
K 252 100%  0% 100%  0% No   
T 254      
S 258      
T 260      
T 264 0.04%  0.03% 0.03%  0.02% No   
S 271 5.1%  2.5% 4.2%  1.9% No   
H 272 5.1%  2.4% 4.2%  1.9% No   
K 278 0.13%  0.07% 0.16%  0.07% No   
Y 282 0.08%  0.07% 0.06%  0.02% No   
H 289 0.06%  0.05% 0.04%  0.01% No   
K 292 0.01%  0.01% 0.01%  0.01% No   
T 293 7.4%  2.8% 23%  12% Yes +16%  12% +220%  188% 
K 294 7.4%  2.8% 23%  12% Yes +16%  12%  
Y 300      
S 302 83%  4% 75%  17% No   
T 303 83%  4% 75%  17% No   
Y 304      
S 308      
T 311 1.6%  0.5% 1.2%  0.7% No   
H 314 0.29%  0.10% 0.25%  0.20% No   
K 321 4.7%  1.6% 3.3%  1.7% No   
Y 323      
K 324 94%  5% 92%  3% No   
K 326      
S 328      
K 330 100%  0% 100%  0% No   
K 338 0.53%  0.14% 0.48%  0.28% No   
T 339      
S 341 27%  3% 22%  8% No   
K 342      
K 344      
Heavy chain – CH3 domain 
Y 353 27%  16% 39%  25% No   
T 354 0.01%  0.00% 0.01%  0.01% No   
S 358 0.11%  0.05% 0.17%  0.08% No   
T 363 0.12%  0.06% 0.19%  0.08% No   
K 364 0.11%  0.05% 0.17%  0.09% No   
S 368 0.03%  0.03% 0.04%  0.03% No   
T 370 7.5%  1.3% 14%  4% Yes +6.5%  3.9% +87%  54% 
K 374 7.5%  1.3% 14%  4% Yes +6.5%  3.9%  
Y 377 0.63%  0.33% 0.65%  0.22% No   
S 379      
S 387      
Y 395      
K 396 0.20%  0.10% 0.05%  0.02% Yes -0.15%  0.10%  
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Residues 
 
Native Stressed 45 °C  
4 h 
Significant? Absolute difference 
(H, K) 
Ratio difference 
(S, T, Y) 
T 397      
T 398 9.6%  4.0% 6.4%  2.8% No   
S 404 9.0%  4.0% 5.7%  2.9% No   
S 407 1.6%  0.4% 0.9%  1.1% No   
Y 411      
S 412      
K 413      
T 415      
K 418      
S 419      
S 428 0.13%  0.06% 0.14%  0.10% No   
S 430 6.0%  0.8% 5.2%  1.0% No   
H 433 13%  3%  15%  2% No   
H 437 14%  2% 11%  2% No   
H 439 1.4%  0.6% 1.4%  0.3% No   
Y 440 0.00%  0.00% 0.05%  0.04% No   
T 441      
K 443 1.1%  0.6% 1.3%  0.7% No   
S 444      
S 446      
S 448 17%  2% 26%  4% Yes +9.1%  5.0% +54%  31% 
K 451      
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Table B.2: DEPC modification percentages for individual residues of rituximab 
under native conditions and after heating to 55 °C for 4 h.  
A difference was considered significant if the p‐value, calculated by performing an 
unpaired T‐test, was less than 0.05 (corresponding to a 95% confidence level, n = 4). Error 
bars shown in a table are standard deviations. Color coding of the cells (introduced below) 
indicates the extent of covalent labeling (CL) change which falls within low (L), medium 
(M), and high (H) bins. 
 
 
Residues 
 
Native Stressed 55 °C  
4 h 
Significant? Absolute difference 
(H, K) 
Ratio difference 
(S, T, Y) 
Light chain - VL domain 
S 5 0.03%  0.01% 0.04%  0.00% No   
S 7      
S 12 0.03%  0.01% 0.02%  0.01% No   
S 14      
K18 0.56%  0.06% 0.66%  0.22% No   
T 20 17%  4% 8%  2% Yes -10%  4% -56%  26% 
T 22      
S 26      
S 27      
S 28      
S 30      
Y 31      
H 33 0.08%  0.02% 0.21%  0.02% Yes +0.14%  0.03%  
K 38 0.15%  0.05% 0.24%  0.02% No   
S 41 0.04%  0.01% 0.02%  0.02% No   
S 42      
K 44 0.06%  0.02% 0.15%  0.01% Yes +0.08%  0.02%  
Y 48 0.09%  0.04% 0.13%  0.01% No   
T 50 0.03%  0.03% 0.05%  0.01% No   
S 51      
S 55      
S 62      
S 64      
S 66 18%  4% 15%  2% No   
T 68 18%  4% 15%  2% No   
S 69      
Y 70 14%  5% 11%  4% No   
S 71      
T 73 53%  14% 86%  3% Yes +32%  15% +61%  32% 
S 75 53%  14% 86%  3% Yes +32%  15% +61%  32% 
T 84 1.3%  0.2% 2.6%  0.5% Yes +1.3%  0.6% +103%  46% 
Y 85 1.3%  0.2% 2.6%  0.5% Yes +1.3%  0.5% +100%  43% 
Y 86      
T 91 0.03%  0.02% 0.10%  0.01% Yes +0.07%  0.02% +225%  196% 
S 92 1.8%  0.6% 2.1%  0.6% No   
T 96 2.0%  0.6% 2.2%  0.6% No   
T 101 0.18%  0.01% 0.14%  0.02% No   
K 102 0.08%  0.02% 0.10%  0.01% No   
K 106      
Light chain - CL domain 
T 108 1.3%  0.4% 1.1%  0.3% No   
S 113 1.0%  0.3% 0.8%  0.1% No   
S 120      
K 125      
S 126      
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Residues 
 
Native Stressed 55 °C  
4 h 
Significant? Absolute difference 
(H, K) 
Ratio difference 
(S, T, Y) 
T 128 5.4%  1.0% 3.1%  0.3% Yes -2.3%  1.1% -42.4%  21.7% 
S 130 5.4%  1.0% 3.1%  0.3% Yes -2.3%  1.1% -42.4%  21.7% 
Y 139      
K 144      
K 148 7.2%  1.7% 9.7%  0.8% No   
S 155      
S 158      
S 161      
T 163 0.00%  0.00% 0.01%  0.01% No   
S 167      
K 168 0.48%  0.19% 0.47%  0.16% No   
S 170      
T 171      
Y 172      
S 173      
S 175      
S 176      
T 177      
T 179      
S 181      
K 182 5.0%  2.1% 19%  10% No   
Y 185 23.5%  0.3% 27%  2% Yes +4%  2% +16%  8% 
K 187 85%  3% 86%  4% No   
H 188 55%  2% 64%  3% Yes +10%  4%  
K 189 60%  3% 66%  3% No   
Y 191 0.74%  0.09% 0.98%  0.33% No   
T 196      
H 197 0.11%  0.03% 0.16%  0.03% No   
S 201      
S 202      
T 205      
K 206 0.37%  0.13% 0.38%  0.10% No   
S 207 4.2%  2.3% 2.8%  2.0% No   
Heavy chain – VH domain 
K 13 2.7%  0.5% 3.7%  0.3% Yes +1.0%  0.6%  
S 17      
K 19 3.5%  0.7% 4.5%  0.4% No   
S 21 24%  4% 11%  4% Yes -13%  6% -55%  27% 
K 23 86%  5% 92%  4% No   
S 25      
Y 27      
T 28      
T 30      
S 31      
Y 32 0.05%  0.03% 0.40%  0.26% No   
H 35 23%  3% 4%  1% Yes -19%  3%  
K 38 30%  2% 22%  3% Yes -8%  3%  
T 40      
Y 52 1.1%  0.2% 1.3%  0.2% No   
T 58 0.12%  0.01% 0.15%  0.02% No   
S 59 0.09%  0.01% 0.09%  0.03% No   
Y 60 0.09%  0.01% 0.09%  0.03% No   
K 63      
K 65      
K 67 23%  7% 33%  2% No   
T 69      
T 71      
K 74 79%  4% 87%  1% Yes +8%  4%  
S 75      
S 76 2.4%  0.2% 1.5%  0.2% Yes -0.8%  0.3% -35%  13% 
S 77 0.01%  0.01% 0.01%  0.01% No   
T 78 0.28%  0.10% 0.26%  0.23% No   
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Residues 
 
Native Stressed 55 °C  
4 h 
Significant? Absolute difference 
(H, K) 
Ratio difference 
(S, T, Y) 
Y 80      
S 84 1.8%  0.7% 1.4%  0.6% No   
S 85 0.32%  0.06% 0.28%  0.14% No   
T 87      
S 88 0.02%  0.01% 0.01%  0.01% No   
S 91 0.25%  0.04% 0.23%  0.09% No   
Y 94 0.25%  0.04% 0.23%  0.09% No   
Y 95      
S 99      
T 100      
Y 101      
Y 102      
Y 107      
T 115 14%  4% 12%  1% No   
T 116      
T 118 71%  3% 59%  7% Yes -12%  7% -17%  11% 
S 120 84%  2% 70%  7% Yes -14%  7% -17%  9% 
Heavy chain – CH1 domain 
S 123 1.2%  0.3% 1.6%  0.2% No   
T 124      
K 125      
S 128 0.92%  0.44% 1.4%  1.0% No   
S 135 1.1%  0.5% 1.3%  1.1% No   
S 136      
K 137      
S 138      
T 139 0.13%  0.07% 0.12%  0.04% No   
S 140 0.03%  0.02% 0.02%  0.01% No   
T 143 0.01%  0.01% 0.01%  0.01% No   
K 151      
Y 153 0.02%  0.02% 0.07%  0.05% No   
T 159      
S 161 1.8%  0.2% 2.2%  0.4% No   
S 164 0.002%  0.001% 0.016%  0.005% Yes +0.014%  0.005% +890%  849% 
T 168 1.3%  0.4% 2.4%  1.2% No   
S 169 0.23%  0.13%  0.35%  0.14% No   
H 172 0.23%  0.13%  0.35%  0.14% No   
T 173 1.1% 0.2% 2.2%  0.7% No   
S 180      
S 181      
Y 184      
S 185      
S 187 10%  3% 11%  2% No   
S 188 10%  3% 10%  2% No   
T 191 4.6%  1.1% 4.3%  0.7% No   
S 194      
S 195      
S 196 0.01%  0.00% 0.05%  0.03% No   
T 199 0.01%  0.00% 0.05%  0.03% No   
T 201      
Y 202      
H 208 0.00%   0.00% 0.00%  0.00% No   
K 209 6.4%  2.0% 8.0%  0.9% No   
S 211 0.00%  0.00% 0.00%  0.00% No   
T 213      
K 214 0.50%  0.38% 0.40%  0.12% No   
K 217      
K 218      
K 222 99%  1% 100%  0% No   
S 223 0.06%  0.04% 0.04%  0.00% No   
Heavy chain – Hinge region and CH2 domain 
K 226 33%  7% 72%  5% Yes +39%  8%  
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Residues 
 
Native Stressed 55 °C  
4 h 
Significant? Absolute difference 
(H, K) 
Ratio difference 
(S, T, Y) 
T 227 1.4%  0.8% 1.6%  1.2% No   
H 228 36%  7% 43%  15% No   
T 229 36%  7% 42%  14% No   
S 243      
K 250      
K 252 100%  0% 100%  0% No   
T 254      
S 258 5.2%  1.8% 3.1%  0.8% No   
T 260 0.70%  0.58% 0.81%  0.33% No   
T 264 11%  2% 16%  11% No   
S 271 10%  1% 15%  11% No   
H 272 
 
0.26%  0.08% 0.24%  0.06% No   
K 278 0.16%  0.10% 0.28%  0.07% No   
Y 282 0.39%  0.02% 0.33%  0.04% No   
H 289 0.49%  0.13% 0.41%  0.03% No   
K 292      
T 293 38%  6% 85%  8% Yes +46%  10% +122%  32% 
K 294      
Y 300 50%  1% 56%  7% No   
S 302 38%  3% 16%  6% Yes -22%  7% -58%  18% 
T 303      
Y 304      
S 308      
T 311      
H 314 0.24%  0.08% 0.23%  0.06% No   
K 321 0.29%  0.04% 0.28%  0.01% No   
Y 323      
K 324      
K 326      
S 328      
K 330 100%  0% 100%  0% No   
K 338 2.4%  1.7% 4.4%  0.5% No   
T 339      
S 341      
K 342      
K 344      
Heavy chain – CH3 domain 
Y 353 0.44%  0.62% 14%  2% Yes +14%  2% +3118%  4418% 
T 354      
S 358      
T 363 0.006%  0.002% 0.012%  0.003% Yes +0.006%  0.003% +111%  67% 
K 364 0.15%  0.07% 0.29%  0.21% No   
S 368 0.02%  0.02% 0.18%  0.01% Yes +0.16%  0.03% +1018%  1537% 
T 370      
K 374 4.1%  1.6% 7.8%  2.0% No   
Y 377 11%  2% 12%  7% No   
S 379 13%  2% 13%  7% No   
S 387 11%  2% 12%  7% No   
Y 395 2.2%  0.8% 2.4%  1.0% No   
K 396 0.82%  0.22% 0.58%  0.27% No   
T 397 0.87%  0.29% 1.0%  0.2% No   
T 398 12%  1% 17%  3% No   
S 404 5.2%  1.3% 4.8%  1.8% No   
S 407 15%  4% 30%  6% Yes +15%  7% +101%  52% 
Y 411 7.5%  5.1% 20%  4% Yes +12%  6% +163%  138% 
S 412      
K 413      
T 415      
K 418 29%  24% 46%  4% No   
S 419 19%  15% 33%  2% No   
S 428 0.86%  0.08% 1.2%  0.4% No   
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Residues 
 
Native Stressed 55 °C  
4 h 
Significant? Absolute difference 
(H, K) 
Ratio difference 
(S, T, Y) 
S 430 6.8%  2.2% 12%  2% No   
H 433 15%  2% 13%  4% No   
H 437 5.8%  2.9% 7.4%  0.9% No   
H 439 5.4%  0.9% 4.2%  3.2% No   
Y 440 0.02%  0.01% 0.02%  0.01% No   
T 441      
K 443 0.47%  0.24% 0.35%  0.07% No   
S 444      
S 446      
S 448 71%  12% 92%  4% Yes +22%  13% +30%  18% 
K 451 41%  16% 79%  7% Yes +37%  18%  
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Table B.3: DEPC modification percentages for individual residues of rituximab 
under native conditions and after heating to 65 °C for 4 h.  
A difference was considered significant if the p‐value, calculated by performing an 
unpaired T‐test, was less than 0.05 (corresponding to a 95% confidence level, n = 4). Error 
bars shown in a table are standard deviations. Color coding of the cells (introduced below) 
indicates the extent of covalent labeling (CL) change which falls within low (L), medium 
(M), and high (H) bins. 
 
 
Residues 
 
Native Stressed 65 °C  
4 h 
Significant? Absolute difference 
(H, K) 
Ratio difference 
(S, T, Y) 
Light chain - VL domain 
S 5 0.03%  0.01% 0.01%  0.01% Yes -0.02%  0.01% -62%  40% 
S 7      
S 12 0.03%  0.01% 0.01%  0.01% No   
S 14      
K18 0.56%  0.06% 0.33%  0.27% No   
T 20 17%  4% 13%  8% No   
T 22      
S 26      
S 27      
S 28      
S 30      
Y 31      
H 33 0.08%  0.02% 0.61%  0.49% No   
K 38 0.15%  0.05% 0.22%  0.06% No   
S 41 0.04%  0.01% 0.12%  0.04% No   
S 42      
K 44 0.06%  0.02% 0.09%  0.04% No   
Y 48 0.09%  0.04% 0.06%  0.01% No   
T 50 0.03%  0.03% 0.00%  0.00% No   
S 51      
S 55      
S 62      
S 64      
S 66 18%  4% 12%  4% No   
T 68 18%  4% 12%  4% No   
S 69      
Y 70 14%  5% 1.8%  2.3% Yes -12%  5% -87%  48% 
S 71      
T 73 53%  14% 73%  13% No   
S 75 53%  14% 73%  13% No   
T 84 1.3%  0.2% 2.9%  1.3% No   
Y 85 1.3%  0.2% 2.9%  1.3% No   
Y 86      
T 91 0.03%  0.02% 0.01%  0.01% No   
S 92 1.8%  0.6% 4.3%  2.2% No   
T 96 2.0%  0.6% 4.3%  2.1% No   
T 101 0.18%  0.01% 0.07%  0.05% Yes -0.11%  0.05 -60%  30% 
K 102 0.08%  0.02% 0.04%  0.02% No   
K 106      
Light chain - CL domain 
T 108 1.3%  0.4% 0.66%  0.32% No   
S 113 1.0%  0.3% 0.52%  0.26% No   
S 120      
K 125      
S 126      
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Residues 
 
Native Stressed 65 °C  
4 h 
Significant? Absolute difference 
(H, K) 
Ratio difference 
(S, T, Y) 
T 128 5.4%  1.0% 3.2%  1.9% No   
S 130 5.4%  1.0% 3.2%  1.9% No   
Y 139      
K 144      
K 148 7.2%  1.7% 4.9%  1.0% No   
S 155      
S 158      
S 161      
T 163 0.00%  0.00% 0.00%  0.00% No   
S 167      
K 168 0.48%  0.19% 0.40%  0.21% No   
S 170      
T 171      
Y 172      
S 173      
S 175      
S 176      
T 177      
T 179      
S 181      
K 182 5.0%  2.1% 13%  8% No   
Y 185 23.5%  0.3% 25%  4% No   
K 187 85%  3% 78%  4% No   
H 188 55%  2% 62%  8% No   
K 189 60%  3% 65%  6% No   
Y 191 0.74%  0.09% 0.98%  0.24% No   
T 196      
H 197 0.11%  0.03% 0.57%  0.22% Yes +0.46%  0.23%  
S 201      
S 202      
T 205      
K 206 0.37%  0.13% 0.61%  0.22% No   
S 207 4.2%  2.3% 2.7%  0.6% No   
Heavy chain – VH domain 
K 13 2.7%  0.5% 3.5%  1.4% No   
S 17      
K 19 3.5%  0.7% 3.4%  1.5% No   
S 21 24%  4% 12%  8% No   
K 23 86%  5% 96%  5% No   
S 25      
Y 27      
T 28      
T 30      
S 31      
Y 32 0.05%  0.03% 0.27%  0.20% No   
H 35 23%  3% 11%  3% Yes -12%  4%  
K 38 30%  2% 38%  10% No   
T 40      
Y 52 1.1%  0.2% 1.4%  0.2% No   
T 58 0.12%  0.01% 0.21%  0.15% No   
S 59 0.09%  0.01% 0.19%  0.16% No   
Y 60 0.09%  0.01% 0.19%  0.16% No   
K 63      
K 65      
K 67 23%  7% 70%  17% Yes +48%  19%  
T 69      
T 71      
K 74 79%  4% 52%  8% Yes -27%  9%  
S 75      
S 76 2.4%  0.2% 4.0%  1.2% No   
S 77 0.01%  0.01% 0.03%  0.01% Yes +0.02%  0.01% +165%  127% 
T 78 0.28%  0.10% 0.16%  0.09% No   
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Residues 
 
Native Stressed 65 °C  
4 h 
Significant? Absolute difference 
(H, K) 
Ratio difference 
(S, T, Y) 
Y 80      
S 84 1.8%  0.7% 1.3%  0.5% No   
S 85 0.32%  0.06% 0.26%  0.09% No   
T 87      
S 88 0.02%  0.01% 0.03%  0.01% No   
S 91 0.25%  0.04% 0.21%  0.06% No   
Y 94 0.25%  0.04% 0.21%  0.06% No   
Y 95      
S 99      
T 100      
Y 101      
Y 102      
Y 107      
T 115 14%  4% 14%  5% No   
T 116      
T 118 71%  3% 55%  5% Yes -16%  6% -22%  9% 
S 120 84%  2% 69%  4% Yes -15%  4% -18%  5% 
Heavy chain – CH1 domain 
S 123 1.2%  0.3% 1.2%  0.2%  No   
T 124      
K 125      
S 128 0.92%  0.44% 0.30%  0.16% No   
S 135 1.1%  0.5% 0.35%  0.34% No   
S 136      
K 137      
S 138      
T 139 0.13%  0.07% 0.23%  0.10% No   
S 140 0.03%  0.02% 0.05%  0.01% No   
T 143 0.01%  0.01% 0.02%  0.01% No   
K 151      
Y 153 0.02%  0.02% 0.01%  0.01% No   
T 159      
S 161 1.8%  0.2% 1.2%  0.2% Yes -0.66%  0.31% -36%  18% 
S 164 0.00%  0.00% 0.02%  0.02% No   
T 168 1.3%  0.4% 2.2%  1.5% No   
S 169 0.23%  0.13%  0.23%  0.18% No   
H 172 0.23%  0.13%  0.23%  0.18% No   
T 173 1.1% 0.2% 1.9%  0.9% No   
S 180      
S 181      
Y 184      
S 185      
S 187 10%  3% 11%  2% No   
S 188 10%  3% 11%  2% No   
T 191 4.6%  1.1% 4.4%  0.1% No   
S 194      
S 195      
S 196 0.01%  0.00% 0.08%  0.02% Yes +0.07%  0.02% +728%  276% 
T 199 0.01%  0.00% 0.05%  0.02% Yes +0.05%  0.02% +689%  396% 
T 201      
Y 202      
H 208 0.00%   0.00% 0.04%  0.01% Yes +0.04%  0.01%  
K 209 6.4%  2.0% 4.0%  1.0% No   
S 211 0.00%  0.00% 0.21%  0.02% Yes +0.21%  0.02% +6074%  5773% 
T 213      
K 214 0.50%  0.38% 0.19%  0.12% No   
K 217      
K 218      
K 222 99%  1% 98%  2% No   
S 223 0.06%  0.04% 0.05%  0.01% No   
Heavy chain – Hinge region and CH2 domain 
K 226 33%  7% 39%  17% No   
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Native Stressed 65 °C  
4 h 
Significant? Absolute difference 
(H, K) 
Ratio difference 
(S, T, Y) 
T 227 1.4%  0.8% 1.2%  0.8% No   
H 228 36%  7% 40%  12% No   
T 229 36%  7% 40%  12% No   
S 243      
K 250      
K 252 100%  0% 100%  0% No   
T 254      
S 258 5.2%  1.8% 1.2%  1.5% Yes -4.0%  2.3% -77%  52% 
T 260 0.70%  0.58% 0.16%  0.10% No   
T 264 11%  2% 9.6%  2.3% No   
S 271 10%  1% 9.3%  2.2% No   
H 272 0.26%  0.08% 0.19%  0.10 No   
K 278 0.16%  0.10% 0.24%  0.03% No   
Y 282 0.39%  0.02% 0.39%  0.08% No   
H 289 0.49%  0.13% 0.34%  0.23% No   
K 292      
T 293 38%  6% 82%  27% No   
K 294      
Y 300 50%  1% 30%  13% No   
S 302 38%  3% 10%  16% Yes -28%  16% -74%  43% 
T 303      
Y 304      
S 308      
T 311      
H 314 0.24%  0.08% 0.20%  0.03% No   
K 321 0.29%  0.04% 0.37%  0.06% No   
Y 323      
K 324      
K 326      
S 328      
K 330 100%  0% 100%  0% No   
K 338 2.4%  1.7% 1.5%  0.4%  No   
T 339      
S 341      
K 342      
K 344      
Heavy chain – CH3 domain 
Y 353 0.44%  0.62% 0.00%  0.00% No   
T 354      
S 358      
T 363 0.006%  0.002% 0.002%  0.001% Yes -0.004  0.002 -66%  40% 
K 364 0.15%  0.07% 0.10%  0.08%  No   
S 368 0.02%  0.02% 0.00%  0.00% No   
T 370      
K 374 4.1%  1.6% 3.5%  2.4% No   
Y 377 11%  2% 8.5%  4.9% No   
S 379 13%  2% 10%  5% No   
S 387 11%  2% 8.5%  4.9% No   
Y 395 2.2%  0.8% 2.3%  0.3% No   
K 396 0.82%  0.22% 0.73%  0.19% No   
T 397 0.87%  0.29% 1.0%  0.2% No   
T 398 12%  1% 16%  10% No   
S 404 5.2%  1.3% 4.9%  2.7%  No   
S 407 15%  4% 23%  12% No   
Y 411 7.5%  5.1% 13%  6% No   
S 412      
K 413      
T 415      
K 418 29%  24% 36%  18% No   
S 419 19%  15% 25%  15% No   
S 428 0.86%  0.08% 0.41%  0.23% Yes -0.45%  0.24% -52%  29% 
S 430 6.8%  2.2% 8.1%  4.6% No   
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Residues 
 
Native Stressed 65 °C  
4 h 
Significant? Absolute difference 
(H, K) 
Ratio difference 
(S, T, Y) 
H 433 15%  2% 16%  3% No   
H 437 5.8%  2.9% 5.2%  0.9% No   
H 439 5.4%  0.9% 2.5%  0.3% Yes -2.9%  0.9%  
Y 440 0.02%  0.01% 0.01%  0.01% Yes -0.01%  0.01% -60%  42% 
T 441      
K 443 0.47%  0.24% 0.25%  0.15% No   
S 444      
S 446      
S 448 71%  12% 47%  9% No   
K 451 41%  16% 5.1%  5.4% Yes -36%  17%  
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